,Article,Date,Symbol,Time,Title,Url
0,"  By Bill BerkrotJan 13 U.S. biotech company Celgene Corp  raised sales and profit forecasts for 2015 and 2017 on Monday, saying its improved long-term outlook was based on current momentum for its blood cancer medicines.The relatively conservative increases, however, and a 2014 forecast that was slightly lower than current Wall Street estimates, dampened shareholder enthusiasm and Celgene shares fell more than 3 percent.""While Celgene tends to be conservative with its guidance, we believe heightened expectations had set a high bar for the stock (prior) to today's release,"" Cowen and Co analyst Eric Schmidt said.Celgene shares had been rising over the past few weeks, touching a new all-time high prior to Monday's announcement.""The numbers for 2014 are a little light of expectations and the stock has been very strong heading into this announcement, so some sell off was probably inevitable,"" said Geoffrey Porges, analyst with Sanford Bernstein.Celgene raised the 2017 forecast for its flagship drug Revlimid by $1 billion to $7 billion, and now expects 2017 sales of $1.5 billion for its newer blood cancer drug Pomalyst, up from a prior view of $1 billion. Celgene Chief Executive Robert Hugin told analysts and investors that the early sale performance of Pomalyst ""certainly exceeded our expectations in the U.S. and Europe.""Celgene Chief Financial Officer Jacqualyn Fourse, in a breakout session following the formal presentation, appeared to leave room for future forecast increases, saying that the numbers ""can evolve.""She called the forecasts ""a new base case"" and said the outlook was ""based on conservative estimates of worldwide pricing."" Fourse also said further upside could be driven by positive results from ongoing late-stage clinical trials.In addition, the long-term forecasts were based on expected growth only from Celgene's blood cancer drugs, which does not take into account potential sales strides by Abraxane, its drug for breast cancer and other solid tumor cancers. ""Abraxane continues to have very meaningful growth,"" JP Morgan analyst Geoff Meacham said in a research note.The forecasts were issued during Celgene's presentation at the annual JP Morgan Healthcare conference in San Francisco.For 2014, Celgene expects sales of $7.3 billion to $7.4 billion and adjusted earnings, excluding one-time items, of $7 to $7.20 per share. Analysts, on average, are looking for sales of $7.43 billion and earnings of $7.29 per share, according to Thomson Reuters I/B/E/S. ""The 2014 guidance looks solid and potentially conservative, given strong commercial momentum,"" Meacham said.For 2015, Celgene now expects sales of $8.5 billion to $9.5 billion and adjusted earnings of $9 to $9.50 per share, up from its prior view of sales of $8 billion to $9 billion and EPS of $8 to $9.For 2017, Celgene sees sales growing to $13 billion to $14 billion, up from its prior view of at least $12 billion, and adjusted earnings of a about $15 per share versus its earlier forecast of $13 to $14 per share.""While positive, we think the magnitude of this guidance raise is generally in-line with buy-side expectations,"" ISI Group analyst Mark Schoenebaum said.The company also provided preliminary results for the fourth quarter of 2013, saying it expects to report adjusted earnings of $1.51 per share, including a 10 cent per share impact from collaboration-related payments.That would be about 4 cents shy of average analysts' expectations of $1.55 per share.Celgene shares were down $5.67, or 3.3 percent, at $164.14 in afternoon trading on Nasdaq.",2014-01-13,CELG,"Mon Jan 13, 2014 | 2:57pm EST",UPDATE 3-Celgene raises forecasts on cancer drug sales strength,http://www.reuters.com//article/celgene-outlook-idUSL2N0KN1CZ20140113?type=companyNews
1,"   By Bill Berkrot  U.S. biotech company Celgene Corp (CELG.O) raised sales and profit forecasts for 2015 and 2017 on Monday, saying its improved long-term outlook was based on current momentum for its blood cancer medicines.The relatively conservative increases, however, and a 2014 forecast that was slightly lower than current Wall Street estimates, were met with dampened shareholder enthusiasm and Celgene shares fell more than 3 percent.""While Celgene tends to be conservative with its guidance, we believe heightened expectations had set a high bar for the stock (prior) to today's release,"" Cowen and Co analyst Eric Schmidt said.Celgene shares had been rising over the past few weeks, touching a new all-time high prior to Monday's announcement.""The numbers for 2014 are a little light of expectations and the stock has been very strong heading into this announcement, so some sell off was probably inevitable,"" said Geoffrey Porges, analyst with Sanford Bernstein.Celgene raised the 2017 forecast for its flagship drug Revlimid by $1 billion to $7 billion, and now expects 2017 sales of $1.5 billion for its newer blood cancer drug Pomalyst, up from a prior view of $1 billion. Celgene Chief Executive Robert Hugin told analysts and investors that the early sale performance of Pomalyst ""certainly exceeded our expectations in the U.S. and Europe.""Celgene Chief Financial Officer Jacqualyn Fourse, in a breakout session following the formal presentation, appeared to leave room for future forecast increases, saying that the numbers ""can evolve.""She called the forecasts ""a new base case"" and said the outlook was ""based on conservative estimates of worldwide pricing."" Fourse also said further upside could be driven by positive results from ongoing late-stage clinical trials.In addition, the long-term forecasts were based on expected growth only from Celgene's blood cancer drugs, which does not take into account potential sales strides by Abraxane, its drug for breast cancer and other solid tumor cancers. ""Abraxane continues to have very meaningful growth,"" JP Morgan analyst Geoff Meacham said in a research note.The forecasts were issued during Celgene's presentation at the annual JP Morgan Healthcare conference in San Francisco.For 2014, Celgene expects sales of $7.3 billion to $7.4 billion and adjusted earnings, excluding one-time items, of $7 to $7.20 per share. Analysts, on average, are looking for sales of $7.43 billion and earnings of $7.29 per share, according to Thomson Reuters I/B/E/S. ""The 2014 guidance looks solid and potentially conservative, given strong commercial momentum,"" Meacham said.For 2015, Celgene now expects sales of $8.5 billion to $9.5 billion and adjusted earnings of $9 to $9.50 per share, up from its prior view of sales of $8 billion to $9 billion and EPS of $8 to $9.For 2017, Celgene sees sales growing to $13 billion to $14 billion, up from its prior view of at least $12 billion, and adjusted earnings of a about $15 per share versus its earlier forecast of $13 to $14 per share.""While positive, we think the magnitude of this guidance raise is generally in-line with buy-side expectations,"" ISI Group analyst Mark Schoenebaum said.Celgene shares were down $5.80, or 3.4 percent, at $164.01 in afternoon trading on Nasdaq.(Reporting by Bill Berkrot; additional reporting by Deena Beasley in San Francisco; Editing by Jeffrey Benkoe and Andrew Hay)",2014-01-13,CELG,"Mon Jan 13, 2014 | 2:02pm EST",Celgene raises forecasts on cancer drug sales strength,http://www.reuters.com//article/us-celgene-outlook-idUSBREA0C13G20140113?type=companyNews
2,"  Jan 13 Celgene Corp raised its sales and profit forecasts for 2015 and 2017 on Monday, saying its improved view was based on its current momentum.It also issued a 2014 forecast that was slightly lower than current Wall Street estimates, and a long-term forecast for sales of its flagship cancer drug Revlimid - $7 billion by 2017 - that the company called relatively conservative.  For 2014, Celgene expects sales of $7.3 billion to $7.4 billion and adjusted earnings, excluding one-time items, of $7 to $7.20 per share. Analysts, on average, are looking for sales of $7.43 billion and earnings of $7.29 per share, according to Thomson Reuters I/B/E/S. ",2014-01-13,CELG,"Mon Jan 13, 2014 | 12:03pm EST","Celgene raises sales, EPS forecasts for 2015, 2017",http://www.reuters.com//article/celgene-outlook-idUSL2N0KK2NK20140113?type=companyNews
3,"  (Adds treatment price, details on how drug works, updates share price)By Bill BerkrotMarch 21 U.S. health regulators approved on Friday a Celgene Corp drug to treat psoriatic arthritis, a type of arthritis associated with the skin disease psoriasis that causes joint pain, stiffness and swelling.The drug, a pill known chemically as apremilast, will be sold under the brand name Otezla. It is also being studied by the U.S. biotechnology company as a treatment for psoriasis and ankylosing spondylitis.Celgene projects Otezla sales of $1.5 billion to $2 billion a year by 2017.""We're cautious about achievability of management's guidance for this product,"" Sanford Bernstein analyst Geoffrey Porges said.""It's a highly competitive category and there are a lot of drugs with greater efficacy,"" added Porges, who forecasts annual sales will reach $800 million by 2019. Celgene has set a wholesale price of about $22,500 for a year of treatment. It expects to begin selling the medicine this month.Both Porges and ISI Group analyst Mark Schoenebaum said the price was higher than they had expected even though it represents about a 25 percent discount to current biologic market leaders.Otezla works by blocking an enzyme called PDE4, or phosphodiesterase 4, associated with inflammation. It offers the convenience of being a pill, while the current leading treatments are injected drugs. ""Relief of pain and inflammation and improving physical function are important treatment goals for patients with active psoriatic arthritis,"" Curtis Rosebraugh, director of the Food and Drug Administration Office of Drug Evaluation II, said in a statement.""Otezla provides a new treatment option for patients suffering from this disease,"" he added.The FDA is expected to make a decision by September on Otezla for psoriasis, a much larger market than psoriatic arthritis. ""We think that the psoriatic arthritis market will be a solid fit for Otezla given the dissatisfaction with current drugs,"" Cantor Fitzgerald analyst Mara Goldstein said in a research note. ""We think the drug has a good chance of widespread use.""Current treatments for the condition include corticosteroids and a class of injected biotech medicines known as tumor necrosis factor (TNF) blockers, such as AbbVie Inc's  Humira and Enbrel from Amgen Inc. The TNF blockers are highly effective but have more potentially serious side effects.As a condition of approval, the FDA is requiring a registry of pregnant women who use the drug so it can assess the risks to them related to Otezla exposure, the agency said.It also said Otezla patients should be monitored for potentially significant weight loss. If unexplained or clinically significant weight loss occurs, the weight loss should be evaluated and discontinuation of treatment should be considered, the FDA said.In clinical trials, the Celgene drug was also associated with an increase in reports of depression by a small percentage of patients.Celgene shares, which had been off as much as 4.6 percent amid a wider biotech selloff on Friday, recovered somewhat and closed down $5.61, or 3.7 percent, at $144.40 on Nasdaq.    (Reporting by Bill Berkrot; Editing by Tom Brown, Marguerita Choy and Peter Galloway)",2014-03-21,CELG,"Fri Mar 21, 2014 | 5:17pm EDT",UPDATE 2-U.S. FDA approves Celgene drug for psoriatic arthritis,http://www.reuters.com//article/celgene-fda-idUSL2N0MI1ED20140321?type=companyNews
4,"   By Bill Berkrot  U.S. health regulators on Friday approved a Celgene Corp drug to treat psoriatic arthritis, a type of arthritis associated with the skin disease psoriasis that causes joint pain, stiffness and swelling.The drug, known chemically as apremilast, will be sold under the brand name Otezla. It is also being studied by the U.S. biotechnology company as a treatment for psoriasis and ankylosing spondylitis.Celgene has projected Otezla sales of $1.5 billion to $2 billion by 2017.""We're cautious about achievability of management's guidance for this product,"" Sanford Bernstein analyst Geoffrey Porges said.""It's a highly competitive category and there are a lot of drugs with greater efficacy,"" added Porges, who is forecasting annual sales reaching $800 million by 2019. ""Relief of pain and inflammation and improving physical function are important treatment goals for patients with active psoriatic arthritis,"" Curtis Rosebraugh, director of the Food and Drug Administration Office of Drug Evaluation II, said in a statement.""Otezla provides a new treatment option for patients suffering from this disease,"" he added. The FDA is expected to make a decision by September on Otezla for psoriasis, a much larger market than psoriatic arthritis.""We think that the psoriatic arthritis market will be a solid fit for Otezla given the dissatisfaction with current drugs,"" Cantor Fitzgerald analyst Mara Goldstein said in a research note. ""We think the drug has a good chance of widespread use.""Current treatments for the condition include corticosteroids and a class of injected biotech medicines known as tumor necrosis factor (TNF) blockers, such as AbbVie Inc's big selling Humira and Remicade from Johnson & Johnson. The TNF blockers are highly effective but have more potential serious side effects. As a condition of approval, the FDA is requiring a registry of pregnant women who use the drug to assess the risks to pregnant women related to Otezla exposure, the agency said.It also said Otezla patients should be monitored for potentially significant weight loss. If unexplained or clinically significant weight loss occurs, the weight loss should be evaluated and discontinuation of treatment should be considered, the FDA said.Celgene shares, which had been off as much as 4.6 percent amid a wider biotech sell-off on Friday, recovered somewhat and were down 3.8 percent at $144.29 in afternoon trading on Nasdaq.(Reporting by Bill Berkrot; Editing by Tom Brown and Marguerita Choy)",2014-03-21,CELG,"Fri Mar 21, 2014 | 3:42pm EDT",FDA approves Celgene drug for psoriatic arthritis,http://www.reuters.com//article/us-celgene-fda-idUSBREA2K1PQ20140321?type=companyNews
5,"  March 21 U.S. health regulators on Friday approved a Celgene Corp drug to treat psoriatic arthritis, a type of arthritis associated with the skin disease psoriasis that causes joint pain, stiffness and swelling.The drug, known chemically a apremilast, will be sold under the brand name Otezla. It is also being studied by the U.S. biotechnology company as a treatment for psoriasis and ankylosing spondylitis.""Relief of pain and inflammation and improving physical function are important treatment goals for patients with active psoriatic arthritis,"" Curtis Rosebraugh, director of the Food and Drug Administration Office of Drug Evaluation II, said in a statement. ""Otezla provides a new treatment option for patients suffering from this disease,"" he added. As a condition of approval, the FDA is requiring a registry of pregnant women who use the drug to assess the risks to pregnant women related to Otezla exposure, the agency said. It also said Otezla patients should be monitored for potentially significant weight loss. If unexplained or clinically significant weight loss occurs, the weight loss should be evaluated and discontinuation of treatment should be considered, the FDA said.    (Reporting by Bill Berkrot; Editing by Tom Brown)",2014-03-21,CELG,"Fri Mar 21, 2014 | 2:28pm EDT",U.S. FDA approves Celgene drug for psoriatic arthritis,http://www.reuters.com//article/celgene-fda-idUSL2N0MI1BP20140321?type=companyNews
6,"   By Jonathan Stempel  Mylan Inc on Thursday sued Celgene Corp to stop the latter's effort to keep generic versions of two drugs that generate $4.5 billion of annual sales off the market.The lawsuit accuses Celgene of maintaining unlawful monopolies over Revlimid, which treats disorders caused by poorly formed blood cells; and Thalomid, which treats lesions associated with a variation of Hansen's Disease, or leprosy.Revlimid is a branded version of lenalidomide, and is a derivative of thalidomide, a drug introduced in the 1950s for which Thalomid is a branded version. Mylan said both drugs can cost more than $100,000 for a year's supply.In its lawsuit filed in the U.S. District Court in Newark, New Jersey, Mylan accused Celgene of using federal limits on the distribution of Revlimid and Thalomid, which were designed to promote the drugs' safety, as a pretext to keep generic drug makers from obtaining their own samples. Mylan said this prevents generic drug makers from conducting ""bioequivalence"" tests required by U.S. regulators before generic drugs can be launched.""The effect of Celgene's conduct is that no generic manufacturer, including Mylan, has been able to bring generic versions of Thalomid and/or Revlimid to market,"" Mylan said. ""Through its illegal actions, Celgene has foreclosed Mylan from even attempting to enter the market."" Greg Geissman, a Celgene spokesman, declined to comment. Celgene is based in Summit, New Jersey, and Mylan is based in Canonsburg, Pennsylvania.The lawsuit seeks to force Celgene to sell Mylan enough Revlimid and Thalomid at market prices to allow for bioequivalence testing. It also seeks compensation for Mylan's inability to sell generic versions of both, and triple damages. In a February 13 regulatory filing, Celgene said it sold $4.28 billion of Revlimid and $244.5 million of Thalomid in 2013, together accounting for nearly 70 percent of all revenue.Celgene also said its exclusive U.S. rights, whether through patents or primary regulatory approvals, to Revlimid and Thalomid expire in 2027 and 2023, respectively.The case is Mylan Pharmaceuticals Inc v. Celgene Corp, U.S. District Court, District of New Jersey, No. 14-02094.(Reporting by Jonathan Stempel in New York; editing by Andrew Hay)",2014-04-03,CELG,"Thu Apr 3, 2014 | 7:08pm EDT","Mylan sues Celgene for blocking Revlimid, Thalomid generics",http://www.reuters.com//article/us-celgene-mylan-lawsuit-idUSBREA322B520140403?type=companyNews
7,"   By Jonathan Stempel | April 3  April 3 Mylan Inc on Thursday sued Celgene Corp to stop the latter's effort to keep generic versions of two drugs that generate $4.5 billion of annual sales off the market.The lawsuit accuses Celgene of maintaining unlawful monopolies over Revlimid, which treats disorders caused by poorly formed blood cells; and Thalomid, which treats lesions associated with a variation of Hansen's Disease, or leprosy.Revlimid is a branded version of lenalidomide, and is a derivative of thalidomide, a drug introduced in the 1950s for which Thalomid is a branded version. Mylan said both drugs can cost more than $100,000 for a year's supply.In its lawsuit filed in the U.S. District Court in Newark, New Jersey, Mylan accused Celgene of using federal limits on the distribution of Revlimid and Thalomid, which were designed to promote the drugs' safety, as a pretext to keep generic drug makers from obtaining their own samples. Mylan said this prevents generic drug makers from conducting ""bioequivalence"" tests required by U.S. regulators before generic drugs can be launched.""The effect of Celgene's conduct is that no generic manufacturer, including Mylan, has been able to bring generic versions of Thalomid and/or Revlimid to market,"" Mylan said. ""Through its illegal actions, Celgene has foreclosed Mylan from even attempting to enter the market."" Greg Geissman, a Celgene spokesman, declined to comment. Celgene is based in Summit, New Jersey, and Mylan is based in Canonsburg, Pennsylvania.The lawsuit seeks to force Celgene to sell Mylan enough Revlimid and Thalomid at market prices to allow for bioequivalence testing. It also seeks compensation for Mylan's inability to sell generic versions of both, and triple damages. In a February 13 regulatory filing, Celgene said it sold $4.28 billion of Revlimid and $244.5 million of Thalomid in 2013, together accounting for nearly 70 percent of all revenue.Celgene also said its exclusive U.S. rights, whether through patents or primary regulatory approvals, to Revlimid and Thalomid expire in 2027 and 2023, respectively.The case is Mylan Pharmaceuticals Inc v. Celgene Corp, U.S. District Court, District of New Jersey, No. 14-02094.   (Reporting by Jonathan Stempel in New York; editing by Andrew Hay)",2014-04-03,CELG,"Thu Apr 3, 2014 | 6:57pm EDT","Mylan sues Celgene for blocking Revlimid, Thalomid generics",http://www.reuters.com//article/celgene-mylan-lawsuit-idUSL1N0MV2A820140403?type=companyNews
8,"  Celgene Corp (CELG.O) on Thursday reported a slightly higher-than-expected first-quarter profit on increased sales of its flagship multiple myeloma drug Revlimid and other oncology products.Excluding special items, Celgene had adjusted earnings of $1.67 per share, topping analysts' average expectations by 2 cents, according to Thomson Reuters I/B/E/S.Net profit fell due to higher research and development costs and increased expenses for launching Abraxane for pancreatic cancer and its new medicines for psoriatic arthritis and multiple myeloma, although the company maintained its full year forecasts as sales also increased.The U.S. biotechnology company posted a net profit of $280 million, or 66 cents per share, compared with a profit of $385 million, or 89 cents per share, a year earlier. Celgene said it continues to expect 2014 revenue of $7.5 billion and adjusted earnings of $7.00 to $7.20 per share. The company sees full-year Revlimid sales of $4.9 billion to $5.0 billion and Abraxane sales of $850 million to $900 million.Total sales for the quarter rose 19 percent to $1.71 billion, just shy of Wall Street estimates of $1.76 billion. Sales of Revlimid rose 14 percent to $1.14 billion for the quarter, which was about in line with Wall Street estimates.The company said it has filed for U.S. and European approval to use the medicine as a first line treatment for multiple myeloma, a label expansion that is widely viewed as the next big sales catalyst for the drug. Sales of Abraxane for breast, lung and pancreatic cancer rose 51 percent to $185 million, falling short of analysts' expectations of about $212 million.Separately, Celgene added to its pipeline of drugs in development by announcing a global license agreement with privately-held Nogra Pharma Ltd to develop and sell a drug for Crohn's disease and other indications. Celgene said it would begin Phase III trials of the drug by the end of this year.(Reporting by Bill Berkrot; Editing by Franklin Paul and Nick Zieminski)",2014-04-24,CELG,"Thu Apr 24, 2014 | 8:25am EDT",Celgene profit down but tops expectations; keeps forecast,http://www.reuters.com//article/us-celgene-results-idUSBREA3N13420140424?type=companyNews
9,"  (Adds outlook, sales and deal details)April 24 Celgene Corp on Thursday reported a slightly higher-than-expected first-quarter profit on increased sales of its flagship multiple myeloma drug Revlimid and other oncology products.Excluding special items, Celgene had adjusted earnings of $1.67 per share, topping analysts' average expectations by 2 cents, according to Thomson Reuters I/B/E/S.Net profit fell due to higher research and development costs and increased expenses for launching Abraxane for pancreatic cancer and its new medicines for psoriatic arthritis and multiple myeloma, although the company maintained its full year forecasts as sales also increased. The U.S. biotechnology company posted a net profit of $280 million, or 66 cents per share, compared with a profit of $385 million, or 89 cents per share, a year earlier.Celgene said it continues to expect 2014 revenue of $7.5 billion and adjusted earnings of $7.00 to $7.20 per share. The company sees full-year Revlimid sales of $4.9 billion to $5.0 billion and Abraxane sales of $850 million to $900 million. Total sales for the quarter rose 19 percent to $1.71 billion, just shy of Wall Street estimates of $1.76 billion.Sales of Revlimid rose 14 percent to $1.14 billion for the quarter, which was about in line with Wall Street estimates. The company said it has filed for U.S. and European approval to use the medicine as a first line treatment for multiple myeloma, a label expansion that is widely viewed as the next big sales catalyst for the drug.Sales of Abraxane for breast, lung and pancreatic cancer rose 51 percent to $185 million, falling short of analysts' expectations of about $212 million.Separately, Celgene added to its pipeline of drugs in development by announcing a global license agreement with privately-held Nogra Pharma Ltd to develop and sell a drug for Crohn's disease and other indications. Celgene said it would begin Phase III trials of the drug by the end of this year.    (Reporting by Bill Berkrot; Editing by Franklin Paul and Nick Zieminski)",2014-04-24,CELG,"Thu Apr 24, 2014 | 8:23am EDT",UPDATE 1-Celgene profit down but tops expectations; keeps forecast,http://www.reuters.com//article/celgene-results-idUSL2N0NG0M720140424?type=companyNews
10,"  Celgene Corp (CELG.O) on Thursday reported lower first quarter profit on higher research and development costs and increased expenses for launching new medicines, although the company maintained its full year forecasts as sales also increased.The U.S. biotechnology company posted a net profit of $280 million, or 66 cents per share, compared with a profit of $385 million, or 89 cents per share, a year earlier.Excluding special items, Celgene had adjusted earnings of $1.67 per share. Analysts on average expected $1.65, according to Thomson Reuters I/B/E/S. Sales of Celgene's flagship multiple myeloma treatment Revlimid rose 14 percent to $1.14 billion for the quarter, which was about in line with Wall Street estimates. The company said it has filed for U.S. and European approval to use the medicine as a first line treatment for multiple myeloma, a label expansion that is widely viewed as the next big sales catalyst for the drug. (Reporting by Bill Berkrot, Editing by Franklin Paul)",2014-04-24,CELG,"Thu Apr 24, 2014 | 7:58am EDT",Celgene first quarter profit falls on higher costs,http://www.reuters.com//article/us-celgene-results-idUSBREA3N10520140424?type=companyNews
11,"  April 24 Celgene Corp on Thursday reported lower first quarter profit on higher research and development costs and increased expenses for launching new medicines, although the company maintained its full year forecasts as sales also increased.The U.S. biotechnology company posted a net profit of $280 million, or 66 cents per share, compared with a profit of $385 million, or 89 cents per share, a year earlier.Excluding special items, Celgene had adjusted earnings of $1.67 per share. Analysts on average expected $1.65, according to Thomson Reuters I/B/E/S. Sales of Celgene's flagship multiple myeloma treatment Revlimid rose 14 percent to $1.14 billion for the quarter, which was about in line with Wall Street estimates. The company said it has filed for U.S. and European approval to use the medicine as a first line treatment for multiple myeloma, a label expansion that is widely viewed as the next big sales catalyst for the drug. (Reporting by Bill Berkrot, Editing by Franklin Paul)",2014-04-24,CELG,"Thu Apr 24, 2014 | 7:58am EDT",Celgene first quarter profit falls on higher costs,http://www.reuters.com//article/celgene-results-idUSL2N0NF1O820140424?type=companyNews
12,"  Celgene Corp said a drug being tested to treat a type of arthritis that affects the spine failed to meet the main goal in a late-stage trial, sending the company's shares down 3 percent premarket.The drug, Otezla, failed to show improvement of at least 20 percent at week 16 when tested on patients with ankylosing spondylitis, or arthritis of the spine, compared to those on a placebo, the company said. [ID:nBw6S6bVra] The company said an analysis of the data showed ""meaningful efficacy"" in a large subset of patients with early-stage disease at week 24.Celgene said it would continue the study unchanged based on a recommendation by an independent data monitoring committee. The drugmaker also said it planned to start another late-stage trial for further data analysis.Otezla is already approved by U.S. health regulators for treatment of adults with active psoriatic arthritis and is being studied for use in psoriasis and other indications including Behcet's disease and Crohn's disease. [ID:nL2N0MI1ED]  Ankylosing spondylitis affects the joints in the spine and the pelvis. It can cause rigidity in the vertebrae that may result in a hunch-forward posture. The company's shares were trading at $84.31 before the bell after closing at $85.72 on the Nasdaq on Tuesday.  (Reporting By Penumudi Amrutha; Editing by Sriraj Kalluvila)",2014-07-09,CELG,"Wed Jul 9, 2014 | 9:06am EDT",Celgene's spondylitis drug misses main goal in trial,http://www.reuters.com//article/us-celgene-study-idUSKBN0FE15120140709?type=companyNews
13,"  (Adds details, background)July 9 Celgene Corp said a drug being tested to treat a type of arthritis that affects the spine failed to meet the main goal in a late-stage trial, sending the company's shares down 3 percent premarket.The drug, Otezla, failed to show improvement of at least 20 percent at week 16 when tested on patients with ankylosing spondylitis, or arthritis of the spine, compared to those on a placebo, the company said.The company said an analysis of the data showed ""meaningful efficacy"" in a large subset of patients with early-stage disease at week 24. Celgene said it would continue the study unchanged based on a recommendation by an independent data monitoring committee. The drugmaker also said it planned to start another late-stage trial for further data analysis.Otezla is already approved by U.S. health regulators for treatment of adults with active psoriatic arthritis and is being studied for use in psoriasis and other indications including Behcet's disease and Crohn's disease. Ankylosing spondylitis affects the joints in the spine and the pelvis. It can cause rigidity in the vertebrae that may result in a hunch-forward posture.The company's shares were trading at $84.31 before the bell after closing at $85.72 on the Nasdaq on Tuesday.    (Reporting By Penumudi Amrutha; Editing by Sriraj Kalluvila)",2014-07-09,CELG,"Wed Jul 9, 2014 | 9:00am EDT",UPDATE 1-Celgene's spondylitis drug misses main goal in trial,http://www.reuters.com//article/celgene-study-idUSL4N0PK3CU20140709?type=companyNews
14,"  July 9 Celgene Corp said its experimental drug for the treatment of a type of arthritis that affects the spine failed to meet the main goal in a late-stage study, sending its shares down 3 percent premarket.Patients suffering from ankylosing spondylitis who were treated with the drug, Otezla, failed to show statistically significant response compared to those on a placebo, the company said.  However, an independent data monitoring committee recommended that the study should continue unchanged.   (Reporting By Penumudi Amrutha; Editing by Sriraj Kalluvila) ",2014-07-09,CELG,"Wed Jul 9, 2014 | 7:28am EDT",Celgene spondylitis drug misses main goal in late-stage study,http://www.reuters.com//article/celgene-study-idUSL4N0PK39720140709?type=companyNews
15,"   By Kate Kelland | LONDON  LONDON An anti-cancer drug made by the U.S. biotech firm Celgene can re-activate hidden HIV in patients so that it can be detected, bringing researchers closer to being able to treat it, Danish scientists said on Tuesday.In a small study presented at an international AIDS conference in Australia, the researchers said the finding was a ""step in the right direction"" toward finding a cure for the viral disease but that many years of research are still needed.""There is still a long way to go and many obstacles to overcome before we can start talking about a cure against HIV,"" said Ole Schmeltz Sogaard, who led the research team from Aarhus University and Aarhus University Hospital in Denmark, in a statement.The drug, known generically as romidepsin and under the brand name Istodax, is licensed to treat a type of cancer called T-cell lymphoma. In this study, however, it was investigated as a potential HIV therapy.Human immunodeficiency virus (HIV) infection can be kept at very low levels by anti-AIDS drugs, but there is still no cure that can eradicate HIV from the body.  Some 35 million people worldwide are infected with HIV, and the global AIDS epidemic has killed 39 million since it began in the 1980s, according to the latest data from the United Nations AIDS program, UNAIDS. Scientists working to find a cure know the virus can hide in a state of hibernation in cells called CD4 cells, which are part of the body's immune system.CD4 cells cannot fight the AIDS virus themselves, but killer T-cells can if they are able to tell whether or not a CD4 cell contains the hibernating HIV.      Sharon Lewin, co-chair of the AIDS2014 conference in Melbourne Australia and a professor of infectious diseases who was not directly involved in this study, said the results of the study were significant and encouraging because they showed ""we can wake up the virus reservoir and make enough of (it) to leave the cell, making it visible to an immune response"".The Danish team gave three once-weekly infusions of romidepsin to six HIV-positive adult patients who were already taking antiretroviral AIDS drugs and whose so-called ""viral load"" was undetectable.They found that romidepsin increased the virus production in HIV-infected cells between 2.1 and 3.9 times above normal and that the viral load in the blood increased to measurable levels in five out of six patients. ""We have now shown that we can activate a hibernating virus with romidepsin and that the activated virus moves into the bloodstream in large amounts,"" Schmeltz Sogaard said in a statement about the results.When the virus is activated and moves toward the bloodstream it leaves a trace on the outside of the infected CD4 cells, he explained. In principle, this means killer T-cells would be able to trace and destroy the HIV-infected CD4 cells.The Danish team said the next step is a larger trial where the researchers will combine romidepsin activation of hidden HIV with an experimental vaccine called Vacc-4x being developed by  the Norwegian biotech firm Bionor Pharma to strengthen the ability of T-cells to fight HIV. (editing by Jane Baird)",2014-07-22,CELG,"Tue Jul 22, 2014 | 8:44am EDT",Celgene drug can drive HIV out of hiding: study,http://www.reuters.com//article/us-health-aids-virus-idUSKBN0FR1AC20140722?type=companyNews
16,"  * Activating hidden virus means it could be detected* Scientists say finding is significant step in AIDS fight* Next step to study Celgene drug with experimental vaccineBy Kate KellandLONDON, July 22 An anti-cancer drug made by the U.S. biotech firm Celgene can re-activate hidden HIV in patients so that it can be detected, bringing researchers closer to being able to treat it, Danish scientists said on Tuesday.In a small study presented at an international AIDS conference in Australia, the researchers said the finding was a ""step in the right direction"" towards finding a cure for the viral disease but that many years of research are still needed.""There is still a long way to go and many obstacles to overcome before we can start talking about a cure against HIV,"" said Ole Schmeltz Sogaard, who led the research team from Aarhus University and Aarhus University Hospital in Denmark, in a statement. The drug, known generically as romidepsin and under the brand name Istodax, is licensed to treat a type of cancer called T-cell lymphoma. In this study, however, it was investigated as a potential HIV therapy.Human immunodeficiency virus (HIV) infection can be kept at very low levels by anti-AIDS drugs, but there is still no cure that can eradicate HIV from the body.Some 35 million people worldwide are infected with HIV, and the global AIDS epidemic has killed 39 million since it began in the 1980s, according to the latest data from the United Nations AIDS program, UNAIDS. Scientists working to find a cure know the virus can hide in a state of hibernation in cells called CD4 cells, which are part of the body's immune system.CD4 cells cannot fight the AIDS virus themselves, but killer T-cells can if they are able to tell whether or not a CD4 cell contains the hibernating HIV.Sharon Lewin, co-chair of the AIDS2014 conference in Melbourne Australia and a professor of infectious diseases who was not directly involved in this study, said the results of the study were significant and encouraging because they showed ""we can wake up the virus reservoir and make enough of (it) to leave the cell, making it visible to an immune response"". The Danish team gave three once-weekly infusions of romidepsin to six HIV-positive adult patients who were already taking antiretroviral AIDS drugs and whose so-called ""viral load"" was undetectable.They found that romidepsin increased the virus production in HIV-infected cells between 2.1 and 3.9 times above normal and that the viral load in the blood increased to measurable levels in five out of six patients.""We have now shown that we can activate a hibernating virus with romidepsin and that the activated virus moves into the bloodstream in large amounts,"" Schmeltz Sogaard said in a statement about the results.When the virus is activated and moves towards the bloodstream it leaves a trace on the outside of the infected CD4 cells, he explained. In principle, this means killer T-cells would be able to trace and destroy the HIV-infected CD4 cells.The Danish team said the next step is a larger trial where the researchers will combine romidepsin activation of hidden HIV with an experimental vaccine called Vacc-4x being developed by  the Norwegian biotech firm Bionor Pharma to strengthen the ability of T-cells to fight HIV.   (editing by Jane Baird)",2014-07-22,CELG,"Tue Jul 22, 2014 | 12:30am EDT",Celgene drug can drive HIV out of hiding -study,http://www.reuters.com//article/health-aids-virus-idUSL6N0PW46L20140722?type=companyNews
17,"   By Bill Berkrot  Celgene Corp (CELG.O) reported a 25 percent rise in second-quarter profit, edging out Wall Street expectations, but a raised 2014 forecast failed to excite investors and its shares fell nearly 4 percent.The U.S. biotechnology company said it now expects full-year adjusted earnings of $3.60 to $3.65 per share and revenue of  $7.60 billion. It had previously forecast earnings of $3.50 to $3.60 per share and revenue of $7.50 billion.""They beat by a penny and raised guidance but only met consensus (expectation), which was already above management's projections,"" said RBC Capital Markets analyst Michael Yee. ""So lots of biotech investors are continuing to flock to Gilead and Biogen, which have more near-term earnings upside and catalysts coming.""Gilead Sciences Inc (GILD.O) and Biogen Idec Inc (BIIB.O) on Wednesday both crushed Wall Street earnings expectations as Gilead's new hepatitis drug Sovaldi racked up a stunning $3.5 billion in second-quarter sales and Biogen's multiple sclerosis drug Tecfidera continued one of the most impressive new drug launches overshadowed only by Sovaldi. ""Celgene was fine but disappointed the bulls after a big recent stock run to its all time highs,"" said Yee.Celgene, which is expected to have several potential catalysts for share increases in 2015, had seen its shares rise nearly 30 percent since early April. Net profit rose to $597.8 million, or 72 cents per share,  from $478.1 million, or 56 cents per share, a year earlier, driven by increased duration of therapy for the company's flagship cancer drug Revlimid. Its sales rose 15 percent to $1.21 billion for the quarter.Excluding special items, Celgene earned 90 cents per share, topping analysts' average expectations by a penny, according to Thomson Reuters I/B/E/S.The next big catalyst for Revlimid will be a U.S. Food and Drug Administration decision expected in February on whether the drug can be used as a first-line, or initial, therapy for multiple myeloma rather than after a prior treatment has failed.  Sales of Abraxane for breast, lung and pancreatic cancer jumped 39 percent to $215 million. The company expects full-year Revlimid sales of $4.95 billion and Abraxane sales of $850 million to $900 million.Total revenue rose 17 percent to $1.87 billion. Celgene's Otezla for psoriatic arthritis had just $5 million in sales in its first quarter as most new patients began therapy with free samples, the company said. ""We are highly confident in our forecast for Otezla sales in the second half and beyond,"" Chief Financial Officer Jacqualyn Fouse said on a conference call.Celgene has forecast annual Otezla sales reaching $1.5 billion to $2 billion by 2017.It said Otezla sales in July would exceed second-quarter sales, and it could win expanded U.S. approval in September for  psoriasis.Celgene shares were down $3.36, or 3.7 percent, at $85.75. (Additional reporting by Anand Basu in Bangalore; Editing by Maju Samuel and James Dalgleish)",2014-07-24,CELG,"Thu Jul 24, 2014 | 12:03pm EDT",Celgene profit rises but revised outlook disappoints,http://www.reuters.com//article/us-celgene-results-idUSKBN0FT25820140724?type=companyNews
18,"  * Second-quarter adjusted EPS $0.90 vs Street view $0.89* Raises 2014 revenue, adjusted earnings-per-share forecast* Shares down 3.7 percent   (Adds analyst, company comment, share move)By Bill BerkrotJuly 24 Celgene Corp reported a 25 percent rise in second-quarter profit, edging out Wall Street expectations, but a raised 2014 forecast failed to excite investors and its shares fell nearly 4 percent.The U.S. biotechnology company said it now expects full-year adjusted earnings of $3.60 to $3.65 per share and revenue of  $7.60 billion. It had previously forecast earnings of $3.50 to $3.60 per share and revenue of $7.50 billion.""They beat by a penny and raised guidance but only met consensus (expectation), which was already above management's projections,"" said RBC Capital Markets analyst Michael Yee. ""So lots of biotech investors are continuing to flock to Gilead and Biogen, which have more near-term earnings upside and catalysts coming.""Gilead Sciences Inc and Biogen Idec Inc on Wednesday both crushed Wall Street earnings expectations as Gilead's new hepatitis drug Sovaldi racked up a stunning $3.5 billion in second-quarter sales and Biogen's multiple sclerosis drug Tecfidera continued one of the most impressive new drug launches overshadowed only by Sovaldi. ""Celgene was fine but disappointed the bulls after a big recent stock run to its all time highs,"" said Yee.Celgene, which is expected to have several potential catalysts for share increases in 2015, had seen its shares rise nearly 30 percent since early April.Net profit rose to $597.8 million, or 72 cents per share,  from $478.1 million, or 56 cents per share, a year earlier, driven by increased duration of therapy for the company's flagship cancer drug Revlimid. Its sales rose 15 percent to $1.21 billion for the quarter. Excluding special items, Celgene earned 90 cents per share, topping analysts' average expectations by a penny, according to Thomson Reuters I/B/E/S.The next big catalyst for Revlimid will be a U.S. Food and Drug Administration decision expected in February on whether the drug can be used as a first-line, or initial, therapy for multiple myeloma rather than after a prior treatment has failed.Sales of Abraxane for breast, lung and pancreatic cancer jumped 39 percent to $215 million.The company expects full-year Revlimid sales of $4.95 billion and Abraxane sales of $850 million to $900 million. Total revenue rose 17 percent to $1.87 billion.Celgene's Otezla for psoriatic arthritis had just $5 million in sales in its first quarter as most new patients began therapy with free samples, the company said.""We are highly confident in our forecast for Otezla sales in the second half and beyond,"" Chief Financial Officer Jacqualyn Fouse said on a conference call.Celgene has forecast annual Otezla sales reaching $1.5 billion to $2 billion by 2017.It said Otezla sales in July would exceed second-quarter sales, and it could win expanded U.S. approval in September for  psoriasis.Celgene shares were down $3.36, or 3.7 percent, at $85.75.   (Additional reporting by Anand Basu in Bangalore; Editing by Maju Samuel and James Dalgleish)",2014-07-24,CELG,"Thu Jul 24, 2014 | 12:01pm EDT",UPDATE 2-Celgene profit rises but revised outlook disappoints,http://www.reuters.com//article/celgene-results-idUSL4N0PZ4JM20140724?type=companyNews
19,"  July 24 Celgene Corp reported a 25 percent increase in quarterly profit, helped by robust sales of its flagship cancer drug, Revlimid.The U.S. biotechnology company's net profit rose to $597.8 million, or 72 cents per share, in the second quarter ended June 30, from $478.1 million, or 56 cents per share, a year earlier. Excluding special items, it earned 90 cents per share. Total revenue rose 17 percent to $1.87 billion. Sales of multiple myeloma treatment Revlimid rose 15 percent to $1.21 billion.   (Reporting by Anand Basu in Bangalore; Editing by Maju Samuel)",2014-07-24,CELG,"Thu Jul 24, 2014 | 7:50am EDT",Celgene profit rises 25 pct up on higher cancer drug sales,http://www.reuters.com//article/celgene-results-idUSL4N0PX50H20140724?type=companyNews
20,"  LONDON Celgene's drug Revlimid should be an option on Britain's state health service for patients with serious bone marrow disorders and a specific chromosomal abnormality, the country's cost agency said on Wednesday.The final draft guidance from the National Institute for Health and Care Excellence (NICE) represents a change of tack after the medicine was rejected last year for treating myelodysplastic syndromes, which can lead to life-threatening diseases including leukaemia.The latest decision follows the submission of revised analyses from Celgene and further information on the company's proposal to limit the cost of the drug. Celgene has agreed to provide Revlimid free of charge for anyone who needs more than 26 monthly cycles of treatment.   The draft guidance is now open for consultation before NICE issues final guidance.   (Reporting by Ben Hirschler; Editing by Pravin Char)",2014-08-19,CELG,"Tue Aug 19, 2014 | 7:03pm EDT",UK cost agency backs Celgene bone marrow drug in change of tack,http://www.reuters.com//article/us-celgene-britain-idUSKBN0GJ2AX20140819?type=companyNews
21,"  LONDON Aug 20 Celgene's drug Revlimid should be an option on Britain's state health service for patients with serious bone marrow disorders and a specific chromosomal abnormality, the country's cost agency said on Wednesday.The final draft guidance from the National Institute for Health and Care Excellence (NICE) represents a change of tack after the medicine was rejected last year for treating myelodysplastic syndromes, which can lead to life-threatening diseases including leukaemia. The latest decision follows the submission of revised analyses from Celgene and further information on the company's proposal to limit the cost of the drug. Celgene has agreed to provide Revlimid free of charge for anyone who needs more than 26 monthly cycles of treatment. The draft guidance is now open for consultation before NICE issues final guidance. (Reporting by Ben Hirschler; Editing by Pravin Char)",2014-08-19,CELG,"Tue Aug 19, 2014 | 7:01pm EDT",UK cost agency backs Celgene bone marrow drug in change of tack,http://www.reuters.com//article/celgene-britain-idUSL5N0QP3D720140819?type=companyNews
22,"  Celgene Corp said the U.S. Food and Drugs Administration has approved the expanded use of its drug Otezla for treating patients with moderate to severe plaque psoriasis.The drug, known chemically as apremilast, is already approved for treating psoriatic arthritis, a type of arthritis associated with the skin disease.The drug is also being studied as a potential treatment for a type of spondylitis.Celgene forecast in March annual Otezla sales of $1.5 billion to $2 billion by 2017.  Psoriasis is a chronic inflammatory disease of the skin resulting from an uncontrolled immune response. Shares of Celgene closed at $93.12 Tuesday on the Nasdaq.  (Reporting by Shailesh Kuber in Bangalore; Editing by Don Sebastian)",2014-09-23,CELG,"Tue Sep 23, 2014 | 5:40pm EDT",Celgene's psoriasis drug gets approval for new indication,http://www.reuters.com//article/us-celgene-fda-approval-idUSKCN0HI2DR20140923?type=companyNews
23,"  (adds background)  (Adds details)Sept 23 Celgene Corp said the U.S. Food and Drugs Administration has approved the expanded use of its drug Otezla for treating patients with moderate to severe plaque psoriasis.The drug, known chemically as apremilast, is already approved for treating psoriatic arthritis, a type of arthritis associated with the skin disease. The drug is also being studied as a potential treatment for a type of spondylitis. Celgene forecast in March annual Otezla sales of $1.5 billion to $2 billion by 2017. Psoriasis is a chronic inflammatory disease of the skin resulting from an uncontrolled immune response.Shares of Celgene closed at $93.12 Tuesday on the Nasdaq.   (Reporting by Shailesh Kuber in Bangalore; Editing by Don Sebastian)",2014-09-23,CELG,"Tue Sep 23, 2014 | 5:20pm EDT",UPDATE 1-Celgene's psoriasis drug gets approval for new indication,http://www.reuters.com//article/celgene-fda-approval-idUSL3N0RO52Y20140923?type=companyNews
24,"  Sept 23 Celgene Corp said U.S. health regulators have approved the expanded use of its drug Otezla for treating patients with moderate to severe plaque psoriasis. The drug, known chemically as apremilast, is already approved for treating psoriatic arthritis, a type of arthritis associated with the skin disease.    (Reporting by Shailesh Kuber in Bangalore; Editing by Don Sebastian)  ",2014-09-23,CELG,"Tue Sep 23, 2014 | 4:11pm EDT",Celgene's psoriasis drug gets approval for new indication,http://www.reuters.com//article/celgene-fda-approval-idUSL3N0RO4Z720140923?type=companyNews
25,"   By Bill Berkrot  Celgene Corp (CELG.O) on Thursday reported third-quarter profit rose 37 percent on a double-digit rise in sales of its flagship multiple myeloma drug Revlimid, and the U.S. biotechnology company expressed great confidence in a closely-watched treatment for Crohn's disease it recently acquired.Celgene shares jumped 5 percent after the company said it was finalizing plans to move the Crohn's drug, GED-301, into Phase III trials following a presentation at a medical meeting this week of midstage data that showed high and durable remission rates.RBC Capital Markets analyst Michael Yee called the data ""strikingly positive"" and said the company's comments gave investors a lot of confidence in the drug.""It could be a multibillion-dollar opportunity,"" he said.Celgene also raised its full-year adjusted earnings forecast by five cents and now expects $3.65 to $3.70 per share. It also now sees 2014 revenue exceeding its previous forecast of $7.60 billion.Revlimid sales increased 19 percent to $1.3 billion as patients were using the medicine for a longer duration. Analysts  were looking for sales of $1.26 billion.  A U.S. Food and Drug Administration decision is expected in February on whether Revlimid can be used as an initial therapy rather than after a prior treatment has failed, which would boost sales. A similar decision pending in Europe is expected in the first half of next year, Celgene said.The company also plans to present data in December with an eye toward significantly increasing the number of patients eligible to receive Revlimid for the blood disorder myelodysplastic syndromes.Celgene said net profit rose to $508 million, or 61 cents per share, from $372 million, or 43 cents per share on a stock split adjusted basis, a year ago.Excluding one-time items, Celgene earned 97 cents a share, exceeding the average analysts' estimate by 2 cents, according to Thomson Reuters I/B/E/S. Revenue totaled $1.98 billion, versus the Wall Street estimate of $1.96 billion.Sales of Abraxane for breast, lung and pancreatic cancer of $212 million fell short of analysts' estimates of $232 million. Celgene said U.S. sales were hurt by competition in breast cancer, but expects pancreatic sales to rise in Europe as the launch there accelerates.The company expects full-year Revlimid sales to slightly exceed $4.95 billion and Abraxane sales to reach $850 million. Celgene's newer multiple myeloma drug Pomalyst had sales of $181 million for the quarter, topping Wall Street estimates of $176 million.""Revlimid and Pomalyst were particularly strong,"" Cowen and Co analyst Eric Schmidt said.Psoriatic arthritis drug Otezla had sales of just $18 million in its first full quarter. A September U.S. approval of Otezla for the skin condition psoriasis, which has a far larger patient population than the related arthritic condition, should help jumpstart sales of the new medicine.Celgene shares rose $5.00, or 5.2 percent, to $98.73 on Nasdaq. (Reporting by Bill Berkrot in New York; Editing by W Simon, Chizu Nomiyama, Jeffrey Benkoe and Andrew Hay)",2014-10-23,CELG,"Thu Oct 23, 2014 | 11:50am EDT",Celgene profit jumps 37 percent; set to move Crohn's drug forward,http://www.reuters.com//article/us-celgene-results-idUSKCN0IC1HZ20141023?type=companyNews
26,"  (Adds analyst comment, sales details, share move)Oct 23 U.S. biotechnology company Celgene Corp  on Thursday reported third-quarter profit rose 37 percent on a double-digit jump in sales of its flagship multiple myeloma drug Revlimid, and raised its full-year earnings forecast.Revlimid sales increased 19 percent to $1.3 billion as patients were using the medicine for a longer duration. Analysts  looked for sales of $1.26 billion.A U.S. Food and Drug Administration decision is expected in February on whether Revlimid can be used as a first-line, or initial, therapy rather than after a prior treatment has failed and could significantly boost sales next year.The company now expects 2014 earnings, excluding items, of $3.65 to $3.70 per share, up from $3.60 to $3.65 per share. It forecast full-year revenue exceeding its previous forecast of $7.60 billion. Celgene posted net profit jumped to $508 million, or 61 cents per share, from $372 million, or 43 cents per share on a stock split adjusted basis, a year ago.Excluding one-time items, Celgene earned 97 cents a share, exceeding the average analyst estimate by 2 cents, according to Thomson Reuters I/B/E/S.""Overall the numbers were good, a couple pennies above expectations with a little boost to the guidance. It's ho hum, but solid,"" said Cowen and Co analyst Eric Schmidt. Revenue totaled $1.98 billion, versus the Wall Street estimate of $1.96 billion.Sales of Abraxane for breast, lung and pancreatic cancer rose 25 percent to $212 million, but shy of analysts' estimates of $232 million. The company expects full-year Revlimid sales to slightly exceed $4.95 billion and Abraxane sales to reach $850 million.Celgene's newer multiple myeloma drug Pomalyst had sales of $181 million for the quarter, topping Wall Street estimates of $176 million. But its newest drug, Otezla, for psoriatic arthritis posted sales of just $18 million.""Revlimid and Pomalyst were particularly strong. Otezla is having a difficult time getting some traction,"" Schmidt said.Celgene shares rose 0.6 percent to $95.39 in premarket trading.   (Reporting by Bill Berkrot in New York; Editing by W Simon, Chizu Nomiyama and Jeffrey Benkoe)",2014-10-23,CELG,"Thu Oct 23, 2014 | 8:55am EDT","UPDATE 2-Celgene 3rd-quarter profit jumps 37 pct, tops forecast",http://www.reuters.com//article/celgene-results-idUSL2N0SI0PM20141023?type=companyNews
27,"  Oct 23 Celgene Corp on Thursday reported third quarter profit rose 37 percent on increased sales of its flagship multiple myeloma medicine Revlimid and strong demand for its other drugs, and the U.S. biotechnology company raised its full-year earnings  forecast.Celgene posted a net profit of $508 million, or 61 cents per share, compared with a profit of $372 million, or 43 cents per share on a stock split adjusted basis, a year ago. Excluding one time items, Celgene earned 97 cents a share.   Analysts on average expected 95 cents, according to Thomson Reuters I/B/E/S.  The company now expects 2014 earnings, excluding items, of $3.65 to $3.70 per share, up from its prior view of $3.60 to $3.65 per share. It said revenue for the full year is now expected to exceed its previous forecast of $7.6 billion.   (Reporting by Bill Berkrot Editing by W Simon)",2014-10-23,CELG,"Thu Oct 23, 2014 | 7:46am EDT",Celgene 3rd quarter profit up 37 percent; edges above forecast,http://www.reuters.com//article/celgene-results-idUSL2N0SH2XS20141023?type=companyNews
28,"  (Removes item on Canadian Solar, which was based on an erroneous report. The error also appeared in previous versions of U.S. Stocks on the move)Dec 8 - (For faster updates on individual market-movers, Eikon users please use search string ""STXBZ US""; for the Day Ahead newsletter, link.reuters.com/mex49s; for the Morning News Call newsletter, link.reuters.com/nex49s)   U.S. stocks dipped on Monday, after soft data in China and Japan raised global growth concerns, while a further drop in oil prices weighed on energy shares. The Dow Jones industrial average was down 0.05 percent at 17,949.84, the S&P 500  was down 0.04 percent at 2,074.5 and the Nasdaq Composite  was up 0.13 percent at $4,787.06.** MCDONALD'S CORP, $92.86, -3.58 pctMcDonald's reported a steeper-than-expected fall in global same-restaurant sales in November and said current-quarter results would be hurt by the after-effects of a supplier scandal in China and a stronger dollar.** MERCK & CO INC, $61.48, -0.02 pct** CUBIST PHARMACEUTICALS INC, $100.69, +35.41 pctMerck said on Monday it would buy Cubist for $8.4 billion plus assumption of debt, giving the major drugmaker an entry into the market for drugs that target so-called superbugs.** BIOLINE RX LTD, $1.66, +12.16 pct** CELGENE CORP, $118.81, +4.10 pctBioLine's blood cancer drug and Celgene's thalassemia drug showed promise in mid-stage studies, the companies said in separate presentations at the American Society of Hematology conference. BioLine's drug, BL-8040, was tested for safety and efficacy in treating patients with acute myeloid leukemia, a type of blood cancer. UBS Investment Research raised its price target on Celgene's stock to $131 from $112, while Cantor Fitzgerald raised it to $130 from $120.** CLUBCORP HOLDINGS INC, $18.36, -7.79 pctThe golf and country club operator said conversion to a real estate investment trust (REIT) is ""not a viable option today. Shareholders Red Alder LLC and ADW Capital Partners LP had asked the company in September to convert into REIT and spin off non-real estate assets. ClubCorp said it had considered other hybrid-REIT structures, but financial and operational risks outweighed the limited tax benefits and uncertain valuation benefits of such conversions. ** DELIA*S INC, $0.0208, +10.05 pctThe teen apparel retailer filed for Chapter 11 bankruptcy protection and said it had hired advisers to help liquidate its assets.** HALCON RESOURCES CORP, $1.57, -10.29 pct** GOODRICH PETROLEUM CORP, $3.37, -9.16 pct** ENERGY XXI LTD, $2.975, -9.30 pct** SANCHEZ ENERGY CORP, $7.72, -11.57 pctBMO Capital Markets cut its ratings and price targets on several oil and gas producers, saying the companies might need to cut capital spending, which would potentially curtail growth and increase debt. ** PRECISION DRILLING CORP ; $5.46, -8.70 pctCanada's largest drilling contractor said it expected 2015 capital spending to be 44 percent lower than this year's already lowered budget as a steep fall in oil prices threaten to render exploration and development project uneconomic.** CONOCOPHILLIPS, $65.58, -3.35 pctConocoPhillips said it would cut its 2015 capital budget by 20 percent, or about $3 billion, compared with this year, marking the biggest spending cut by a U.S. oil and gas company in dollar terms as global oil prices hit five-year lows.** HANWHA SOLARONE CO LTD, $1.53, -5.56 pct The solar power company said it will buy Germany-based affiliate Q Cell Investment Co Ltd in a deal valued at about $1.2 billion to avoid U.S. tariffs on China-made products.** INFOSYS LTD,$32.27, -4.14 pctSome of the founders of Infosys Ltd sold shares worth $1.1 billion in India's second-largest IT services exporter on Monday, cashing in on a more than 20 percent gain in the stock since the company picked its first outsider as chief executive.The shares were sold by N.R. Narayana Murthy, Nandan Nilekani, S.D. Shibulal and K. Dinesh, members a group of seven engineers who founded Infosys in 1981 by pooling together $250, stock market filings showed.** TASER INTERNATIONAL INC, $23.29, -6.16 pctLadenburg cut its rating on the stun-gun maker's stock to ""neutral"" from ""buy"", according to Theflyonthewall.com.** AMGEN INC, $172.37, +1.85 pctNovartis said its copycat version of Amgen's Neupogen for patients with low white blood cell counts works as well as the original drug in a late-stage trial.Separately, the top U.S. patent appeals court has upheld the dismissal of a lawsuit brought by Sandoz Inc that sought to shield its planned version of Amgen's psoriasis and arthritis drug Enbrel from patent lawsuits.** BLACKBERRY LTD, $10.86, +1.69 pctThe Canadian smartphone maker and NantHealth, a healthcare-focused data provider, launched a secure cancer genome browser on Sunday, giving doctors the ability to access patients' genetic data on the BlackBerry Passport smartphone.     (Compiled by Sneha Banerjee in Bengaluru; Editing by Simon Jennings and Joyjeet Das)",2014-12-08,CELG,"Mon Dec 8, 2014 | 2:44pm EST","CORRECTED-BUZZ-U.S. Stocks on the Move-McDonald's, Taser, ClubCorp, Celgene",http://www.reuters.com//article/markets-usa-stocks-pulse-idUSL3N0TS4DK20141208?type=companyNews
29,"   By Bill Berkrot  Celgene Corp (CELG.O) on Thursday said early first quarter sales trends indicate the year is off to a strong start, and that it has growth drivers in place to meet or exceed its 2015 and long- term forecasts.Earlier this month, the U.S. biotechnology company issued a 2020 forecast that called for revenue to exceed $20 billion, up from $7.56 billion in 2014.On a conference call with analysts on Thursday, Celgene said it expects $17 billion of that to come from existing products, such as its flagship multiple myeloma drug Revlimid and Abraxane for breast, lung and pancreatic cancer.The remaining sales would come from label expansions of current medicines and six new product introductions, such as a high profile treatment for Crohn's disease. The company noted that not all the new programs have to be successful to reach that $3 billion sales target.""We are confident that key growth drivers exist to meet or exceed 2015 and longer term forecasts,"" Chief Operating Officer Mark Alles said.  Jackie Fouse, head of hematology and oncology, said Abraxane was becoming the standard of care for pancreatic cancer in the United States.Combinations of Abraxane with a variety of highly promising new drugs that spur the immune system to fight cancer, currently being tested, were not included in any sales forecasts, said Fouse. ""That's upside potential that we have.""Celgene is awaiting U.S. and European approvals this year for use of Revlimid for newly diagnosed multiple myeloma patients rather than just after prior treatment has failed, which should help increase sales. In addition, Fouse said the company has received reimbursement approval for Revlimid in Russia and anticipates  pricing approval in Mexico.The company also expressed confidence that its newer multiple myeloma drug, Pomalyst, would become a multibillion-dollar drug. Celgene targeted 2017 sales of $1.5 billion, up from 2014 sales of $690 million. Celgene posted $47 million in fourth quarter sales of Otezla, its new drug for psoriatic arthritis and psoriasis, and said new prescriptions accelerated significantly since the September U.S. psoriasis approval.The company is looking at Otezla launches in U.K., Germany and Nordic countries in early 2015, followed by launches in other European markets the same year. It is eyeing an approval in Japan in 2016.Celgene also announced plans to initiate eight Phase I clinical programs in 2015 as it advances drugs in its early stage pipeline. (Reporting by Bill Berkrot; editing by Gunna Dickson)",2015-01-29,CELG,"Thu Jan 29, 2015 | 11:54am EST",Celgene says 2015 off to strong start; key growth drivers in place,http://www.reuters.com//article/us-celgene-outlook-idUSKBN0L224120150129?type=companyNews
30,"   By Bill Berkrot  Jan 29 Celgene Corp on Thursday said early first quarter sales trends indicate the year is off to a strong start, and that it has growth drivers in place to meet or exceed its 2015 and long- term forecasts.Earlier this month, the U.S. biotechnology company issued a 2020 forecast that called for revenue to exceed $20 billion, up from $7.56 billion in 2014.On a conference call with analysts on Thursday, Celgene said it expects $17 billion of that to come from existing products, such as its flagship multiple myeloma drug Revlimid and Abraxane for breast, lung and pancreatic cancer.The remaining sales would come from label expansions of current medicines and six new product introductions, such as a high profile treatment for Crohn's disease. The company noted that not all the new programs have to be successful to reach that $3 billion sales target. ""We are confident that key growth drivers exist to meet or exceed 2015 and longer term forecasts,"" Chief Operating Officer Mark Alles said.Jackie Fouse, head of hematology and oncology, said Abraxane was becoming the standard of care for pancreatic cancer in the United States.Combinations of Abraxane with a variety of highly promising new drugs that spur the immune system to fight cancer, currently being tested, were not included in any sales forecasts, said Fouse. ""That's upside potential that we have."" Celgene is awaiting U.S. and European approvals this year for use of Revlimid for newly diagnosed multiple myeloma patients rather than just after prior treatment has failed, which should help increase sales.In addition, Fouse said the company has received reimbursement approval for Revlimid in Russia and anticipates  pricing approval in Mexico. The company also expressed confidence that its newer multiple myeloma drug, Pomalyst, would become a multibillion-dollar drug. Celgene targeted 2017 sales of $1.5 billion, up from 2014 sales of $690 million.Celgene posted $47 million in fourth quarter sales of Otezla, its new drug for psoriatic arthritis and psoriasis, and said new prescriptions accelerated significantly since the September U.S. psoriasis approval.The company is looking at Otezla launches in U.K., Germany and Nordic countries in early 2015, followed by launches in other European markets the same year. It is eyeing an approval in Japan in 2016.Celgene also announced plans to initiate eight Phase I clinical programs in 2015 as it advances drugs in its early stage pipeline.   (Reporting by Bill Berkrot; editing by Gunna Dickson)",2015-01-29,CELG,"Thu Jan 29, 2015 | 11:52am EST",Celgene says 2015 off to strong start; key growth drivers in place,http://www.reuters.com//article/celgene-outlook-idUSL1N0V822B20150129?type=companyNews
31,  Jan 29 Celgene Corp :  * Says early Q1 trends indicate strong start to year  * Says plans to initiate 8 new phase i clinical programs in 2015  * Says received Revlimid reimbursement approval in Russia  * Says anticipates Revlimid pricing approval in Mexico  * Says growth drivers exist to meet or exceed 2015 and longer term forecasts   ,2015-01-29,CELG,"Thu Jan 29, 2015 | 10:19am EST",BRIEF-Celgene says year off to strong start,http://www.reuters.com//article/celgene-results-idUSWEN00EOL20150129?type=companyNews
32,"   By Toni Clarke | WASHINGTON  WASHINGTON The U.S. Food and Drug Administration has expanded the authorized use of Celgene Corp's cancer drug Revlimid to include newly diagnosed patients with multiple myeloma, the company said on Wednesday.Previously the drug was only approved for patients who had received at least one previous therapy. Physicians in the United States have long been prescribing Revlimid for new patients on an ""off-label"" basis, but the company had not been allowed to promote its use in this population.The FDA's action means Celgene can market Revlimid, in combination with a different drug, dexamethasone, as a treatment for all multiple myeloma patients and helps validate the company's premise that treating patients earlier and for a longer period of time increases progression-free survival.The approval is expected to only modestly increase sales in the United States since doctors are already prescribing the drug for newly diagnosed patients. In Europe, where physicians are not allowed to prescribe off-label, the situation is different. Celgene expects European regulators to also approve the drug for newly-diagnosed patients within the next few weeks. If they do, the move could add meaningfully to sales.About 50 percent of patients with multiple myeloma are newly diagnosed. The remainder have received one or more prior therapies.Revlimid generated total sales in 2014 of $2.92 billion in the United States and $2.06 billion in the rest of the world. The drug is approved in 70 countries for previously treated patients. The company hopes approvals in the U.S. and Europe will pave the way for other countries to also approve the drug for newly diagnosed patients. John Newman, an analyst at Canaccord Genuity, said in a research note that he expects sales of Revlimid to reach $10 billion by 2020.About 93,600 patients are living with multiple myeloma in Europe and about 88,499 patients are living with it in the United States, Celgene said. Revlimid is also approved in the United States and some other countries for a group of blood disorders known as myelodysplastic syndromes. It is also approved in the United States for patients with mantle cell lymphoma whose disease has progressed after two prior therapies.Celgene's shares were up 1.4 percent to $117.96 in Wednesday morning trade on Nasdaq. (Editing by Grant McCool)",2015-02-18,CELG,"Wed Feb 18, 2015 | 11:04am EST",FDA approves new use for Celgene's cancer drug Revlimid,http://www.reuters.com//article/us-fda-celgene-approval-idUSKBN0LM1JW20150218?type=companyNews
33,"   By Toni Clarke | WASHINGTON  WASHINGTON Feb 18 The U.S. Food and Drug Administration has expanded the authorized use of Celgene Corp's  cancer drug Revlimid to include newly diagnosed patients with multiple myeloma, the company said on Wednesday.Previously the drug was only approved for patients who had received at least one previous therapy. Physicians in the United States have long been prescribing Revlimid for new patients on an ""off-label"" basis, but the company had not been allowed to promote its use in this population.The FDA's action means Celgene can market Revlimid, in combination with a different drug, dexamethasone, as a treatment for all multiple myeloma patients and helps validate the company's premise that treating patients earlier and for a longer period of time increases progression-free survival.The approval is expected to only modestly increase sales in the United States since doctors are already prescribing the drug for newly diagnosed patients. In Europe, where physicians are not allowed to prescribe off-label, the situation is different. Celgene expects European regulators to also approve the drug for newly-diagnosed patients within the next few weeks. If they do, the move could add meaningfully to sales.About 50 percent of patients with multiple myeloma are newly diagnosed. The remainder have received one or more prior therapies. Revlimid generated total sales in 2014 of $2.92 billion in the United States and $2.06 billion in the rest of the world. The drug is approved in 70 countries for previously treated patients. The company hopes approvals in the U.S. and Europe will pave the way for other countries to also approve the drug for newly diagnosed patients.John Newman, an analyst at Canaccord Genuity, said in a research note that he expects sales of Revlimid to reach $10 billion by 2020. About 93,600 patients are living with multiple myeloma in Europe and about 88,499 patients are living with it in the United States, Celgene said.Revlimid is also approved in the United States and some other countries for a group of blood disorders known as myelodysplastic syndromes. It is also approved in the United States for patients with mantle cell lymphoma whose disease has progressed after two prior therapies.Celgene's shares were up 1.4 percent to $117.96 in Wednesday morning trade on Nasdaq.   (Editing by Grant McCool)",2015-02-18,CELG,"Wed Feb 18, 2015 | 11:00am EST",U.S. FDA approves new use for Celgene's cancer drug Revlimid,http://www.reuters.com//article/fda-celgene-approval-idUSL1N0VS11220150218?type=companyNews
34,"  FRANKFURT Morphosys and Celgene have agreed to end their cooperation on MOR202, but clinical trials of the drug candidate will continue, Morphosys said on Thursday.Morphosys said it aimed to release first clinical data from the ongoing phase 1/2a trial at a medical conference in 2015.It also raised its 2015 profit guidance, saying it expected to post 2015 earnings before interest and tax (EBIT) of between 9 and 16 million euros ($9.8-17.5 million), because it can book revenue this year that had been deferred as part of the cooperation and it will receive a one-time payment from Celgene for development costs. ($1 = 0.9160 euros)   (Reporting by Maria Sheahan; Editing by David Holmes)",2015-03-26,CELG,"Thu Mar 26, 2015 | 12:45pm EDT","Morphosys, Celgene end cooperation on MOR202 drug candidate",http://www.reuters.com//article/us-morphosys-outlook-celgene-idUSKBN0MM2AR20150326?type=companyNews
35,"  FRANKFURT Morphosys still believes that its MOR202 compound has a good chance of becoming a success after U.S. drugmaker Celgene scrapped cooperation on the drug candidate, the German company's chief executive told a newspaper.""We are still testing the MOR202 compound in the first clinical phase and still see it as promising,"" German weekly Welt am Sonntag quoted Simon Moroney as saying in an interview published on Sunday.The compound is viewed as a possible treatment for multiple myeloma, a form of blood cancer.  Morphosys and Celgene agreed last month to end their cooperation on MOR202, pushing Morphosys' stock down more than 20 percent.""Investors' initial reaction is always the same. First everyone thinks that the project is dead if a cooperation fails,"" Moroney said. He said Morphosys would make further decisions on the future of MOR202 once a Phase 1/2a trial of the compound was completed, adding he expected results of the trial to be available by the end of the year.  (Reporting by Maria Sheahan; editing by Andrew Roche)",2015-04-05,CELG,"Sat Apr 4, 2015 | 8:07pm EDT",Morphosys CEO says MOR202 drug candidate still promising: newspaper,http://www.reuters.com//article/us-morphosys-drug-idUSKBN0MW00320150405?type=companyNews
36,"  FRANKFURT, April 5 Morphosys still believes that its MOR202 compound has a good chance of becoming a success after U.S. drugmaker Celgene scrapped cooperation on the drug candidate, the German company's chief executive told a newspaper.""We are still testing the MOR202 compound in the first clinical phase and still see it as promising,"" German weekly Welt am Sonntag quoted Simon Moroney as saying in an interview published on Sunday.The compound is viewed as a possible treatment for multiple myeloma, a form of blood cancer. Morphosys and Celgene agreed last month to end their cooperation on MOR202, pushing Morphosys' stock down more than 20 percent. ""Investors' initial reaction is always the same. First everyone thinks that the project is dead if a cooperation fails,"" Moroney said. He said Morphosys would make further decisions on the future of MOR202 once a Phase 1/2a trial of the compound was completed, adding he expected results of the trial to be available by the end of the year.   (Reporting by Maria Sheahan; editing by Andrew Roche)",2015-04-05,CELG,"Sat Apr 4, 2015 | 8:01pm EDT",Morphosys CEO says MOR202 drug candidate still promising - newspaper,http://www.reuters.com//article/morphosys-drug-idUSL6N0X10B820150405?type=companyNews
37,"   By Ben Hirschler | LONDON  LONDON AstraZeneca (AZN.L) is getting a $450 million windfall by letting Celgene (CELG.O) develop a prized immunotherapy drug for blood cancers but its chief executive insists the deal is about strategy, not cash.Some investors are worried about the drugmaker's reliance on such ""externalization"" deals to fill a short-term revenue gap. Deutsche Bank analyst Richard Parkers said income from these agreements was of ""questionable sustainability"".Chief Executive Pascal Soriot, however, said he had been looking for a partner in blood cancers since last year and by teaming up with U.S.-based Celgene, a leader in haematology, AstraZeneca would accelerate its drug's path to market.AstraZeneca will effectively give away around half the sales of its drug MEDI4736 in blood cancers under the Celgene agreement, but Soriot said the deal would unlock value that the British company could not have achieved on its own. ""We could do it ourselves but with a partner in haematology we will do much, much better,"" he told reporters in a conference call. ""It's more strategically driven than financially driven, though of course the financial aspects also help."" AstraZeneca believes blood cancers could represent 40 percent of the total cancer market, yet Soriot said it did not include this in a $45 billion 2023 sales forecast issued last year as it was not clear then how it would tap the market.AstraZeneca has extensive experience in solid tumors, but not blood cancers, which is a highly specialized field involving different groups of doctors.Citi analyst Andrew Baum said the Celgene collaboration made sense given AstraZeneca's absence of expertise and Celgene's desire to expand its presence in immuno-oncology (I-O). AstraZeneca is up against several I-O rivals, such as Bristol-Myers Squibb (BMY.N), Merck (MRK.N) and Roche ROG.VX,  and Soriot argued that by getting into bed with Celgene it would be at a competitive advantage in the blood cancer space.  Under the deal, AstraZeneca will book sales of MEDI4736 in blood cancers and will pay Celgene an initial royalty of 70 percent, which will decrease to approximately half of sales over a period of four years.    (This version of the story corrects royalty details in the final paragraph)   (Editing by Keith Weir)",2015-04-24,CELG,"Fri Apr 24, 2015 | 10:09am EDT","AstraZeneca insists Celgene deal about strategy, not cash",http://www.reuters.com//article/us-astrazeneca-results-celgene-idUSKBN0NF10F20150424?type=companyNews
38,"  (Corrects royalty details in final paragraph)By Ben HirschlerLONDON, April 24 AstraZeneca is getting a $450 million windfall by letting Celgene develop a prized immunotherapy drug for blood cancers but its chief executive insists the deal is about strategy, not cash.Some investors are worried about the drugmaker's reliance on such ""externalisation"" deals to fill a short-term revenue gap. Deutsche Bank analyst Richard Parkers said income from these agreements was of ""questionable sustainability"".Chief Executive Pascal Soriot, however, said he had been looking for a partner in blood cancers since last year and by teaming up with U.S.-based Celgene, a leader in haematology, AstraZeneca would accelerate its drug's path to market. AstraZeneca will effectively give away around half the sales of its drug MEDI4736 in blood cancers under the Celgene agreement, but Soriot said the deal would unlock value that the British company could not have achieved on its own.""We could do it ourselves but with a partner in haematology we will do much, much better,"" he told reporters in a conference call. ""It's more strategically driven than financially driven, though of course the financial aspects also help."" AstraZeneca believes blood cancers could represent 40 percent of the total cancer market, yet Soriot said it did not include this in a $45 billion 2023 sales forecast issued last year as it was not clear then how it would tap the market.AstraZeneca has extensive experience in solid tumours, but not blood cancers, which is a highly specialised field involving different groups of doctors. Citi analyst Andrew Baum said the Celgene collaboration made sense given AstraZeneca's absence of expertise and Celgene's desire to expand its presence in immuno-oncology (I-O).AstraZeneca is up against several I-O rivals, such as Bristol-Myers Squibb, Merck and Roche,  and Soriot argued that by getting into bed with Celgene it would be at a competitive advantage in the blood cancer space.Under the deal, AstraZeneca will book sales of MEDI4736 in blood cancers and will pay Celgene an initial royalty of 70 percent, which will decrease to approximately half of sales over a period of four years.            (Editing by Keith Weir)",2015-04-24,CELG,"Fri Apr 24, 2015 | 10:07am EDT","CORRECTED-AstraZeneca insists Celgene deal about strategy, not cash",http://www.reuters.com//article/astrazeneca-results-celgene-idUSL5N0XL1Y420150424?type=companyNews
39,"  April 24 AstraZeneca media conference call:* CEO says no comment on Pfizer, completely focused on developing pipeline* CEO says has nothing against large m&a but smaller acquisitions more realistic for company* CEO says Celgene deal will bring PD-L1 to patients much faster * CEO says Celgene deal will unlock value that AZ could not unlock by itself * CEO says will have to price immuno-oncology combinations at appropriate level to maximise access* CEO says immuno-oncology is a marathon, not easy to see who will ultimately be successful * CEO says previous forecasts for cancer drug sales in 2023 did not include blood cancers, so Celgene deal offers upside* Exec says potential of blood cancer treatments is about 40 percent of entire cancer market  Further company coverage:    (Reporting By Ben Hirschler)",2015-04-24,CELG,"Fri Apr 24, 2015 | 5:12am EDT","BRIEF-AstraZeneca open to acquisitions, smaller deals more likely",http://www.reuters.com//article/idUSL5N0XL1JY20150424?type=companyNews
40,"  * Strikes cancer drug deals with Celgene and Innate Pharma* Q1 sales down 6 pct at $6.06 bln vs $5.98 bln consensus* Core EPS down 7 pct at $1.08 vs consensus $1.07* Drugmaker reiterates financial forecasts for year   (Adds analyst comment, latest shares)By Ben HirschlerLONDON, April 24 AstraZeneca has sharpened its focus on cancer drugs with two new deals as it looks beyond a hit to sales and profits from the launch of cheap copies of its popular stomach acid pill Nexium in the vital U.S. market.The drugmaker, which saw off a $118 billion bid by Pfizer  last year, said on Friday its sales fell by a slightly less than expected 6 percent to $6.06 billion in the first quarter, hurt by Nexium generics and the strong dollar, its reporting currency. Core earnings per share, which exclude certain items, fell 7 percent but came in 1 cent above forecasts at $1.08.The results were helped by the partial sell-off of a number of drugs, leaving some investors sceptical and the shares fell 2 percent by 0805 GMT.Chief Executive Pascal Soriot said its new cancer alliance with Celgene would maximise the potential of immune system-boosting drugs in blood cancers and a tie-up with Innate Pharma would further strengthen immuno-oncology. AstraZeneca will get an upfront payment of $450 million from Celgene by giving it the right to work with MEDI4736, a so-called anti-PD-L1 immune system medicine, in blood cancers. Innate will receive an initial $250 million from AstraZeneca.Despite the loss of sales on profitable old drugs like Nexium and Crestor for cholesterol, which loses U.S. patent protection next year, AstraZeneca argues new cancer drugs can help lift sales to $45 billion in 2023 from 2014's $26 billion.Analysts view the forecast as a stretch, although confidence is building in its immuno-oncology portfolio, with the next focus being updates at the May 29-June 2 American Society of Clinical Oncology meeting. AstraZeneca now has 72 oncology trials under way, including 31 in immuno-oncology.In the short-term, Soriot has his work cut out to hit 2015 financial targets and the Celgene deal highlights a drive to gain revenue by ""externalisation"", or selling rights to some research, which generated $309 million in the quarter.""Quarterly results confirm that this 'engineering' is needed if management is to hit its full-year EPS targets,"" Bernstein analyst Tim Anderson said in a note.The group reiterated its forecast of a low single-digit percent increase in 2015 core earnings at constant exchange rates, despite a mid single-digit percent fall in sales.Industry analysts had on average forecast first-quarter group sales of $5.98 billion and earnings of $1.07 cents, according to Thomson Reuters.     (Reporting by Ben Hirschler; Editing by Keith Weir)",2015-04-24,CELG,"Fri Apr 24, 2015 | 4:23am EDT",UPDATE 2-AstraZeneca looks beyond Nexium hit with new cancer deals,http://www.reuters.com//article/astrazeneca-results-idUSL5N0XL0T720150424?type=companyNews
41,"  * Apple and Celgene weigh* Jobless claims lowest since 2000* Indexes gain slightly in April* Indexes down: Dow 1.1 pct, S&P 1 pct, Nasdaq 1.6 pct   (Updates close with LinkedIn, solar company shares down after the bell, Gilead up, small caps down, new quote)By Caroline ValetkevitchApril 30 U.S. stocks, led by the Nasdaq, sold off on Thursday as Apple shares declined, and tech and biotech quarterly results disappointed.Upbeat economic reports added to uncertainty about the outlook for interest rates, a day after data showed the U.S. economy had slowed to a crawl in the first quarter and the Federal Reserve pointed to weakness in the labor market and other areas of the U.S. economy.Despite the day's decline, all three major indexes posted slight gains for April. The Nasdaq biotech index dropped 3.1 percent on Thursday, led by a 4.5 percent fall in Celgene, which reported lower-than-expected quarterly revenue.The decline marked a fifth day of losses for the biotech index, which was down 8.1 percent for the week so far.The Nasdaq fell for a fourth straight day, and was off 3 percent from Friday's record closing high. The S&P tech index  slid 1.6 percent, the day's worst-performing sector, while small-cap stocks also underperformed. The Russell 2000 small-cap index was down 2.2 percent. Apple, down 2.7 percent at $125.15, was the biggest drag on the three major indexes. The company limited the availability of the Apple Watch after a key component was found to be defective, according to the Wall Street Journal.""Biotechs and tech were leaders and now they've reversed,"" said Peter Cardillo, chief market economist at Rockwell Global Capital in New York.""Earnings don't really support the valuations at this time, and I think the market needs to correct a bit. As we go into May I would say the best prescription would be to sell in May and go away.""The Dow Jones industrial average fell 195.01 points, or 1.08 percent, to 17,840.52, the S&P 500 lost 21.34 points, or 1.01 percent, to 2,085.51 and the Nasdaq Composite  dropped 82.22 points, or 1.64 percent, to 4,941.42. For the month, the Dow was up 0.4 percent, the S&P 500 gained 0.9 percent and the Nasdaq rose 0.8 percent.The day's data included a report showing the number of Americans filing new claims for unemployment benefits tumbled to a 15-year low last week.After the bell, LinkedIn shares fell 24 percent to $191.70 and Gilead shares gained 3.2 percent to $103.69 following the release of results. First Solar and SunPower both declined after hours following results.During the regular session, Baidu declined 8.5 percent to $200.28 after China's dominant Internet search engine provider reported its slowest quarterly revenue growth rate in almost seven years.S&P 500 earnings for the first quarter now are expected to have risen 1.1 percent, Thomson Reuters data showed, while revenue was expected to be down 3.2 percent.Declining issues outnumbered advancing ones on the NYSE by 2,355 to 693; on the Nasdaq, 2,131 issues fell and 647 advanced. About 8.5 billion shares changed hands on U.S. exchanges, compared with the 6.3 billion daily average for the month to date, according to BATS Global Markets.   (Editing by Savio D'Souza, Meredith Mazzilli and Steve Orlofsky)",2015-04-30,CELG,"Thu Apr 30, 2015 | 5:57pm EDT",US STOCKS-Wall St drops with tech shares; LinkedIn falls late,http://www.reuters.com//article/markets-stocks-usa-idUSL1N0XR3W020150430?type=companyNews
42,"  * Apple and Celgene weigh* Jobless claims lowest since 2000* Indexes post slight gains for April* Indexes down: Dow 1.1 pct, S&P 1 pct, Nasdaq 1.6 pct   (Updates to close)By Caroline ValetkevitchApril 30 U.S. stocks sold off on Thursday, led by a drop in the Nasdaq, as Apple shares declined and results in tech and biotech names disappointed.Upbeat economic reports added to uncertainty about the outlook for interest rates, a day after data showed the U.S. economy slowed to a crawl in the first quarter and the Federal Reserve pointed to weakness in the labor market and other areas of the U.S. economy.Despite the day's decline, all three major indexes posted slight gains for April. The Nasdaq biotech index dropped 3.1 percent, led by a 4.5 percent fall in Celgene, which reported lower-than-expected quarterly revenue.The decline marked a fifth day of losses for the biotech index, bringing losses in the index to 8.1 percent for the week so far. The Nasdaq fell for its fourth straight session, while the S&P tech index fell 1.6 percent, the day's worst-performing sector.Apple was down 2.7 percent at $125.15 and was the biggest drag on the Dow, S&P 500 and the Nasdaq. The company limited the availability of the Apple Watch after a key component was found to be defective, according to the Wall Street Journal.""We didn't get a rally off of the Fed statement and that kind of set the stage for this morning,"" said Bucky Hellwig, senior vice president at BB&T Wealth Management in Birmingham, Alabama. ""It didn't add any clarity. That kind of tied in with not a lousy earnings season but a flattish earnings season. There's just not a compelling reason to buy.""The Dow Jones industrial average fell 195.01 points, or 1.08 percent, to 17,840.52, the S&P 500 lost 21.34 points, or 1.01 percent, to 2,085.51 and the Nasdaq Composite  dropped 82.22 points, or 1.64 percent, to 4,941.42.For the month, the Dow was up 0.4 percent, the S&P 500 gained 0.9 percent and the Nasdaq rose 0.8 percent. The day's data included a report showing the number of Americans filing new claims for jobless benefits tumbled to a 15-year low last week, which suggested the economy is picking up.Among other decliners, Yelp shares slumped 23.2 percent to $39.39 a day after the consumer review website operator forecast second-quarter revenue below analysts' expectations.Baidu declined 8.5 percent to $200.28 after China's dominant Internet search engine provider posted its slowest quarterly revenue growth rate in almost seven years.S&P 500 earnings for the first quarter now are forecast to have increased 1.1 percent from a year ago, Thomson Reuters data showed, while revenue is forecast to be down 3.2 percent.Declining issues outnumbered advancing ones on the NYSE by 2,355 to 693; on the Nasdaq, 2,131 issues fell and 647 advanced.The benchmark S&P 500 index posted six new 52-week highs and three new lows; the Nasdaq Composite recorded 39 new highs and 91 new lows.About 7.8 billion shares changed hands on U.S. exchanges, compared with the 6.3 billion daily average for the month to date, according to data from BATS Global Markets.    (Editing by Savio D'Souza and Meredith Mazzilli)",2015-04-30,CELG,"Thu Apr 30, 2015 | 4:32pm EDT",US STOCKS-Wall St drops with tech shares; indexes up for month,http://www.reuters.com//article/markets-stocks-usa-idUSL1N0XR3CM20150430?type=companyNews
43,"   By Bill Berkrot  Celgene Corp's dependence on its big-selling multiple myeloma drug Revlimid raised investor concerns on Thursday as sales of its other medicines fell short of expectations.Celgene shares fell 5 percent after the company reported quarterly results in which Revlimid shored up profits. Industry analysts see room for Revlimid to grow much further, with some estimating the drug will nearly double annual sales in coming years. But investors may be hesitating as Celgene faces a legal challenge that could cut its exclusive sales rights in Europe by a year or two. The European Patent Office hearing on a Revlimid patent that runs through 2024 is set for May 7.""Nobody seems to want to buy the stock in front of May 7,"" said RBC Capital Markets analyst Michael Yee. ""Once we get past that, I think the stock rebounds.""Revlimid sales of $1.34 billion in the first quarter were in line with expectations and especially strong in the United States. Sales of the cancer drug Abraxane, and newer medicines Pomalyst for multiple myeloma and Otezla for psoriatic arthritis and psoriasis all fell short of forecasts. Inventory stocking, higher co-pays and demands by payers for larger Otezla rebates contributed to first quarter weakness, analysts said. The New Jersey-based company said it now sees 2015 Revlimid sales at or above $5.7 billion, the high end of its prior forecast range. The drug accounts for about 60 percent of Celgene revenue.Patients are using the treatment longer to keep their cancer at bay, the company said. In addition, U.S. and European regulators recently expanded approvals to allow its use in newly diagnosed multiple myeloma patients, which will drive growth.     Cantor Fitzgerald analyst Mara Goldstein forecast Revlimid sales reaching $10 billion by 2020 if its duration of use and geographic expansion continues to grow, along with approvals or new uses.  ""It's a high class problem to have,"" she said of the company's dependence on Revlimid. She predicts Revlimid will decline as a percentage of profit ""not because it's declining, but because other products are growing. That's a very positive dynamic."" Celgene said it anticipates ""significant market share gains over coming months and years"" with reimbursements for newly diagnosed patients in Europe, and with an expected approval in Japan for such patients around the end of the year. The company is also conducting five late-stage trials of Revlimid in a variety of lymphomas. ""It's always less risky to expand the opportunities for an existing drug than to invest in advancing a new drug,""  Bernstein analyst Geoffrey Porges said. ""They happen to have a great drug that still has a lot of runway in front of it.""Investors still have high hopes for future blockbuster sales of Celgene's experimental drug for Crohn's disease. The company is also collaborating with AstraZeneca to test Abraxane and other Celgene products in combination with experimental Astra drugs that spur the immune system to fight cancer.Such partnerships ""suggest there's going to be a huge range of revenue opportunities for them five to 10 years from now,"" Porges said. (Reporting by Bill Berkrot; Editing by Michele Gershberg and Chris Reese)",2015-04-30,CELG,"Thu Apr 30, 2015 | 3:59pm EDT",Celgene sales highlight Revlimid dependence ahead of patent ruling,http://www.reuters.com//article/us-celgene-revlimid-idUSKBN0NL2IS20150430?type=companyNews
44,"   By Bill Berkrot | April 30  April 30 Celgene Corp's dependence on its big-selling multiple myeloma drug Revlimid raised investor concerns on Thursday as sales of its other medicines fell short of expectations.Celgene shares fell 5 percent after the company reported quarterly results in which Revlimid shored up profits. Industry analysts see room for Revlimid to grow much further, with some estimating the drug will nearly double annual sales in coming years.But investors may be hesitating as Celgene faces a legal challenge that could cut its exclusive sales rights in Europe by a year or two. The European Patent Office hearing on a Revlimid patent that runs through 2024 is set for May 7.""Nobody seems to want to buy the stock in front of May 7,"" said RBC Capital Markets analyst Michael Yee. ""Once we get past that, I think the stock rebounds."" Revlimid sales of $1.34 billion in the first quarter were in line with expectations and especially strong in the United States. Sales of the cancer drug Abraxane, and newer medicines Pomalyst for multiple myeloma and Otezla for psoriatic arthritis and psoriasis all fell short of forecasts. Inventory stocking, higher co-pays and demands by payers for larger Otezla rebates contributed to first quarter weakness, analysts said.The New Jersey-based company said it now sees 2015 Revlimid sales at or above $5.7 billion, the high end of its prior forecast range. The drug accounts for about 60 percent of Celgene revenue.Patients are using the treatment longer to keep their cancer at bay, the company said. In addition, U.S. and European regulators recently expanded approvals to allow its use in newly diagnosed multiple myeloma patients, which will drive growth. Cantor Fitzgerald analyst Mara Goldstein forecast Revlimid sales reaching $10 billion by 2020 if its duration of use and geographic expansion continues to grow, along with approvals or new uses.""It's a high class problem to have,"" she said of the company's dependence on Revlimid. She predicts Revlimid will decline as a percentage of profit ""not because it's declining, but because other products are growing. That's a very positive dynamic."" Celgene said it anticipates ""significant market share gains over coming months and years"" with reimbursements for newly diagnosed patients in Europe, and with an expected approval in Japan for such patients around the end of the year. The company is also conducting five late-stage trials of Revlimid in a variety of lymphomas.""It's always less risky to expand the opportunities for an existing drug than to invest in advancing a new drug,""  Bernstein analyst Geoffrey Porges said. ""They happen to have a great drug that still has a lot of runway in front of it.""Investors still have high hopes for future blockbuster sales of Celgene's experimental drug for Crohn's disease. The company is also collaborating with AstraZeneca to test Abraxane and other Celgene products in combination with experimental Astra drugs that spur the immune system to fight cancer.Such partnerships ""suggest there's going to be a huge range of revenue opportunities for them five to 10 years from now,"" Porges said.   (Reporting by Bill Berkrot; Editing by Michele Gershberg and Chris Reese)",2015-04-30,CELG,"Thu Apr 30, 2015 | 3:57pm EDT",Celgene sales highlight Revlimid dependence ahead of patent ruling,http://www.reuters.com//article/celgene-revlimid-idUSL1N0XR2I220150430?type=companyNews
45,"  * Apple and Celgene weigh* Jobless claims lowest since 2000* Indexes down: Dow 1.4 pct, S&P 1.3 pct, Nasdaq 1.9 pct   (Updates to late afternoon)By Caroline ValetkevitchApril 30 U.S. stocks sold off in late trading on Thursday, with the Nasdaq on track for a fourth straight day of losses, as Apple shares declined and economic data reignited concerns about the outlook for interest rates.The day's data, including a report showing the number of Americans filing new claims for jobless benefits tumbled to a 15-year low last week, suggested the economy is picking up.  It comes a day after the Federal Reserve pointed to weakness in the labor market and other areas of the U.S. economy. ""We didn't get a rally off of the Fed statement, and that kind of set the stage for this morning because we got the first-time claims number which was very strong. And that kind of colored the statement more hawkish for the Fed,"" said Bucky Hellwig, senior vice president at BB&T Wealth Management in Birmingham, Alabama.The Nasdaq biotech index dropped 3.2 percent, led by a 3.9 percent fall in Celgene, which reported lower-than-expected quarterly revenue. Apple was down 2.7 percent at $125.20 and was the biggest drag on the Dow, S&P 500 and the Nasdaq. The company limited the availability of the Apple Watch after a key component was found to be defective, according to the Wall Street Journal.At 3:10 p.m., the Dow Jones industrial average fell 248.6 points, or 1.38 percent, to 17,786.93, the S&P 500  lost 28.33 points, or 1.34 percent, to 2,078.52 and the Nasdaq Composite dropped 98.70 points, or 1.96 percent, to 4,924.94.Among other decliners, Yelp shares slumped 23.7 percent to $39.10 a day after the consumer review website operator forecast second-quarter revenue below analysts' expectations. The S&P 500 tech sector  was down 1.6 percent, among the day's worst-performing sectors. Also in the tech space, Baidu declined 8.3 percent to $200.85 after China's dominant Internet search engine provider posted its slowest quarterly revenue growth rate in almost seven years.S&P 500 earnings for the first quarter now are forecast at up 1.1 percent, Thomson Reuters data showed, while revenue is forecast down 3.2 percent.Declining issues outnumbered advancing ones on the NYSE by 2,318 to 685, for a 3.38-to-1 ratio on the downside; on the Nasdaq, 2,084 issues fell and 654 advanced for a 3.19-to-1 ratio favoring decliners.The benchmark S&P 500 index was posting 6 new 52-week highs and 1 new low; the Nasdaq Composite was recording 36 new highs and 79 new lows.     (Additional reporting by Tanya Agrawal; Editing by Savio D'Souza and Meredith Mazzilli)",2015-04-30,CELG,"Thu Apr 30, 2015 | 3:18pm EDT",US STOCKS-Wall St drops with tech shares; Nasdaq down for 4th day,http://www.reuters.com//article/markets-stocks-usa-idUSL1N0XR2SS20150430?type=companyNews
46,"  * Apple and Celgene weigh on Nasdaq, S&P 500* Jobless claims lowest since 2000* Consumer confidence rises less than expected in March* Indexes down: Dow 0.6 pct, S&P 0.6 pct, Nasdaq 1 pct   (Updates to early afternoon)By Tanya AgrawalApril 30 Wall Street was lower in afternoon trading on Thursday as Apple weighed on major indexes and investors digested a mixed batch of economic data.Nine of the 10 major S&P sectors were down, with the technology index retreating 1.2 percent. The Nasdaq biotech index dropped 2.2 percent, led by Celgene .Apple fell as much as 2.6 percent to $125.25 and was the biggest drag on the Dow, S&P 500 and the Nasdaq. The company limited the availability of the Apple Watch after a key component was found to be defective, according to the Wall Street Journal. Investors were also digesting a mixed bag of economic data which came in a day after data showed that the U.S. economy slowed to a crawl in the first quarter.While the number of Americans filing new claims for jobless benefits tumbled to a 15-year low last week, consumer spending rose less-than-expected in March as personal income stayed flat.Scott Brown, chief economist at Raymond James, said investors were operating in a period of high uncertainty.""I think its very, very healthy to see some back and forth in the equity markets. Economic data is still going to be a bit mixed in the near term and that can be used as a crutch for the markets."" At 13:24 p.m. EDT (1724 GMT) the Dow Jones industrial average was down 102.53 points, or 0.57 percent, at 17,933, the S&P 500 was down 12.79 points, or 0.61 percent, at 2,094.06 and the Nasdaq Composite was down 51.74 points, or 1.03 percent, at 4,971.90.Celgene fell 3.5 percent to $109.28 and was the biggest drag on the biotech index after the company blamed the dollar for its lower-than-expected quarterly revenue. The stock was the second biggest drag on the S&P 500 and the Nasdaq.Baidu declined 7.1 percent to $203.25 after China's dominant Internet search engine provider posted its slowest quarterly revenue growth rate in almost seven years. ""The tech sector is a very ""risk-on"" sector and is the sector most sensitive to perceived rate hikes, so you're seeing some reshuffling in portfolios,"" said Brian Fenske, head of sales trading at ITG in New York.Google, IBM and Intel were down by 1.2 to 1.8 percent.Yelp shares slumped as much as 24 percent to a near two-year low of $39.25 a day after the operator of consumer review website forecast second-quarter revenue below analysts' expectations.Colgate-Palmolive slipped 2.1 percent to $67.08 after cutting its full-year profit forecast for the second time, saying the impact of the dollar would worsen.Earnings expected after the close on Thursday include Dow component Visa, insurer AIG and LinkedIn.Declining issues outnumbered advancing ones on the NYSE by 2,188 to 781, for a 2.80-to-1 ratio on the downside; on the Nasdaq, 1,918 issues fell and 786 advanced for a 2.44-to-1 ratio favoring decliners.The benchmark S&P 500 index was posting 6 new 52-week highs and 1 new lows; the Nasdaq Composite was recording 34 new highs and 69 new lows.   (Editing by Savio D'Souza)",2015-04-30,CELG,"Thu Apr 30, 2015 | 1:28pm EDT",US STOCKS-Wall St falls on mixed economic data; Apple weighs,http://www.reuters.com//article/markets-stocks-usa-idUSL4N0XR7B920150430?type=companyNews
47,"  * Jobless claims lowest since 2000* Consumer confidence rises less than expected in March* Apple and Celgene weigh on Nasdaq, S&P 500* Indexes down: Dow 0.5 pct, S&P 0.5 pct, Nasdaq 0.9 pct   (Changes comment, updates prices)By Tanya AgrawalApril 30 Wall Street was lower in midday trading on Thursday as Apple weighed on major indexes and investors digested a mixed batch of economic data.All the 10 major S&P sectors were down, with the technology index retreating 0.9 percent. The Nasdaq biotech index  dropped 1.8 percent.Apple fell as much as 2.5 percent to $125.45 and was the biggest drag on the Dow, S&P 500 and the Nasdaq. The company limited availability of the Apple Watch after a key component was found to be defective, according to a report. Investors were also digesting a mixed bag of economic data which came in a day after data showed that the U.S. economy slowed to a crawl in the first quarter.While the number of Americans filing new claims for jobless benefits tumbled to a 15-year low last week, consumer spending rose less-than-expected in March as personal income stayed flat.Scott Brown, chief economist at Raymond James, said investors were operating in a period of high levels of uncertainty. ""I think its very, very healthy to see some back and forth in the equity markets. Economic data is still going to be a bit mixed in the near term and that can be used as a crutch for the markets.""At 12:05 p.m. EDT (1605 GMT) the Dow Jones industrial average was down 82.97 points, or 0.46 percent, at 17,952.56, the S&P 500 was down 10.62 points, or 0.5 percent, at 2,096.23 and the Nasdaq Composite was down 43.55 points, or 0.87 percent, at 4,980.10.Celgene fell 4.1 percent to $108.51 and was the biggest drag on the biotech index after the company blamed the dollar for its lower-than-expected quarterly revenue. The stock was the second biggest drag on the S&P 500 and the Nasdaq.Baidu declined 6.8 percent to $204.03 after China's dominant Internet search engine provider posted its slowest quarterly revenue growth rate in almost seven years. ""The tech sector is a very ""risk-on"" sector and is the sector most sensitive to perceived rate hikes, so you're seeing some reshuffling in portfolios,"" said Brian Fenske, head of sales trading at ITG in New York.Google, IBM and Intel were all down between 1.0 to 1.5 percent.Yelp shares slumped as much as 22 percent to a near two-year low of $40.04 a day after the operator of consumer review website forecast second-quarter revenue below analysts' expectations.Colgate-Palmolive slipped 2.4 percent to $66.85 after cutting its full-year profit forecast for the second time, saying the impact of the dollar would worsen.Earnings expected after the close on Thursday include Dow component Visa, insurer AIG and LinkedIn.Declining issues outnumbered advancing ones on the NYSE by 2,231 to 698, for a 3.20-to-1 ratio on the downside; on the Nasdaq, 1,948 issues fell and 704 advanced for a 2.77-to-1 ratio favoring decliners.   (Editing by Savio D'Souza)",2015-04-30,CELG,"Thu Apr 30, 2015 | 12:11pm EDT",US STOCKS-Wall St falls on mixed economic data; Apple weighs,http://www.reuters.com//article/markets-stocks-usa-idUSL4N0XR75K20150430?type=companyNews
48,"  U.S. biotechnology company Celgene Corp (CELG.O) posted a lower-than-expected quarterly revenue, hit by a stronger dollar, but said the dollar would not hurt full-year sales and profit more that it had already forecast.Shares of the company, which got nearly 41 percent of its revenue from outside the United States last year, fell just over 2 percent before the bell on Thursday.Celgene in late January had forecast 2015 adjusted profit of $4.60-$4.75 per share, on net product sales of $9.0-$9.5 billion, including a near $100 million impact from currency fluctuations.The dollar .DXY had climbed nearly 9 percent against a basket of major currencies from January to March.Celgene's total revenue rose 20 percent to $2.08 billion in the first quarter ended March 31, but fell short of analysts' average estimate of $2.11 billion, according to Thomson Reuters I/B/E/S. Celgene said net product sales also rose 20 percent in the quarter, but was hurt by 2 percent due to currency headwinds.Sales of the company's flagship multiple myeloma drug, Revlimid, rose 17.4 percent to $1.34 billion, roughly in line with the consensus estimate of $1.33 billion, according to Deutsche Bank's Robyn Karnauskas. U.S. and European regulators in February allowed Revlimid's use in newly diagnosed multiple myeloma patients.Celgene's net profit soared to $718.9 million, or 86 cents per share, from $279.7 million, or 33 cents per share. Excluding one-time items, its profit of $1.07 per share beat the average analyst estimate by one cent.The Summit, New Jersey-based company's stock was down 2 percent at $110.75 premarket on Thursday. (Reporting by Natalie Grover in Bengaluru; Editing by Savio D'Souza)",2015-04-30,CELG,"Thu Apr 30, 2015 | 10:49am EDT",Celgene revenue rises less than expected due to strong dollar,http://www.reuters.com//article/us-celgene-results-idUSKBN0NL1XG20150430?type=companyNews
49,"  * Jobless claims lowest since 2000* Consumer confidence rises less than expected in March* Apple and Celgene weigh on Nasdaq, S&P 500* Indexes down: Dow 0.7 pct, S&P 0.7 pct, Nasdaq 1 pct   (Updates to open)By Tanya AgrawalApril 30 Wall Street opened lower on Thursday as Apple weighed on the major indexes and Celgene  led a fall in biotech stocks, more than offsetting encouraging economic data.All the 10 major S&P sectors were down, with the technology index retreating 1.1 percent. The Nasdaq biotech index  dropped 1.7 percent.Apple fell 2.3 percent to $125.70 and was the biggest drag on the Dow, S&P 500 and the Nasdaq. The company limited availability of the Apple Watch after a key component supplied by a Chinese company was found to be defective, according to the Wall Street Journal. Equity markets were weak despite the release of encouraging economic data earlier in the day.The number of Americans filing new claims for jobless benefits tumbled to a 15-year low last week and consumer spending rose in March, signs the economy was regaining momentum after stumbling badly in the first quarter.""I think we're going to see cleaner data come out in the second quarter and with the jobless claims being at their lowest levels in 15 years, that certainly points towards a strengthening labor market which has been a clear focus point of the Fed,"" said Mark Luschini, chief market strategist at Janney Montgomery Scott in Philadelphia. At 10:30 a.m. EDT (1430 GMT) the Dow Jones industrial average was down 123.88 points, or 0.69 percent, at 17,911.65, the S&P 500 was down 14.73 points, or 0.7 percent, at 2,092.12 and the Nasdaq Composite was down 47.89 points, or 0.95 percent, at 4,975.75.Celgene fell 3.4 percent to $109.39 and was the biggest drag on biotech stocks after the biotechnology company blamed the dollar for its lower-than-expected quarterly revenue. The stock was the second biggest drag on the S&P 500 and the Nasdaq.Baidu declined 5.9 percent to $206 after China's dominant Internet search engine provider posted its slowest quarterly revenue growth rate in almost seven years.Companies continue to cite the strong dollar, which has climbed nearly 9 percent against a basket of major currencies from January to March, for weak results and forecasts. Colgate-Palmolive fell 1.9 percent to $67.17 after cutting its full-year profit forecast for the second time, saying the impact of the dollar would worsen.Automotive supplier BorgWarner also cited the dollar for a fall in quarterly revenue. Its stock dropped 4.2 percent to $58.35.ConocoPhillips fell 0.62 percent to $67.94 after it reported a sharp fall in quarterly profit, hurt by a steep decline in crude oil prices.Yelp shares slumped 18.1 percent to $42.00 a day after the operator of consumer review website forecast second-quarter revenue below analysts' expectations.Earnings expected after the close on Thursday include Dow component Visa, insurer AIG and LinkedIn.Declining issues outnumbered advancing ones on the NYSE by 2,348 to 524, for a 4.48-to-1 ratio on the downside; on the Nasdaq, 1,948 issues fell and 557 advanced for a 3.50-to-1 ratio favoring decliners.   (Editing by Savio D'Souza)",2015-04-30,CELG,"Thu Apr 30, 2015 | 10:39am EDT","US STOCKS-Wall St opens lower as Apple, Celgene weigh",http://www.reuters.com//article/markets-stocks-usa-idUSL4N0XR6S420150430?type=companyNews
50,  April 30 Celgene Corp * Says now expects 2015 Revlimid sales at or above upper end of forecast range of $5.6 billion to $5.7 billion  Further company coverage:    (Reporting By Bill Berkrot)  ,2015-04-30,CELG,"Thu Apr 30, 2015 | 10:20am EDT",BRIEF-Celgene sees 2015 Revlimid sales at or above high end of forecast range,http://www.reuters.com//article/idUSL1N0XR1JW20150430?type=companyNews
51,"  (In paragraph 7 corrects spelling of analyst's name to Liisa Bayko from Lisa Bayko)By Olivia OranMay 6 The hefty premium Alexion Pharmaceuticals Inc has agreed to pay to acquire Synageva BioPharma Corp highlights how the popularity of so-called orphan drug makers is leading to valuations many investors now deem frothy.Alexion shares fell as much as 10 percent on Wednesday on investor concerns the $8.4 billion cash and stock deal overvalued Synageva, whose drug for a rare and potentially fatal condition that causes a build-up of fat in the blood and liver awaits regulatory approval.Alexion offered Synageva nearly a 140 percent premium, versus an average takeover premium of 41 percent for biotechnology companies so far this year, according to Thomson Reuters data.Other recent big deals involving orphan drug makers that focus on rare diseases include Teva Pharmaceutical Industries Ltd's $3.5 billion purchase of Auspex Pharmaceuticals announced in March and Shire Plc's acquisition of NPS Pharmaceuticals for $5.2 billion in January. Reuters also reported last week that Pfizer Inc had made a preliminary offer for rare-disease drug maker Swedish Orphan Biovitrium AB. Orphan drug companies are seen as attractive because they can typically charge higher prices for their drugs, which serve small patient populations. The U.S. Food and Drug Administration's approval process for these drugs is also often quicker - around 10 months versus at least 1 year for non-orphan drugs. This is because these drugs treat serious or life threatening diseases when other treatment options may not exist.""Rare-disease companies are profitable businesses and the cost to market a product is pretty low, which makes them attractive targets,"" said Liisa Bayko, an analyst with JMP Securities. ""The drugs seem to sell themselves to some degree."" In turn, major drug companies such as Pfizer, Celgene Corp  and Novartis AG are investing heavily in orphan drugs. While rare diseases were historically ignored by large pharmaceutical companies in favor of those with larger patient populations such as cardiac disease and diabetes, orphan made up almost half of the 41 new drugs approved by the FDA last year.Sales of orphan drugs are expected to grow at an annual rate of almost 11 percent per year through 2020, compared with 4 percent for drugs treating larger populations, according to a recent report from research firm EvaluatePharma.However, some experts argue that orphan drug companies do not necessarily make for the best investments, because they are overvalued by the market and may carry R&D risk.""When you have large pharmaceutical companies that aren't already in the orphan sector paying large premiums, it enters into really risky territory,"" said Steve Brozak, president of WBB Securities LLC. ""It's going to be problematic for companies and investors that don't understand all the processes of manufacturing, development and patient advocacy.""U.S. pharmaceutical merger activity has topped $107.3 billion so far this year, more than double the volume a year ago.    (Reporting by Olivia Oran in New York; Editing by Greg Roumeliotis and Steve Orlofsky)",2015-05-06,CELG,"Wed May 6, 2015 | 4:41pm EDT",CORRECTED-Rich Synageva M&A premium epitomizes appetite for orphan drugs,http://www.reuters.com//article/raredisease-ma-idUSL1N0XX1FB20150506?type=companyNews
52,"   By Bill Berkrot  Celgene Corp on Thursday said the European Patent Office revoked a key patent on the company's flagship multiple myeloma drug Revlimid, a move that could shave a year or two from the medicine's exclusivity in Europe.The so-called polymorph patent in question would have kept cheaper versions of Revlimid off the European market until September 2024.The New Jersey-based biotechnology company said it plans to  appeal the ruling, a process that could take at least three years to run its course. ""While this would remain under appeal, the patent remains valid and enforceable during that time,"" said Celgene spokesman Greg Geissman.Other Revlimid patents provide Celgene with protection in Europe through 2022 or 2023.  ""The worst-case scenario in the EU for Celgene would be generic entry in July 2022, after the expiration of their composition of matter patent,"" Evercore ISI analyst Mark Schoenebaum said in a research note, adding that the appeals process could take as long as five years.A similar patent challenge is under way in the United States. But due to differences in U.S. patent law, both the company and analysts have said the European ruling is highly unlikely to be a predictor of the outcome in the world's largest market. Revlimid, which had worldwide sales of $1.34 billion in the first quarter, accounts for about 60 percent of total Celgene revenue. Celgene shares were up $2.8 percent at $111.66 on Nasdaq.  (Editing by Alden Bentley and Ted Botha)",2015-05-07,CELG,"Thu May 7, 2015 | 12:20pm EDT",EU patent office revokes Celgene Revlimid patent; appeal planned,http://www.reuters.com//article/us-celgene-patent-idUSKBN0NS1WB20150507?type=companyNews
53,"  (Adds company comment on appeal, analyst comment, background, share price)By Bill BerkrotMay 7 Celgene Corp on Thursday said the European Patent Office revoked a key patent on the company's flagship multiple myeloma drug Revlimid, a move that could shave a year or two from the medicine's exclusivity in Europe.The so-called polymorph patent in question would have kept cheaper versions of Revlimid off the European market until September 2024.The New Jersey-based biotechnology company said it plans to  appeal the ruling, a process that could take at least three years to run its course. ""While this would remain under appeal, the patent remains valid and enforceable during that time,"" said Celgene spokesman Greg Geissman.Other Revlimid patents provide Celgene with protection in Europe through 2022 or 2023. ""The worst-case scenario in the EU for Celgene would be generic entry in July 2022, after the expiration of their composition of matter patent,"" Evercore ISI analyst Mark Schoenebaum said in a research note, adding that the appeals process could take as long as five years.A similar patent challenge is under way in the United States. But due to differences in U.S. patent law, both the company and analysts have said the European ruling is highly unlikely to be a predictor of the outcome in the world's largest market. Revlimid, which had worldwide sales of $1.34 billion in the first quarter, accounts for about 60 percent of total Celgene revenue.Celgene shares were up $2.8 percent at $111.66 on Nasdaq.(Editing by Alden Bentley and Ted Botha)",2015-05-07,CELG,"Thu May 7, 2015 | 12:16pm EDT",UPDATE 1-EU patent office revokes Celgene Revlimid patent; appeal planned,http://www.reuters.com//article/celgene-patent-idUSL1N0XY26Q20150507?type=companyNews
54,"  May 7 Celgene Corp on Thursday said the European Patent Office revoked a key patent on the company's flagship multiple myeloma drug Revlimid, a move that could shave a year or two from the medicine's exclusivity in Europe.The so-called polymorph patent in question would have kept cheaper versions of Revlimid off the European market until 2024.  (Reporting by Bill Berkrot; Editing by Alden Bentley) ",2015-05-07,CELG,"Thu May 7, 2015 | 11:54am EDT",EU patent office revokes Celgene Revlimid patent; appeal planned,http://www.reuters.com//article/celgene-patent-idUSL1N0XY24Q20150507?type=companyNews
55,"   By Rosmi Shaji and Bill Berkrot  Celgene Corp on Monday launched a 10-year partnership with Juno Therapeutics, announcing a $1 billion investment aimed at bringing to market Juno technologies that harness the immune system to treat cancer and autoimmune diseases.The biotech companies, in a conference call to discuss the multi-faceted deal, said they anticipate potential product approvals in 2020.The huge vote of confidence propelled Juno's shares more than 40 percent higher to $65.75 in heavy extended trading.      Celgene will pay Juno about $150 million upfront and buy about 9.1 million newly issued Juno shares at $93 each,  double Juno's closing price on Monday. Juno had about 90.4 million shares outstanding as of May 4, according to a regulatory filing.At the heart of the deal are new treatments that use  Chimeric Antigen Receptor Technology (CAR-T) and T Cell Receptor (TCR) technologies, red-hot areas of immunotherapy that have driven up the share prices of several small companies, such as Juno, Kite Pharma Inc and Bluebird Bio Inc.  ""Juno has the best-in-class CAR-T and T cell receptors,"" Celgene Chief Executive Bob Hugin said.  Celgene, which said it does not expect deal costs to affect near-term profit and loss, will have the option to buy up to 30 percent of Juno's common stock between the ninth and 10th year of the collaboration, provided it exercises an option to raise its stake to 19.9 percent between years four and five.""Celgene is making a big commitment to CAR-T as we think this will be an important hematological platform,"" RBC Capital Partners analyst Michael Yee wrote in a note. Each company will also have options to partner on certain drugs in the other's pipeline, with the upfront costs dependent upon how far along those assets are in development.The harnessing of T cells and other components of the immune system to attack tumors can have dramatic, long-lasting effects on advanced cancers, potentially transforming the $100 billion global oncology drug market. T-cell receptors (TCRs) are a class of compounds that make it easier for the immune cells to identify and destroy cancer cells. CAR-T cells actually take the immune cells and modify them into more potent cancer killers.Kite and Bluebird said this month that they would partner to develop and market a new class of T-cell therapies for HPV-associated cancers.Kite shares rose more than 8 percent in extended trading after the Juno deal was announced. (Reporting by Rosmi Shaji in Bengaluru and Bill Berkrot in New York; Editing by Joyjeet Das and Don Sebastian)",2015-06-29,CELG,"Mon Jun 29, 2015 | 7:00pm EDT",Celgene to invest $1 billion in Juno to partner in cancer therapies,http://www.reuters.com//article/us-celgene-deals-juno-idUSKCN0P92OL20150629?type=companyNews
56,"  (New throughout, adds company comments from conference call, updates shares)By Rosmi Shaji and Bill BerkrotJune 29 Celgene Corp on Monday launched a 10-year partnership with Juno Therapeutics, announcing a $1 billion investment aimed at bringing to market Juno technologies that harness the immune system to treat cancer and autoimmune diseases.The biotech companies, in a conference call to discuss the multi-faceted deal, said they anticipate potential product approvals in 2020.The huge vote of confidence propelled Juno's shares more than 40 percent higher to $65.75 in heavy extended trading.Celgene will pay Juno about $150 million upfront and buy about 9.1 million newly issued Juno shares at $93 each,  double Juno's closing price on Monday. Juno had about 90.4 million shares outstanding as of May 4, according to a regulatory filing. At the heart of the deal are new treatments that use  Chimeric Antigen Receptor Technology (CAR-T) and T Cell Receptor (TCR) technologies, red-hot areas of immunotherapy that have driven up the share prices of several small companies, such as Juno, Kite Pharma Inc and Bluebird Bio Inc.""Juno has the best-in-class CAR-T and T cell receptors,"" Celgene Chief Executive Bob Hugin said. Celgene, which said it does not expect deal costs to affect near-term profit and loss, will have the option to buy up to 30 percent of Juno's common stock between the ninth and 10th year of the collaboration, provided it exercises an option to raise its stake to 19.9 percent between years four and five.""Celgene is making a big commitment to CAR-T as we think this will be an important hematological platform,"" RBC Capital Partners analyst Michael Yee wrote in a note.Each company will also have options to partner on certain drugs in the other's pipeline, with the upfront costs dependent upon how far along those assets are in development. The harnessing of T cells and other components of the immune system to attack tumors can have dramatic, long-lasting effects on advanced cancers, potentially transforming the $100 billion global oncology drug market.T-cell receptors (TCRs) are a class of compounds that make it easier for the immune cells to identify and destroy cancer cells. CAR-T cells actually take the immune cells and modify them into more potent cancer killers.Kite and Bluebird said this month that they would partner to develop and market a new class of T-cell therapies for HPV-associated cancers.Kite shares rose more than 8 percent in extended trading after the Juno deal was announced.   (Reporting by Rosmi Shaji in Bengaluru and Bill Berkrot in New York; Editing by Joyjeet Das and Don Sebastian)",2015-06-29,CELG,"Mon Jun 29, 2015 | 6:59pm EDT",UPDATE 2-Celgene to invest $1 bln in Juno to partner in cancer therapies,http://www.reuters.com//article/celgene-deals-juno-idUSL3N0ZF0AI20150629?type=companyNews
57,"  (Corrects spelling of Celgene in the headline)June 29 Celgene Corp and Juno Therapeutics Inc said they signed a deal to develop and commercialize immunotherapies for the treatment of cancer and autoimmune diseases. Juno will receive about $150 million upfront, and will sell 9.1 million shares of its common stock at $93 each to Celgene, the companies said on Monday.  Shares of Juno were up 61 percent in extended trading.   (Reporting by Rosmi Shaji in Bengaluru; Editing by Joyjeet Das)",2015-06-29,CELG,"Mon Jun 29, 2015 | 5:05pm EDT","REFILE-Celgene, Juno collaborate to develop cancer therapies",http://www.reuters.com//article/celgene-deals-juno-idUSL3N0ZF09U20150629?type=companyNews
58,"  July 10 Siegfried Holding Ltd :* Siegfried and Celgene, American bio-technology company, have put their existing close cooperation on a firm long-term footing  * Agreement, which replaces a cooperation agreement signed in 2006, includes acquisition of a production building in pharmapark Siegfried in Zofingen  Source text: bit.ly/1grkvSS Further company coverage:    (Gdynia Newsroom) ",2015-07-10,CELG,"Fri Jul 10, 2015 | 1:00am EDT",BRIEF-Siegfried Holding and Celgene sign long-term cooperation agreement,http://www.reuters.com//article/idUSFWN0ZP00T20150710?type=companyNews
59,"   By Bill Berkrot  Celgene Corp said on Tuesday it would buy Receptos Inc for $7.2 billion in a move that will give the U.S. biotechnology company a potential multibillion-dollar drug in late stage development for inflammatory bowel disease and multiple sclerosis.Celgene, whose shares rose nearly 6 percent in extended trading to $130.15, said it would pay $232 per share in cash for the smaller biotech. Receptos shares closed at $207.18 on Nasdaq and rose to $228.14 after hours.Celgene has been on something of a deal spree in recent months. The Receptos move comes just two weeks after Celgene said it would invest $1 billion in Juno Therapeutics to gain access to its cancer immunotherapy portfolio in a deal that would allow Celgene to buy up to 30 percent of Juno over the next decade.The company also has collaborations with Agios Pharmaceuticals, which has a very promising leukemia drug in development as well as other oncology prospects, and with AstraZeneca in immuno-oncology.""We have been fortunate to have been able to act on several major transactions that position us for sustained and enhanced long-term growth,"" Celgene Chief Executive Bob Hugin said on a conference call.    ""The Receptos acquisition provides a transformational opportunity for Celgene to impact multiple therapeutic areas,""  Hugin said.The deal should give Celgene lucrative new revenue sources, accelerating earning growth beginning in 2019, Hugin said, adding that ""it will be a key driver of growth well beyond 2020."" The acquisition is expected to cut into Celgene earnings in 2016 and 2017 and be neutral in 2018, the company said.""They found a very largely derisked late stage asset that can really move the needle,"" said Cowen and Co analyst Eric Schmidt. ""And they didn't seemingly overpay, so it's a pretty good deal."" Receptos in April reported positive data in ulcerative colitis from a midstage trial of its experimental oral drug ozanimod, the medicine at the heart of the Celgene deal.Phase III ozanimod trials are underway for both ulcerative colitis and relapsing MS. The drug could be approved for MS in 2018, Celgene said, putting the company into a new therapeutic area. Phase III colitis data are expected in 2018. Celgene forecast peak annual ozanimod sales of $4 billion to $6 billion for UC and MS.The drug also has potential use in Crohn's disease, psoriasis and atopic dermatitis, Celgene said. Those are all conditions with very large patient populations.Given its confidence in ozanimod, Celgene raised its 2020 financial targets. It now expects product sales to exceed $21 billion and adjusted earnings to exceed $13 per share, up from prior 2020 forecasts of sales greater than $20 billion and earnings of $12.50 per share. Celgene also reported preliminary second quarter results and updated its full-year forecast.It now expects 2015 adjusted earnings of $4.75 to $4.85 per share, up from its previous range of $4.60 to $4.75. It still sees 2015 product sales of $9 billion to $9.5 billion.For the second quarter, Celgene reported revenue of $2.28 billion, up 22 percent from the year-ago quarter.It said it expected to report net earnings of 43 cents per share, down from 72 cents a year ago, due to expenses for collaboration payments. It said adjusted earnings would be about $1.23 per share, up from 90 cents a year ago and above Wall Street expectations of $1.14.J.P. Morgan and Citi are acting as financial advisors to Celgene on the Receptos transaction. Centerview Partners LLC is acting as financial advisor to Receptos. Legal counsel for Celgene is Proskauer Rose LLP, and Receptos legal counsel is Latham & Watkins LLP. (Reporting by Bill Berkrot in New York; editing by Cynthia Osterman)",2015-07-14,CELG,"Tue Jul 14, 2015 | 7:21pm EDT",Celgene to buy Receptos for $7.2 billion; gains promising drug,http://www.reuters.com//article/us-receptos-m-a-celgene-idUSKCN0PO2OB20150714?type=companyNews
60,"  (Adds forecasts, analyst comment, Q2 earnings, background, company comment)By Bill BerkrotJuly 14 Celgene Corp said on Tuesday it would buy Receptos Inc for $7.2 billion in a move that will give the U.S. biotechnology company a potential multibillion-dollar drug in late stage development for inflammatory bowel disease and multiple sclerosis.Celgene, whose shares rose nearly 6 percent in extended trading to $130.15, said it would pay $232 per share in cash for the smaller biotech. Receptos shares closed at $207.18 on Nasdaq and rose to $228.14 after hours.Celgene has been on something of a deal spree in recent months. The Receptos move comes just two weeks after Celgene said it would invest $1 billion in Juno Therapeutics to gain access to its cancer immunotherapy portfolio in a deal that would allow Celgene to buy up to 30 percent of Juno over the next decade.The company also has collaborations with Agios Pharmaceuticals, which has a very promising leukemia drug in development as well as other oncology prospects, and with AstraZeneca in immuno-oncology.""We have been fortunate to have been able to act on several major transactions that position us for sustained and enhanced long-term growth,"" Celgene Chief Executive Bob Hugin said on a conference call.""The Receptos acquisition provides a transformational opportunity for Celgene to impact multiple therapeutic areas,""  Hugin said. The deal should give Celgene lucrative new revenue sources, accelerating earning growth beginning in 2019, Hugin said, adding that ""it will be a key driver of growth well beyond 2020.""The acquisition is expected to cut into Celgene earnings in 2016 and 2017 and be neutral in 2018, the company said.""They found a very largely derisked late stage asset that can really move the needle,"" said Cowen and Co analyst Eric Schmidt. ""And they didn't seemingly overpay, so it's a pretty good deal."" Receptos in April reported positive data in ulcerative colitis from a midstage trial of its experimental oral drug ozanimod, the medicine at the heart of the Celgene deal.Phase III ozanimod trials are underway for both ulcerative colitis and relapsing MS. The drug could be approved for MS in 2018, Celgene said, putting the company into a new therapeutic area. Phase III colitis data are expected in 2018.Celgene forecast peak annual ozanimod sales of $4 billion to $6 billion for UC and MS.The drug also has potential use in Crohn's disease, psoriasis and atopic dermatitis, Celgene said. Those are all conditions with very large patient populations. Given its confidence in ozanimod, Celgene raised its 2020 financial targets. It now expects product sales to exceed $21 billion and adjusted earnings to exceed $13 per share, up from prior 2020 forecasts of sales greater than $20 billion and earnings of $12.50 per share.Celgene also reported preliminary second quarter results and updated its full-year forecast.It now expects 2015 adjusted earnings of $4.75 to $4.85 per share, up from its previous range of $4.60 to $4.75. It still sees 2015 product sales of $9 billion to $9.5 billion.For the second quarter, Celgene reported revenue of $2.28 billion, up 22 percent from the year-ago quarter.It said it expected to report net earnings of 43 cents per share, down from 72 cents a year ago, due to expenses for collaboration payments. It said adjusted earnings would be about $1.23 per share, up from 90 cents a year ago and above Wall Street expectations of $1.14.J.P. Morgan and Citi are acting as financial advisors to Celgene on the Receptos transaction. Centerview Partners LLC is acting as financial advisor to Receptos. Legal counsel for Celgene is Proskauer Rose LLP, and Receptos' legal counsel is Latham & Watkins LLP.   (Reporting by Bill Berkrot in New York; editing by Cynthia Osterman)",2015-07-14,CELG,"Tue Jul 14, 2015 | 7:20pm EDT",UPDATE 2-Celgene to buy Receptos for $7.2 bln; gains promising drug,http://www.reuters.com//article/receptos-ma-celgene-idUSL4N0ZU5GT20150714?type=companyNews
61,"  July 14 Celgene Corp said it agreed to buy Receptos Inc for about $7.2 billion to expand its pipeline with Receptos' immune-inflammatory bowel drug, Ozanimod.Celgene will pay $232 in cash for every Receptos share, representing a 12 percent premium to the company's closing price on Tuesday.  Ozanimod is in late-stage trials for inflammatory bowel disease and multiple sclerosis.   (Reporting by Amrutha Penumudi in Bengaluru; Editing by Maju Samuel) ",2015-07-14,CELG,"Tue Jul 14, 2015 | 5:15pm EDT",Celgene to buy Receptos for $7.2 bln,http://www.reuters.com//article/receptos-ma-celgene-idUSL4N0ZU5FS20150714?type=companyNews
62,"   By Chuck Mikolajczak  U.S. stocks edged lower on Wednesday following comments from Federal Reserve Chair Janet Yellen, as a decline in energy shares outweighed gains in the financial sector in the latter stages of trading. The energy sector .SPNY, down 1.6 percent, was the worst performer of the 10 major S&P groups as oil prices retreated on concerns increased exports from Iran will add to a global supply glut. Brent LCOc1 settled down $1.46 at $57.05 while U.S. crude CLc1 settled down $1.63 at $51.41 a barrel.""We were positive the whole day and we sort of lost our gains right at the tail end,"" said Phil Orlando, chief equity market strategist at Federated Investors in New York. ""If crude were to be going down, that would mean there is an assumption this deal may get through Congress or the Presidents veto wont get overturned by Congress such that this Iranian flood of crude comes onto the market.""Financials .SPSY, up 0.7 percent, helped curb declines. The group was buoyed by a 3.2 percent rise in Bank of America (BAC.N) to $17.68 and a 3.8 percent gain in U.S. Bancorp (USB.N) to $45.53 after their quarterly results.The S&P snapped a four-session winning streak, its longest run of gains since January.  Celgene (CELG.O) climbed 7 percent to $131.39 after touching a record high of $135.98. The company said it would buy Receptos RCPT.O to get a potential multibillion-dollar drug.Yellen said she expects the economy to grow steadily for the rest of the year, allowing the Fed to hike rates, but gave no direct hint on the timing or pace of a hike. The Fed is broadly expected to hike rates in September or December.The Fed's Beige Book showed U.S. economic activity continued to expand from mid-May through June, with lower energy prices helping boost consumer spending but remaining a drag on manufacturing. The Dow Jones industrial average .DJI fell 3.41 points, or 0.02 percent, to 18,050.17, the S&P 500 .SPX lost 1.55 points, or 0.07 percent, to 2,107.4 and the Nasdaq Composite .IXIC dropped 5.95 points, or 0.12 percent, to 5,098.94.Corporate America is expected to report its worst sales decline in nearly six years in the second quarter, while profit is expected to have fallen 2.9 percent, according to Thomson Reuters estimates. The effect of uncertainty in Chinese markets and the strong dollar will also be in focus.Yum Brands (YUM.N) fell 2.9 percent to $88.88. The owner of Pizza Hut and KFC reported its fourth straight quarter of falling sales, indicating it is still struggling to regain lost ground in China after a food safety scandal last year. The Nasdaq is likely to get a lift on Thursday on the heels of results from Intel (INTC.O) and Netflix (NFLX.O) after the market close. Intel jumped 5.4 percent to $31.30 while Netflix surged 10.4 percent to $108.20 in extended trade, sending Nasdaq e-mini NQc1 futures up nearly 20 points. Declining issues outnumbered advancing ones on the NYSE by 1,841 to 1,223, for a 1.51-to-1 ratio on the downside; on the Nasdaq, 1,826 issues fell and 998 advanced for a 1.83-to-1 ratio favoring decliners.The benchmark S&P 500 index posted 30 new 52-week highs and 16 new lows; the Nasdaq Composite recorded 140 new highs and 64 new lows.Volume was light, with about 6.09 billion shares traded on U.S. exchanges, below the 6.66 billion average so far this month, according to BATS Global Markets. (Reporting by Chuck Mikolajczak; Editing by Nick Zieminski and Meredith Mazzilli)",2015-07-15,CELG,"Wed Jul 15, 2015 | 4:40pm EDT",Wall Street edges lower as energy weighs,http://www.reuters.com//article/us-markets-stocks-idUSKCN0PP1CB20150715?type=companyNews
63,"  Celgene Corp's (CELG.O) effort to reduce dependence on its flagship cancer drug through the $7.2 billion bet on Receptos Inc's RCPT.O potential blockbuster drug won the backing of Wall Street.        Shares of Celgene and Receptos rose as much as 11 percent to record highs on Wednesday.Cowen & Co's Eric Schmidt said the deal could be a ""steal"" for Celgene, if Receptos' ozinamod proves successful, while Baird Equity Research's Brian Skorney drew parallels to Gilead Sciences Inc (GILD.O) acquisition of Pharmasset Inc in 2011.Gilead spent $11 billion to buy Pharmasset and its portfolio of experimental hepatitis C treatments, which now command a sizable portion of the U.S. market under the brands Sovaldi and Harvoni.Celgene's offer to buy Receptos comes just under three weeks after it said it would invest $1 billion in Juno Therapeutics Inc (JUNO.O), which is developing cancer treatments that belong to a new class of therapies.Healthcare sector has seen a record wave of deal-making since the start of 2014, stretching from large drugmakers buying up smaller rivals to consolidation among makers of generic medicines and tie-ups between insurers. Buying Receptos gives Celgene access to ozinamod, a product that it estimates to have peak annual sales of $4-$6 billion in treating ulcerative colitis and multiple sclerosis.Celgene's Revlimid had worldwide sales of $1.34 billion in the first quarter.  Celgene receives about 60 percent of revenue from Revlimid but the multiple myeloma drug's patents have been challenged in United States and Europe.Tuesday's deal dilutes concerns over potential generic threat to the cancer treatment, analysts wrote.""We like the fact that ozinamod is a largely derisked asset with large commercial potential that is capable of augmenting longer-term growth...,"" Schmidt wrote. Barclays Capital's Geoff Meacham called the deal price ""fair,"" with Nomura analysts adding that the price represented a steep discount relative to recent deals.Celgene shares rose to $135.98 while Receptos rose to $229.44. (Reporting by Vidya L Nathan in Bengaluru; Editing by Don Sebastian)",2015-07-15,CELG,"Wed Jul 15, 2015 | 1:13pm EDT",Wall Street lauds Celgene's $7.2 billion Receptos buy,http://www.reuters.com//article/us-receptos-m-a-idUSKCN0PP26H20150715?type=companyNews
64,"  * Turmoil abroad unlikely to hit U.S. economy - Yellen* Nasdaq biotech index hits record high on Celgene deal* Bank of America rises after profit more than doubles* Macy's rises after Starboard announces stake* Indexes up: Dow 0.07 pct, S&P 0.09 pct, Nasdaq 0.16 pct   (Updates to early afternoon)By Tanya AgrawalJuly 15 U.S. stocks were marginally higher in afternoon trading on Wednesday, set for a fifth straight day of gains, after Federal Reserve Chair Janet Yellen said the turmoil abroad was unlikely to affect the U.S. economy and that the Fed was on track to raise interest rates this year.Bank of America rose 3 percent to $17.66, poised for its best day in five months, after reporting its biggest quarterly profit in nearly four years. The stock was the biggest boost to the S&P 500 financial index, which was the top gainer among the 10 major S&P 500 sectors. Celgene jumped as much as 10.7 percent to a record high of $135.98 after the company said it would buy Receptos  to get a potential multibillion-dollar drug. Celgene's gains helped push the Nasdaq biotech index to hit a record high for the third time in three weeks.Yellen said she expects the economy to grow steadily for the rest of the year, allowing the Fed to hike rates, but gave no direct hint on the timing or pace of a hike. The Fed is broadly expected to hike rates in September or December.""A rate hike will be additive to the U.S. equities as the U.S. economy requires something other than crisis-era rates,"" said Terry Sandven, chief equity strategist at U.S. Bank Wealth Management in Minneapolis. ""The pace of the rate hike is more important than the timing of it as investors remain in pause mode with a modest downward basis.""At 12:43 p.m. ET (1643 GMT), the Dow Jones industrial average was up 11.95 points, or 0.07 percent, at 18,065.53 and the Nasdaq Composite was up 8.24 points, or 0.16 percent, at 5,113.13.The S&P 500 was up 1.94 points, or 0.09 percent, at 2,110.89, just 1 percent away from its May record high of $2134.72.Five of the 10 major S&P 500 sectors were lower, with the energy index's 0.97 percent fall leading the decliners. Oil prices fell as traders took profits from the past two days of gains. Corporate America is expected to report its worst sales decline in nearly six years in the second quarter, while profit is expected to have fallen 2.9 percent, according to Thomson Reuters estimates. The effect of the uncertainty in the Chinese markets and the strong dollar will also be in focus.Yum Brands fell 2.9 percent to $89.37 after the owner of Pizza Hut and KFC reported its fourth straight quarter of falling sales, indicating it is still struggling to regain lost ground in China after a food scandal last year.Macy's jumped as much as 7 percent to $71.35 after investment firm Starboard Value said it had taken a stake in the retail chain.Netflix was down 1.6 percent at $98.71 in its first day of trade after a seven-for-one stock split. Netflix and Intel are scheduled to report after the markets close.Declining issues outnumbered advancers on the NYSE by 1,756 to 1,195. On the Nasdaq, 1,615 issues fell and 1,077 advanced.The S&P 500 index posted 27 new 52-week highs and seven new lows, while the Nasdaq recorded 121 new highs and 41 new lows.   (Editing by Savio D'Souza)",2015-07-15,CELG,"Wed Jul 15, 2015 | 1:09pm EDT",US STOCKS-Wall St higher; financial stocks lead,http://www.reuters.com//article/markets-stocks-usa-idUSL4N0ZV57K20150715?type=companyNews
65,"  * Turmoil abroad unlikely to hit U.S. economy - Yellen* Nasdaq biotech index hits record high on Celgene deal* Bank of America rises after profit more than doubles* Delta Air Lines warning weighs on airline stocks* Indexes up: Dow 0.17 pct, S&P 0.2 pct, Nasdaq 0.36 pct   (Adds details, changes comment, updates prices)By Tanya AgrawalJuly 15 U.S. stocks were modestly higher on Wednesday, set for a fifth straight day of gains, after Federal Reserve Chair Janet Yellen said the turmoil abroad was unlikely to affect the U.S. economy and that the Fed was on track to raise interest rates this year.Yellen said she expects the economy to grow steadily for the rest of the year, allowing the Fed to hike rates, but gave no direct hint on the timing or pace of a hike.""A rate hike will be additive to the U.S. equities as the U.S. economy requires something other than crisis-era rates,"" said Terry Sandven, chief equity strategist at U.S. Bank Wealth Management in Minneapolis. ""The pace of the rate hike is more important than the timing of it as investors remain in pause mode with a modest downward basis.""Investor also await the outcome of a Greek parliament vote, where Prime Minister Alexis Tsipras is struggling to persuade unhappy leftist lawmakers to vote for a package of austerity measures and economic reforms to secure a bailout.At 11:01 a.m. ET (1501 GMT) the Dow Jones industrial average  was up 29.83 points, or 0.17 percent, at 18,083.41. The S&P 500 was up 4.29 points, or 0.2 percent, at 2,113.24 and the Nasdaq composite was up 18.45 points, or 0.36 percent, at 5,123.34.Seven of the 10 major S&P 500 sectors were lower, but Bank of America and Celgene helped the financial  and healthcare indexes, respectively, buck the trend. Bank of America shares rose 3.2 percent to $17.67, poised for its best day in five months, after the bank reported its biggest quarterly profit in nearly four years.Celgene jumped as much as 10.7 percent to a record high of $135.98 after the company said it would buy Receptos  for $7.2 billion to get a potential multibillion-dollar drug.Celgene's gains helped push the Nasdaq biotech index  up more than 2 percent to hit a record high for the third time in three weeks.Corporate America is expected to report its worst sales decline in nearly six years in the second quarter, while profit is expected to have fallen 2.9 percent, according to Thomson Reuters estimates. ""More important than the second-quarter results is the guidance that companies give for the second half of the year especially consumer staples and industrials,"" said Jeremy Zirin, chief investment strategist at UBS Wealth Management.The uncertainty in the Chinese markets and the strong dollar will also be in focus this earnings season.Delta Air Lines fell 1.7 percent to $42.94 after the carrier forecast a third-quarter drop in unit revenue, saying the strong dollar was hurting demand abroad. The warning weighed on other airline stocks.Yum Brands fell 2.7 percent to $89.47 after the owner of Pizza Hut and KFC reported its fourth straight quarter of falling sales, indicating it is still struggling to regain lost ground in China after a food scandal last year.Netflix was down 0.3 percent at $100.03 after it started trade for the first time after a seven-for-one stock split. Netflix and Intel are scheduled to report after the markets close.Declining issues outnumbered advancers on the NYSE by 1,686. On the Nasdaq, 1,336 issues fell and 1,226 advanced.The S&P 500 index showed 21 new 52-week highs and four new lows, while the Nasdaq recorded 106 new highs and 27 new lows.   (Editing by Savio D'Souza)",2015-07-15,CELG,"Wed Jul 15, 2015 | 11:34am EDT",US STOCKS-Wall St up as Fed says on track to raise rates in 2015,http://www.reuters.com//article/markets-stocks-usa-idUSL4N0ZV51520150715?type=companyNews
66,"  (Adds LafargeHolcim, Energy Transfer Partners, EWE)July 15 The following bids, mergers, acquisitions and disposals were reported by 1330 GMT on Wednesday:** Celgene Corp said it would buy Receptos Inc  for $7.2 billion in a move that would give the U.S. biotechnology company a potential multibillion-dollar drug in late stage development for inflammatory bowel disease and multiple sclerosis.** Wells Fargo & Co said it was looking at more financial assets being unloaded by General Electric's GE Capital unit after it bought $9 billion of real estate loans from the conglomerate.** LafargeHolcim plans to complete the integration of Lafarge and Holcim by the end of next year following their merger and confirmed plans to save 1.4 billion euros ($1.5 billion) within three years.** Pipeline company Energy Transfer Partners said it would sell convenience store operator Susser Holdings to its unit Sunoco LP for about $1.94 billion in cash and stock.** Advtech, South Africa's second-biggest private education firm, confirmed it had received a takeover offer from larger rival Curro Holdings. ** The chief executive of Fiat Chrysler Automobiles (FCA)  Sergio Marchionne does not plan to make another offer to merge with General Motors after being rejected by its U.S. rival four months ago, the New York Times quoted him as saying.** Russian state conglomerate Rostec wants to get rights to develop Sukhoi Log, one of the world's largest untapped gold deposits in Siberia's Irkutsk region, a source close to Rostec told Reuters.** German utility EWE has received an offer for its majority stake in eastern German gas transmission company VNG AG, it said. ** Malaysia's debt-laden state fund 1Malaysia Development Bhd (1MDB) has welcomed Tenaga Nasional Bhd's  interest in almost all its power assets, adding that it had also received interest from other parties.** Hedge fund Paulson & Co has taken a stake in Syngenta AG  and could push for the Swiss pesticide maker's board to accept a takeover offer from U.S. seed company Monsanto Co,  people familiar with the matter said.** Struggling German engineering services firm Bilfinger  has won two deals to manage real estate for major European banks, a month after its new chief executive took office. ** Delta Air Lines has been proposed as a sponsor to rehabilitate Skymark Airlines Inc by the bankrupt Japanese carrier's biggest creditor - a plan that challenges a separate proposal that has put forward ANA Holdings as a sponsor.** Ryanair will bid for the slots IAG has agreed to release at London's Gatwick airport as a condition of its takeover of Aer Lingus, Ryanair Chief Executive Michael O'Leary said.** U.S. investment fund Apollo Global Management is interested in buying Raiffeisen's bank in Slovenia, Finance daily newspaper reported.** Lender BOC Hong Kong Holdings Ltd plans to sell subsidiary Nanyang Commercial Bank for HK$68 billion ($8.8 billion) in the city's largest sale to date.** The Turkish Privatisation Administration has opened tenders for the privatization of a combined cycle and gas turbine power plant in Aliaga and a natural gas plant in Bursa in northwest Turkey, the Official Gazette said.** Belgian insurance group Ageas is planning to sell its operations in Hong Kong in a deal valued at above $1 billion, corporate finance news specialist Mergermarket wrote.     ($1 = 7.75 Hong Kong dollars)  ($1 = 0.91 euros)   (Compiled by Kshitiz Goliya in Bengaluru)",2015-07-15,CELG,"Wed Jul 15, 2015 | 9:30am EDT",Deals of the day- Mergers and acquisitions,http://www.reuters.com//article/deals-day-idUSL4N0ZV3II20150715?type=companyNews
67,  July 16 Bionor Pharma ASA :* Enters into romidepsin supply agreement enabling advancement of its HIV therapeutic vaccine with Vacc-4x into full scale clinical Phase II * Says has signed an agreement with Celgene Corporation securing a continued supply of romidepsin (Istodax)  Source text for Eikon:  Further company coverage:    (Gdynia Newsroom),2015-07-16,CELG,"Thu Jul 16, 2015 | 1:41am EDT",BRIEF-Bionor Pharma agrees with Celgene on continued supply of romidepsin,http://www.reuters.com//article/idUSASM000B1A20150716?type=companyNews
68,"   By Andrew Chung | NEW YORK  NEW YORK Celgene Corp, one of the world's largest biotechnology companies, has accused U.S. hedge fund manager Kyle Bass of attempting to profit from his attempts to wipe out several major drug patents through his Coalition for Affordable Drugs.The company asked the U.S. Patent and Trademark Office on Tuesday to sanction Bass and others behind the group by throwing out its challenges to Celgene's patents.The industry is watching the sanctions attempt closely because it could doom Bass' much-publicized effort to kill what he calls undeserving patents and to lower drug prices.Celgene said Bass' real motive was to make money short-selling pharmaceutical shares that drop when a patent review is filed. Bass and his partners want ""to line their own pockets at the expense of public pharmaceutical companies and their shareholders,"" Celgene said in legal papers.Neither Bass nor a spokeswoman for his $2 billion Dallas-based Hayman Capital Management was immediately available for comment on Wednesday.In February, Bass began to file reviews to eliminate drug patents through a procedure called inter partes review. Since then, the coalition has filed 16 of them, including five against Celgene. Drug companies are worried because the reviews, which began in 2012 as part of the America Invents Act, are cancelling patents at a high rate. They have lobbied Congress to prevent hedge funds from launching reviews.Bass has said big companies were improperly extending patent protection in questionable ways, such as changing dosage or packaging, to keep drug prices high. But New Jersey-based Celgene said Bass was not trying to help the public by lowering prices, citing media reports of his short-selling strategy. It said his partner was Erich Spangenberg, whom the company called a ""patent troll"" and had already threatened to file reviews on Celgene's patents in 2014.Bass' first review, on Feb. 10 against an Acorda Therapeutics patent on the Ampyra multiple sclerosis drug, led to a nearly 10 percent drop in the company's stock price.Celgene's patents cover methods to ensure that thalidomide and related cancer drugs, which can cause severe birth defects, are only given to approved patients who are not pregnant.Bass' coalition asked the patent office to initiate a review, saying the methods were obvious and did not merit legal protection in the first place.",2015-07-29,CELG,"Wed Jul 29, 2015 | 5:42pm EDT",Celgene says patent-fighting hedge fund manager wants to short its shares,http://www.reuters.com//article/celgene-lawsuit-hedgefund-idUSL1N1093NL20150729?type=companyNews
69,"   By Andrew Chung | NEW YORK  NEW YORK Celgene Corp, one of the world's largest biotechnology companies, has accused U.S. hedge fund manager Kyle Bass of attempting to profit from his attempts to wipe out several major drug patents through his Coalition for Affordable Drugs. The company asked the U.S. Patent and Trademark Office on Tuesday to sanction Bass and others behind the group by throwing out its challenges to Celgene's patents. The industry is watching the sanctions attempt closely because it could doom Bass' much-publicized effort to kill what he calls undeserving patents and to lower drug prices. Celgene said Bass' real motive was to make money short-selling pharmaceutical shares that drop when a patent review is filed. Bass and his partners want ""to line their own pockets at the expense of public pharmaceutical companies and their shareholders,"" Celgene said in legal papers.  Neither Bass nor a spokeswoman for his $2 billion Dallas-based Hayman Capital Management was immediately available for comment on Wednesday.In February, Bass began to file reviews to eliminate drug patents through a procedure called inter partes review. Since then, the coalition has filed 16 of them, including five against Celgene. Drug companies are worried because the reviews, which began in 2012 as part of the America Invents Act, are cancelling patents at a high rate. They have lobbied Congress to prevent hedge funds from launching reviews.  Bass has said big companies were improperly extending patent protection in questionable ways, such as changing dosage or packaging, to keep drug prices high. But New Jersey-based Celgene said Bass was not trying to help the public by lowering prices, citing media reports of his short-selling strategy. It said his partner was Erich Spangenberg, whom the company called a ""patent troll"" and had already threatened to file reviews on Celgene's patents in 2014. Bass' first review, on Feb. 10 against an Acorda Therapeutics patent on the Ampyra multiple sclerosis drug, led to a nearly 10 percent drop in the company's stock price. Celgene's patents cover methods to ensure that thalidomide and related cancer drugs, which can cause severe birth defects, are only given to approved patients who are not pregnant. Bass' coalition asked the patent office to initiate a review, saying the methods were obvious and did not merit legal protection in the first place. (Reporting by Andrew Chung; Editing by Lisa Von Ahn)",2015-07-29,CELG,"Wed Jul 29, 2015 | 4:15pm EDT",Celgene says patent-fighting hedge fund manager wants to short its shares,http://www.reuters.com//article/us-celgene-lawsuit-hedgefund-idUSKCN0Q32IZ20150729?type=companyNews
70,"   By Andrew Chung | NEW YORK, July 29  NEW YORK, July 29 Celgene Corp, one of the world's largest biotechnology companies, has accused U.S. hedge fund manager Kyle Bass of attempting to profit from his attempts to wipe out several major drug patents through his Coalition for Affordable Drugs.The company asked the U.S. Patent and Trademark Office on Tuesday to sanction Bass and others behind the group by throwing out its challenges to Celgene's patents.The industry is watching the sanctions attempt closely because it could doom Bass' much-publicized effort to kill what he calls undeserving patents and to lower drug prices.Celgene said Bass' real motive was to make money short-selling pharmaceutical shares that drop when a patent review is filed. Bass and his partners want ""to line their own pockets at the expense of public pharmaceutical companies and their shareholders,"" Celgene said in legal papers.Neither Bass nor a spokeswoman for his $2 billion Dallas-based Hayman Capital Management was immediately available for comment on Wednesday.In February, Bass began to file reviews to eliminate drug patents through a procedure called inter partes review. Since then, the coalition has filed 16 of them, including five against Celgene. Drug companies are worried because the reviews, which began in 2012 as part of the America Invents Act, are cancelling patents at a high rate. They have lobbied Congress to prevent hedge funds from launching reviews.Bass has said big companies were improperly extending patent protection in questionable ways, such as changing dosage or packaging, to keep drug prices high. But New Jersey-based Celgene said Bass was not trying to help the public by lowering prices, citing media reports of his short-selling strategy. It said his partner was Erich Spangenberg, whom the company called a ""patent troll"" and had already threatened to file reviews on Celgene's patents in 2014.Bass' first review, on Feb. 10 against an Acorda Therapeutics patent on the Ampyra multiple sclerosis drug, led to a nearly 10 percent drop in the company's stock price.Celgene's patents cover methods to ensure that thalidomide and related cancer drugs, which can cause severe birth defects, are only given to approved patients who are not pregnant.Bass' coalition asked the patent office to initiate a review, saying the methods were obvious and did not merit legal protection in the first place.   (Reporting by Andrew Chung; Editing by Lisa Von Ahn)",2015-07-29,CELG,"Wed Jul 29, 2015 | 4:01pm EDT",Celgene says patent-fighting hedge fund manager wants to short its shares,http://www.reuters.com//article/celgene-lawsuit-hedgefund-idUSL1N10923X20150729?type=companyNews
71,"   By Deena Beasley  Oct 16 The most influential source for U.S. oncology treatment guidelines on Friday unveiled ratings aimed at helping doctors and patients assess the costs versus benefits of current therapies for two types of blood cancer.The National Comprehensive Cancer Network (NCCN), a nonprofit alliance of 26 leading cancer centers, said its new ""Evidence Blocks"" for multiple myeloma and chronic myelogenous leukemia are the first in a series that by the end of next year will encompass all oncology therapies, other than surgery or radiation. The blocks give each therapy a score of between one and five in five categories: efficacy, safety, quality and consistency of evidence and affordability. They will supplement NCCN's widely followed guidelines for oncology care.In examples released on Friday, NCCN rated primary treatments for CML: Bristol-Myers Squibb's Sprycel, and Novartis AG's Gleevec and Tasigna. Ratings for all three were nearly identical: highly effective and very expensive. For newly diagnosed myeloma patients eligible for a stem cell transplant, NCCN lists six ""preferred"" regimens, four of which contain Takeda Pharmaceutical Co's Velcade and various chemotherapies, one that includes Celgene Corp's  Revlimid and another that combines Velcade and Revlimid. The Velcade/Revlimid/dexamethasone regimen is rated as the most effective and the most expensive. NCCN lists Amgen Inc's Kyprolis, in combination with Revlimid and dexamethasone, as another upfront therapy for myeloma. The Kyprolis regimen was rated highly effective, mildly toxic, average in terms of evidence, mainly consistent in terms of trial data, and very expensive.Multiple myeloma is a type of blood cancer that develops in the bone marrow, while CML starts in certain blood-forming cells of the bone marrow. Multiple myeloma is diagnosed in about 27,000 Americans each year, and CML is occurs in about 7,000, according to the American Cancer Society.   (Reporting By Deena Beasley; Editing by David Gregorio)",2015-10-16,CELG,"Fri Oct 16, 2015 | 3:00pm EDT","U.S. oncology group rates blood cancer regimens, including cost",http://www.reuters.com//article/health-cancer-affordability-idUSL1N12G1B520151016?type=companyNews
72,"   By Vidya L Nathan  Celgene Corp (CELG.O) posted its smallest revenue growth in five quarters due to slower sales of its two key cancer drugs. The drugmaker's shares fell as much as 6.7 percent to $118.61, wiping out $6.77 billion from the company's market value.Lower-than-expected sales growth of Revlimid and Abraxane pushed the company's revenue below the average analyst estimate and profit to just above expectations. ""Notably, this goes against the trend in large-cap biotech, where the vast majority of companies beat on the top or bottom line and raised guidance,"" Barclay's analyst Geoffrey Meacham said in a note.    Growing sales of expensive new cancer drugs and other treatments helped top U.S. drugmakers such as Pfizer Inc (PFE.N), Merck & Co (MRK.N) and Bristol-Myers Squibb Co (BMY.N) post stronger-than-expected quarterly profits last month.Celgene's total revenue rose 17.7 percent to $2.33 billion in the third quarter, but still fell short of the average analyst estimate of $2.40 billion, according to Thomson Reuters I/B/E/S. Revlimid sales grew 11.8 percent to $1.45 billion in the quarter ended Sept. 30, slower than the 15 percent sales growth it registered in each of the last four quarters.""Revlimid appears to suffer a bit from adverse seasonality, and possibly also (foreign exchange) in ex-US geographies,"" Cowen and Co analysts wrote in a note.The drug's international sales rose 3.4 percent to $558.3 million, which analysts said were below their expectations. Celgene cut its full-year sales forecast for Abraxane to a range of $950 million-$1.25 billion, down from $1.00 billion-$1.25 billion three months ago.    Jackie Fouse, Celgene's president of hematology and oncology unit, said Abraxane was facing competition in the United States from newer treatments for lung cancer.Celgene posted net loss of $34.1 million, or 4 cents per share in the quarter, compared with a net profit of $508.5 million, or 61 cents per share, a year earlier. Net loss for the quarter included $751.8 million in collaboration costs and $231.6 million in costs related to the company's acquisition of Receptos Inc announced in July. New Jersey-based Celgene earned $1.23 per share in the quarter, excluding items, marginally beating the average analysts' estimate of $1.22 per share.While the company kept its adjusted profit forecast for the year unchanged, it also cut its full-year profit view to $2.02-$2.24 per share from $2.17-$2.46 it forecast earlier. (Reporting by Vidya L Nathan in Bengaluru; Editing by Saumyadeb Chakrabarty and Anil D'Silva)",2015-11-05,CELG,"Thu Nov 5, 2015 | 11:09am EST",Celgene's revenue misses as key cancer drug sales slow,http://www.reuters.com//article/us-celgene-results-idUSKCN0SU1SV20151105?type=companyNews
73,"  * Q3 rev $2.33 bln vs. est. $2.40 bln* Revlimid int'l sales below expectations - analysts* Company says Abraxane faces competition from rival treatments* Q3 profit $1.23/shr vs. est. $1.22/shr* Shares down as much as 6.7 pct   (Adds analyst comment, company comments; update shares)By Vidya L NathanNov 5 Celgene Corp posted its smallest revenue growth in five quarters due to slower sales of its two key cancer drugs.The drugmaker's shares fell as much as 6.7 percent to $118.61, wiping out $6.77 billion from the company's market value. Lower-than-expected sales growth of Revlimid and Abraxane pushed the company's revenue below the average analyst estimate and profit to just above expectations.""Notably, this goes against the trend in large-cap biotech, where the vast majority of companies beat on the top or bottom line and raised guidance,"" Barclay's analyst Geoffrey Meacham said in a note.Growing sales of expensive new cancer drugs and other treatments helped top U.S. drugmakers such as Pfizer Inc , Merck & Co and Bristol-Myers Squibb Co  post stronger-than-expected quarterly profits last month. Celgene's total revenue rose 17.7 percent to $2.33 billion in the third quarter, but still fell short of the average analyst estimate of $2.40 billion, according to Thomson Reuters I/B/E/S.Revlimid sales grew 11.8 percent to $1.45 billion in the quarter ended Sept. 30, slower than the 15 percent sales growth it registered in each of the last four quarters.""Revlimid appears to suffer a bit from adverse seasonality, and possibly also (foreign exchange) in ex-US geographies,"" Cowen and Co analysts wrote in a note.The drug's international sales rose 3.4 percent to $558.3 million, which analysts said were below their expectations. Celgene cut its full-year sales forecast for Abraxane to a range of $950 million-$1.25 billion, down from $1.00 billion-$1.25 billion three months ago.Jackie Fouse, Celgene's president of hematology and oncology unit, said Abraxane was facing competition in the United States from newer treatments for lung cancer.Celgene posted net loss of $34.1 million, or 4 cents per share in the quarter, compared with a net profit of $508.5 million, or 61 cents per share, a year earlier.Net loss for the quarter included $751.8 million in collaboration costs and $231.6 million in costs related to the company's acquisition of Receptos Inc announced in July.New Jersey-based Celgene earned $1.23 per share in the quarter, excluding items, marginally beating the average analysts' estimate of $1.22 per share.While the company kept its adjusted profit forecast for the year unchanged, it also cut its full-year profit view to $2.02-$2.24 per share from $2.17-$2.46 it forecast earlier.   (Reporting by Vidya L Nathan in Bengaluru; Editing by Saumyadeb Chakrabarty and Anil D'Silva)",2015-11-05,CELG,"Thu Nov 5, 2015 | 11:06am EST",UPDATE 3-Celgene's revenue misses as key cancer drug sales slow,http://www.reuters.com//article/celgene-results-idUSL3N1304U420151105?type=companyNews
74,"  Nov 5 Drugmaker Celgene Corp posted an 18 percent jump in quarterly revenue as demand for its cancer and psoriasis drugs increased.The company's revenue rose to $2.33 billion in the quarter ended Sept. 30 from $1.98 billion a year earlier.  Celgene posted a net loss of $34.1 million, or 4 cents per share, in the quarter compared with a net profit of $508.5 million, or 61 cents per share, a year earlier.    (Reporting by Vidya L Nathan in Bengaluru; Editing by Savio D'Souza) ",2015-11-05,CELG,"Thu Nov 5, 2015 | 7:35am EST","Celgene revenue rises on demand for cancer, psoriasis drugs",http://www.reuters.com//article/celgene-results-idUSL3N1304TF20151105?type=companyNews
75,"  Nov 30 The U.S. Food and Drug Administration said on Monday it had approved a drug to be sold by Bristol-Myers Squibb Co as a treatment for a form of blood cancer.The FDA said it approved the treatment, Empliciti, to be used in multiple myeloma patients in combination with Celgene Corp's Revlimid and common anti-inflammatory drug dexamethasone. (1.usa.gov/1lpWQEo)The National Cancer Institute estimates there will be 26,850 new cases of multiple myeloma and 11,240 related deaths in the United States in 2015.Research has shown that combination treatments increase the time that multiple myeloma patients survive without the disease. The FDA said that Empliciti is the second immuno-oncology treatment for multiple myeloma to be approved, after Johnson & Johnson's Darzalex.Bristol-Myers and AbbVie Inc co-developed the drug, but Empliciti will be sold only by Bristol-Myers. The company is considered the leader among drugmakers racing to develop a new wave of cancer treatments that harness the immune system, including its recently approved immuno-oncology product Opdivo. Opdivo was approved in December for advanced melanoma and was approved in March to treat the less-common squamous type of non-small cell lung cancer.Sales of Opdivo reached $305 million the latest quarter, putting it on track to become a blockbuster product.Bristol-Myers shares were down about 1 percent at $67.22 on Monday morning on the New York Stock Exchange.   (Reporting by Vidya L Nathan in Bengaluru; Editing by Ted Kerr)",2015-11-30,CELG,"Mon Nov 30, 2015 | 11:02am EST",FDA approves new Bristol-Myers treatment for multiple myeloma,http://www.reuters.com//article/bristol-myers-fda-idUSL3N13P5JE20151130?type=companyNews
76,"   By Natalie Grover  Celgene Corp said it would allow for the sale of a generic version of its flagship multiple myeloma drug, Revlimid, in the United States over a year before patents covering the drug expire.The company said it would provide India-based Natco Pharma Ltd and its U.S. partner, Arrow International Limited,  a unit of Allergan Plc, the license to Celgene's patents required to manufacture and market an unlimited quantity of generic Revlimid beginning Jan. 31, 2026 as part of a patent litigation settlement. Patents covering Revlimid in the United States expire in April 2027.Natco will also receive a ""volume-limited"" license to sell in the United States commencing in March 2022, Celgene said. ""Though this represents a compromise, overall we view the settlement as a positive, removing a major overhang on shares and enabling a clearer road toward lower-risk long-term growth,"" Jefferies analysts wrote in a note. Revlimid is a big seller for the biotechnology company and accounted for about 63 percent of the $2.3 billion in total sales earned in the quarter ended Sept. 30.Summit, New Jersey based Celgene's stock rose about 9  percent to $121 in extended trade.",2015-12-22,CELG,"Tue Dec 22, 2015 | 6:02pm EST",Celgene settles U.S. patent litigation for top seller Revlimid,http://www.reuters.com//article/celgene-revlimid-idUSL1N14B26320151222?type=companyNews
77,"  Celgene Corp said it would allow for the sale of a generic version of its flagship multiple myeloma drug, Revlimid, in the United States over a year before patents covering the drug expire.The company said it would provide India-based Natco Pharma Ltd and its U.S. partner, Arrow International Limited,  a unit of Allergan Plc, the license to Celgene's patents required to manufacture and market an unlimited quantity of generic Revlimid beginning Jan. 31, 2026 as part of a patent litigation settlement. Patents covering Revlimid in the United States expire in April 2027.Natco will also receive a ""volume-limited"" license to sell in the United States commencing in March 2022, Celgene said. ""Though this represents a compromise, overall we view the settlement as a positive, removing a major overhang on shares and enabling a clearer road toward lower-risk long-term growth,"" Jefferies analysts wrote in a note.  Revlimid is a big seller for the biotechnology company and accounted for about 63 percent of the $2.3 billion in total sales earned in the quarter ended Sept. 30. Summit, New Jersey based Celgene's stock rose about 9 percent to $121 in extended trade.   (Reporting by Natalie Grover in Bengaluru; Editing by Sriraj Kalluvila and Dan Grebler)",2015-12-22,CELG,"Tue Dec 22, 2015 | 5:57pm EST",Celgene settles U.S. patent litigation for top seller Revlimid,http://www.reuters.com//article/us-celgene-revlimid-idUSKBN0U52DO20151222?type=companyNews
78,"  Dec 22 Celgene Corp said it would allow the sale of a generic version of its flagship multiple myeloma drug, Revlimid, in the United States more than a year before the drug's patent expires.The company said it would allow India-based Natco Pharma Ltd  and its U.S. partner to market an unlimited quantity of generic Revlimid beginning Jan. 31, 2026 as part of a patent litigation settlement. Patents covering Revlimid expire in April 2027. The sale is subject to Natco securing U.S. Food and Drug Administration approval to market the copycat version. Natco will also receive a ""volume-limited"" license to sell in the United States commencing in March 2022, Celgene said.     (Reporting by Natalie Grover in Bengaluru; Editing by Sriraj Kalluvila)",2015-12-22,CELG,"Tue Dec 22, 2015 | 5:00pm EST",Celgene to allow sale of generic Revlimid before patent expiry,http://www.reuters.com//article/celgene-revlimid-idUSL3N14B4QL20151222?type=companyNews
79,"  Jan 11 Celgene Corp Chief Executive Officer Bob Hugin on Monday said he would step down as of March 1 and hand the reins to current President and Chief Operating Officer Mark Alles.Shares of Celgene, which also issued a 2016 sales and earnings forecast slightly below Wall Street expectations, fell more than 7 percent.Hugin, who will remain executive chairman and continue to lead the board of directors of the U.S. biotechnology company, made the surprise succession announcement to open the annual JP Morgan Healthcare Conference in San Francisco. He has been part of Celgene management for nearly 17 years and CEO since 2010. Jacqualyn Fouse, who currently heads the company's global hematology and oncology operations, will become president and COO, while Scott Smith, head of immunology and inflammation, will add the role of chair of the global management committee, Hugin said.The company said it expects 2016 sales of $10.5 billion to $11 billion and adjusted earnings of $5.50 to $5.70 per share.  Analysts on average are forecasting sales of $11.14 billion and adjusted earnings of $5.68 per share, according to Thomson Reuters I/B/E/S. Celgene also forecast 2016 sales of its flagship multiple myeloma drug Revlimid of $6.6 billion to $6.7 billion, roughly in line with Wall Street expectations. Hugin said he was very optimistic about the company meeting or exceeding its 2020 sales targets.Celgene shares were down 7.1 percent at $101.21 on Nasdaq.   (Reporting by Bill Berkrot; Editing by James Dalgleish)",2016-01-11,CELG,"Mon Jan 11, 2016 | 11:52am EST",Celgene names Alles CEO from March 1; shares fall 7 pct,http://www.reuters.com//article/celgene-ceo-idUSL2N14V1IE20160111?type=companyNews
80,  Celgene Corp* Ceo says very optimistic about meeting or exceeding 2020 targets * Sees 2016 sales $10.5 billion to $11 billion * Celgene sees 2016 revlimid sales $6.6 billion to $6.7 billion * $5.70  Source text for Eikon:  Further company coverage:,2016-01-11,CELG,"Mon Jan 11, 2016 | 11:10am EST",BRIEF-Celgene sees 2016 adjusted eps $5.50-$5.70,http://www.reuters.com//article/idUSL2N14V18R20160111?type=companyNews
81,"  Drugmaker Celgene Corp's (CELG.O) quarterly profit missed estimates as research and development costs surged and sales growth of its blockbuster cancer drug, Revlimid, slowed further.The company's shares fell about 5 percent Thursday morning, a day when most biotech stocks drifted lower. The broader Nasdaq biotech industry .NBI was down 2 percent.Revlimid sales rose about 8 percent in the fourth quarter from the third quarter. They rose 12 percent in the third quarter from the second quarter.The U.S. biotechnology company, however, assured investors about the long-term prospects of Revlimid, saying the drug will likely gain approval for new indications and reach new markets as more trial data comes in.Sales of the multiple myeloma drug came in at $1.56 billion - in line with consensus estimates - accounting for about 61 percent of the company's total revenue in the quarter ended Dec. 31.The company said the drug is expected to generate sales of $6.6 billion-$6.7 billion in 2016, roughly in line with Wall Street expectations. Celgene has been spending heavily to expand Revlimid's use and geographical reach as well as to develop other drugs.For the fourth quarter, Celgene's adjusted R&D expenses jumped about 36 percent to $649 million, including a $70 million milestone payment for OncoMed Pharmaceuticals Inc (OMED.O).The company, which bought Receptos Inc last year to gain access to its inflammatory bowel disease drug, on Thursday forecast first-quarter adjusted profit of $1.27-$1.30 per share. Wall Street analysts were expecting the company to earn $1.30 per share on average. Celgene's net profit fell to $561 million, or 69 cents per share, in the fourth quarter, from $613.9 million, or 74 cents per share, a year earlier.Excluding items, the company earned $1.18 per share, underwhelming the average analyst estimate of $1.22, according to Thomson Reuters I/B/E/S. The company's revenue rose about 23 percent to $2.56 billion in the quarter. Analysts were expecting revenue of about $2.54 billion. The company stuck to its 2016 earnings and revenue forecast it issued earlier in January, which was slightly below analysts' expectations.Chief Executive Bob Hugin said earlier this month he would step down as of March 1 and hand over the reins to President and Chief Operating Officer Mark Alles. (Reporting by Natalie Grover in Bengaluru; Editing by Sriraj Kalluvila and Saumyadeb Chakrabarty)",2016-01-28,CELG,"Thu Jan 28, 2016 | 11:35am EST",UPDATE 2-Celgene's profit misses estimates as costs rise,http://www.reuters.com//article/celgene-results-idUSL3N15C4YZ?type=companyNews
82,"  Jan 28 U.S. biotechnology company Celgene Corp  reported a  23 percent rise in quarterly revenue due to higher demand for its flagship multiple myeloma drug, Revlimid.The company's revenue rose to $2.56 billion in the fourth quarter ended Dec. 31, from $2.09 billion a year earlier. Net profit fell to $561 million, or 69 cents per share, from $613.9 million, or 74 cents per share.  (Reporting by Natalie Grover in Bengaluru; Editing by Sriraj Kalluvila)",2016-01-28,CELG,"Thu Jan 28, 2016 | 7:40am EST",Celgene's quarterly revenue rises 23 pct,http://www.reuters.com//article/celgene-results-idUSL3N15C4Y3?type=companyNews
83,"  NEW YORK The tumble in share prices for biotechnology stocks has created some buying opportunities, with drugmakers Celgene Corp (CELG.O) and Gilead Sciences (GILD.O) poised for a 30 percent rise over the next year, Barron's said. Both companies currently rely on closely related medications for the bulk of their income, creating risk, but the potential for diversification either through developing new treatments or being bought out could provide substantial upside, the publication said. Celgene, which specializes in treatments for a blood plasma cell cancer called myeloma, could see double-digit growth for its Revlimid drug for years to come, with significant growth potential from overseas, Barron's said.  Despite negative publicity related to high prices on its hepatitis-C drugs, Gilead Sciences' products often cure patients within months, the publication said.""That word, cure, isn't used often enough by Big Pharma,"" Barron's said.  The company also expects to generate $85 billion in cumulative free cash through 2020, which the publication said it could use to buy new medicines or repurchase shares.   (Reporting By Luc Cohen; Editing by Sandra Maler)",2016-02-08,CELG,"Sun Feb 7, 2016 | 9:38pm EST","Celgene, Gilead Sciences shares could rise 30 percent: Barron's",http://www.reuters.com//article/us-pharmaceuticals-stocks-idUSKCN0VH053?type=companyNews
84,"  April 14 Agios Pharmaceuticals :* Co and Celgene Corp agreed to defer from April 14, 2016 to June 1, 2016 selection process for allocating rights to certain discovery programs  * Co and Celgene are in talks as to an alternative approach for determining their respective rights to such discovery programs  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) ",2016-04-14,CELG,"Thu Apr 14, 2016 | 4:25pm EDT","BRIEF-Agios, Celgene Corp to defer selection process for allocating rights to certain discovery programs",http://www.reuters.com//article/idUSFWN17H0SY?type=companyNews
85,"  U.S. biotechnology company Celgene Corp (CELG.O) reported first-quarter revenue that fell just shy of analysts estimates due to the stronger dollar, sending the company's shares down 1.5 percent in premarket trading.The company's revenue, which includes product sales and other revenue, rose about 21 percent to $2.51 billion in the three months ended March 31.Analysts on average were expecting revenue of $2.57 billion, according to Thomson Reuters I/B/E/S.Sales of Celgene's flagship multiple myeloma drug, Revlimid, rose 17 percent to $1.57 billion, accounting for about 58.5 percent of total product sales in the quarter. Celgene's net income rose to $800.7 million, or 99 cents per share, from $718.9 million, or 86 cents per share.Excluding items, it earned $1.32 per share, beating analysts estimates of $1.27. Celgene, which bought Receptos Inc last year to gain access to its inflammatory bowel disease drug, nudged up its 2016 net product sales forecast to $10.75-$11.00 billion from $10.50-$11.00 billion. The company said it now expects to adjusted earnings of between $5.60 and $5.70 per share this year, up from its previous estimate of $5.50 to $5.70. (Reporting by Natalie Grover in Bengaluru; Editing by Savio D'Souza)",2016-04-28,CELG,"Thu Apr 28, 2016 | 8:39am EDT",Celgene revenue rises less than expected due to strong dollar,http://www.reuters.com//article/us-celgene-results-idUSKCN0XP1MG?type=companyNews
86,"  April 28 Celgene Corp* Celgene reports first quarter 2016 operating and financial results* Q1 revenue $2.512 billion versus I/B/E/S view $2.58 billion* Q1 earnings per share $0.99* Q1 earnings per share view $1.28 -- Thomson Reuters I/B/E/S* 2016 guidance: raising lower-end of ranges for net product sales and adjusted diluted EPS* 2017 financial targets updated; 2020 financial targets on-track * Revlimid sales for Q1 increased 17 percent to $1,574 million* Abraxane sales for Q1 were $225 million, a 1 percent increase year-over-year* Sees 2016 total product sales $10.75 billion -$11.0 billion * Sees 2016 revlimid sales approximately $6.7 billion* Total net product sales are expected to be in range of $12.7 billion to $13.0 billion for 2017* 2017 revlimid net sales are expected to be approximately $8.0 billion versus previous target of $7.0 billion * 2017 adjusted diluted EPS is expected to be in range of $6.75 to $7.00 versus previous target of $7.25* Sees 2016 adjusted diluted EPS $5.60 to $5.70* Sees 2016 GAAP diluted EPS $4.26 to $4.56* FY2016 earnings per share view $5.68, revenue view $11.12 billion -- Thomson Reuters I/B/E/S* FY2017 earnings per share view $7.20, revenue view $13.08 billion -- Thomson Reuters I/B/E/S  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)",2016-04-28,CELG,"Thu Apr 28, 2016 | 8:14am EDT",BRIEF-Celgene reports Q1 earnings $0.99/shr,http://www.reuters.com//article/idUSASD08FS7?type=companyNews
87,"  April 28 U.S. biotechnology company Celgene Corp  reported a 20.7 percent rise in quarterly revenue, helped by higher demand for its flagship multiple myeloma drug, Revlimid.The company's revenue rose to $2.51 billion in the first quarter ended March 31, from $2.08 billion a year earlier.  Net income rose to $800.7 million, or 99 cents per share, from $718.9 million, or 86 cents per share.   (Reporting by Natalie Grover in Bengaluru; Editing by Savio D'Souza) ",2016-04-28,CELG,"Thu Apr 28, 2016 | 7:39am EDT",Celgene revenue rises about 21 pct,http://www.reuters.com//article/celgene-results-idUSL3N17T4VK?type=companyNews
88,  May 3 Triphase Accelerator Corp: * Expanding current collaboration with Celgene Corp in development of marizomib for potential treatment of malignant gliomasb  Source text for Eikon:  Further company coverage:  ,2016-05-03,CELG,"Tue May 3, 2016 | 10:10am EDT",BRIEF-Triphase expands current collaboration with Celgene in development of marizomib,http://www.reuters.com//article/idUSFWN1800TX?type=companyNews
89,"  May 17 Agios Pharmaceuticals Inc* Agios and Celgene establish new collaboration in metabolic immuno-oncology and amend certain rights from 2010 agreement* Agios to receive $200 million upfront payment * Ag-120 rights outside United States transferred to Agios* Companies modified certain rights from their 2010 collaboration * As of August 15, 2016, neither party will have financial or other obligations to each other related to AG-120 * After expiration of discovery phase of 2010 agreement, other cancer metabolism programs discovered at co will remain owned by co* Exploratory research, drug discovery and early development will be led by Agios    Source text for Eikon:    Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)",2016-05-17,CELG,"Tue May 17, 2016 | 5:03pm EDT","BRIEF-Agios Pharmaceuticals, Celgene establish new collaboration in metabolic immuno-oncology",http://www.reuters.com//article/idUSFWN18E0MC?type=companyNews
90,"  May 31 Bionor Pharma ASA :* Says maintains its focus on HIV immunotherapy and overall strategy to further advance VACC-4x in clinical development in combination with other medicines* Deploys so called Shock and Kill approach for achieving a functional cure for HIV infection* Says will continue investigating combination of Vacc-4x with latency reversing agent (romidepsin, supplied by Celgene Corporation; marketed as Istodax) to first educate immune system to recognize and kill infected cells* It is expected that a third agent will be needed for purpose of further improving immune response * Enrollment of first patient in BIOSKILL is planned for Q1 2017* Is currently planning BIOSKILL, multicenter placebo-controlled proof of concept Phase II clinical trial * Is currently planning exploratory Phase I/II trial to evaluate immune regulating agent administered in triple agent regimen with VACC-4x and romidepsin (BIONAB)* Capital need is now estimated by board to about 230 million - 270 million Norwegian crowns * Previously, estimated capital need until Q1 2019 to 375 million - 425 million crowns* Long-Term funding initially will be covered by an equity offering to fund company through following 6-12 months* Will seek to reduce costs for running company by relocating to other facilities in Norway, Denmark, and U.S.* Will investigate possibilities of securing remainder of long-term capital need through equity, non-dilutive means, or a combination thereof  Source text for Eikon:  Further company coverage:    (Gdynia Newsroom)",2016-05-31,CELG,"Tue May 31, 2016 | 1:40am EDT","BRIEF-Bionor Pharma: Updated clinical strategy, reduced capital needs",http://www.reuters.com//article/idUSFWN18R059?type=companyNews
91,"   By Ransdell Pierson  Johnson & Johnson's therapy for advanced multiple myeloma sharply reduced the risk of disease progression when taken with two standard treatments for the blood cancer, according to research the company hopes will pave the way for wider use of the treatment.The drug, Darzalex, received U.S. approval in November for use by itself among patients who had received at least three prior treatments for myeloma, a cancer of infection-fighting white blood cells. Data from a late-stage trial involving 498 patients who had previously undergone one or more myeloma treatments was released on Sunday. In the study, one group received Takeda Pharmaceutical Co's Velcade and the steroid dexamethasone, while the other group received Darzalex in combination with those two drugs. After more than seven months, 61 percent fewer patients taking the Darzalex combination experienced a worsening of their disease compared with those taking the standard two-drug regimen, meeting the trial's main goal. The median time to progression of disease has not yet been reached for the Darzalex group, compared with 7.2 months for patients taking the two-drug combo.The study was stopped in March after an independent data monitoring committee found the Darzalex regimen showed a statistically significant benefit. Some 19 percent of patients in the Darzalex group showed no further sign of disease, versus 9 percent of those taking  Velcade and dexamethasone. Significant disease reduction was seen in 83 percent taking the Darzalex regimen, versus 63 percent in the two-drug combination.The findings were presented at the annual meeting of the American Society of Clinical Oncology, in Chicago.The infused medicine, which has a list price of $135,000 for the first full year of treatment, blocks the CD38 protein found on myeloma cells. It was approved based on favorable data from two smaller trials, including a study in which tumors shrank in 29 percent of patients. Dr. Antonio Palumbo, the study's lead researcher, said in an interview that overall toxicity in the Darzalex regimen was similar to that seen with the two standard treatments. That may help the J&J drug become a second-line treatment, in combination with Velcade and dexamethasone, he said.The most common side effects for both drug combinations included low blood platelets, diarrhea and anemia.  Palumbo, melanoma unit chief at the University of Torino, Italy, said data from another late-stage study of Darzalex is expected later this month and will probably mirror strong results seen in his own study. In that trial, patients received Darzalex in combination with Celgene Corp's leading Revlimid (lenalidomide) treatment and with dexamethasone.Mark Wildgust, global head of hematology at J&J, said the company hopes the trial results will allow it to market Darzalex as an earlier treatment, and in combination with standard medicines.The National Cancer Institute estimates there are 26,850 new cases of multiple myeloma each year in the United States. The average life expectancy is four years. (Reporting by Ransdell Pierson; Editing by Leslie Adler)",2016-06-05,CELG,"Sun Jun 5, 2016 | 7:34am EDT","J&J myeloma drug, in combo regimen, delays worsening of the disease",http://www.reuters.com//article/health-cancer-johnsonandjohnson-idUSL1N18U2G8?type=companyNews
92,"  June 10 Acceleron Pharma Inc :* Acceleron and Celgene announce updated results from an ongoing Phase 2 study of Luspatercept in beta-thalassemia presented at the 21st congress of the European Hematology Association * Longer term data with investigational drug Luspatercept show sustained increases in hemoglobin levels, reduced transfusion burden * Results showed 51% of patients with lower risk MDS treated with Luspatercept (n=49) achieved increased hemoglobin levels * Results showed 36% of patients achieved a hemoglobin increase of at least 1.5 g/dl in Luspatercept 3-month base study  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",2016-06-10,CELG,"Fri Jun 10, 2016 | 7:21am EDT","BRIEF-Acceleron, Celgene says data with Luspatercept show increases in hemoglobin levels",http://www.reuters.com//article/idUSFWN1920EG?type=companyNews
93,  June 13 Bionor Pharma ASA : * Says scientific collaborations include possible extension of ongoing collaboration with Celgene Corporation   Source text for Eikon:  Further company coverage:    (Gdynia Newsroom)  ,2016-06-13,CELG,"Mon Jun 13, 2016 | 10:18am EDT",BRIEF-Bionor Pharma says possible extension of alliance with Celgene,http://www.reuters.com//article/idUSFWN1950CF?type=companyNews
94,  June 15 Celgene Corp :* Celgene announces additional $3 billion share repurchase authorization  * Now has a total of approximately $5.3 billion available from previous authorizations plus new authorization  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780) ,2016-06-15,CELG,"Wed Jun 15, 2016 | 7:40am EDT",BRIEF-Celgene announces additional $3 bln share repurchase authorization,http://www.reuters.com//article/idUSASC08U4N?type=companyNews
95,"  (Adds dropped words in second and third bullets)July 19 Jounce Therapeutics:* Jounce Therapeutics says to receive upfront payment of $225 million and $36 million equity investment, up to $2.3 billion in future milestone payments * Jounce Therapeutics announces global strategic collaboration with Celgene to develop, commercialize immuno-oncology treatments for cancer patients * Jounce Therapeutics says Celgene to get options to jointly develop JTX-2011, additional immunotherapies targeting B cells, T regulatory cells * Celgene has option to opt-in at defined stages of development across programs; after opt-in, cos to share u.s. Profits, losses  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",2016-07-19,CELG,"Tue Jul 19, 2016 | 8:00am EDT",CORRECTED-BRIEF-Jounce Therapeutics to collaborate with Celgene to develop immuno-oncology therapies,http://www.reuters.com//article/idUSB8N19C02T?type=companyNews
96,"  Celgene Corp said on Monday that its flagship drug Revlimid failed to extend survival as a maintenance therapy for a type of blood cancer after patients had responded to prior treatment.As a result, the U.S. biotechnology company said it would not seek an additional approval for Revlimid for that use, and its shares fell more than 2 percent.Revlimid, a multiple myeloma treatment with annual sales of about $6 billion, was being tested versus a placebo in patients whose diffuse large B-cell lymphoma had responded to initial treatment with Roche's Rituxan and chemotherapy. Approval as a maintenance therapy, used to prevent recurrence and improve survival, can significantly add to sales as the drugs are taken long term.While the Revlimid study delayed progression of the disease, no survival benefit was seen, the company said. The trial was conducted along with the Lymphoma Study Association.  Celgene said it will continue to study Revlimid in a variety of lymphomas.  (Reporting by Bill Berkrot; Editing by Sandra Maler)",2016-07-25,CELG,"Mon Jul 25, 2016 | 5:33pm EDT",Celgene drug fails to extend survival in lymphoma study,http://www.reuters.com//article/us-celgene-revlimid-idUSKCN1052CU?type=companyNews
97,"  Celgene Corp said on Monday that its flagship drug Revlimid failed to extend survival as a maintenance therapy for a type of blood cancer after patients had responded to prior treatment.As a result, the U.S. biotechnology company said it would not seek an additional approval for Revlimid for that use, and its shares fell more than 2 percent.Revlimid, a multiple myeloma treatment with annual sales of about $6 billion, was being tested versus a placebo in patients whose diffuse large B-cell lymphoma had responded to initial treatment with Roche's Rituxan and chemotherapy. Approval as a maintenance therapy, used to prevent recurrence and improve survival, can significantly add to sales as the drugs are taken long term.While the Revlimid study delayed progression of the disease, no survival benefit was seen, the company said. The trial was conducted along with the Lymphoma Study Association.  Celgene said it will continue to study Revlimid in a variety of lymphomas.  (Reporting by Bill Berkrot; Editing by Sandra Maler)",2016-07-25,CELG,"Mon Jul 25, 2016 | 5:33pm EDT",Celgene drug fails to extend survival in lymphoma study,http://www.reuters.com//article/celgene-revlimid-idUSL1N1AB1OG?type=companyNews
98,"  July 25 Celgene Corp :* Interim analysis of overall survival, a key secondary endpoint, showed no benefit in revlimid* Based upon these interim results, Celgene does not currently plan to seek approval for this indication * Says is also exploring multiple clinical candidates in non-hodgkin lymphomas and T-cell lymphomas * Celgene and LYSARC provide update on the phase III 'remarc' study of revlimid maintenance treatment in patients with diffuse large B-cell lymphoma responding to first-line R-chop therapy * Remarc achieved primary endpoint of a statistically significant improvement in progression-free survival for patients receiving revlimid  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",2016-07-25,CELG,"Mon Jul 25, 2016 | 4:44pm EDT",BRIEF-Celgene and LYSARC provide update on the phase III study,http://www.reuters.com//article/idUSASC08Y4Q?type=companyNews
99,"   By Bill Berkrot | NEW YORK  NEW YORK Celgene Corp raised its 2016 profit forecast and exceeded expectations for second-quarter earnings on Thursday on the strength of its flagship multiple myeloma drug Revlimid and growth in newer medicines, sparking a 2 percent jump in its shares.Revlimid sales soared about 18 percent to $1.70 billion, above Wall Street's consensus estimate of about $1.66 billion.With Revlimid sales driven by new patient market share gains and longer duration of use, Celgene raised the full-year sales forecast for the medicine to $6.8 billion from $6.7 billion.Celgene suffered a setback this week in efforts to expand Revlimid's uses when the drug failed to extend survival as a maintenance therapy for a type of lymphoma after patients had responded to prior treatment.But the company said it would be wrong to draw conclusions from that data regarding three other late-stage Revlimid lymphoma trials in different patient populations and treatment settings, and expressed confidence in its potential there.""Lymphoma will be a major growth driver in 2020 and beyond,"" Michael Pehl, head of hematology and oncology, told analysts on a conference call. Celgene's new psoriasis drug Otezla, which is also being tested for atopic dermatitis and ulcerative colitis, posted sales of $274 million in the quarter.""Otezla is on its way to hitting the $1 billion revenue milestone this year,"" said Chief Operating Officer Jackie Fouse, adding that it would become the company's fourth blockbuster product.The company also highlighted the potential of its experimental Crohn's disease drug GED-301 as a key future growth driver, with important data expected this quarter. ""If that data looks good, we think that could be a big catalyst for the stock,"" said RBC Capital Markets analyst Michael Yee, who called it a potential $2 billion a year product.Celgene raised its adjusted earnings forecast for 2016 to a range of $5.70 to $5.75 per share, from $5.60 to $5.70.Excluding items, Celgene earned $1.44 per share in the quarter, topping analysts' average expectations by 6 cents, according to Thomson Reuters I/B/E/S. ""They continue to execute and outperform,"" Yee said, calling Celgene a standout among large biotechs.Total revenue rose about 21 percent to $2.75 billion in the quarter, roughly in line with estimates.Net income rose to $598.2 million, or 75 cents per share, from $356.2 million, or 43 cents per share, a year earlier.Celgene shares rose 2.2 percent to $110.44 on Nasdaq after rising as high as $111.70. (Additional reporting by Natalie Grover in Bengaluru; Editing by Maju Samuel and Jeffrey Benkoe)",2016-07-28,CELG,"Thu Jul 28, 2016 | 11:04am EDT",Sales of flagship drug Revlimid drive Celgene profit; forecast raised,http://www.reuters.com//article/us-celgene-results-idUSKCN1081FO?type=companyNews
100,"   By Bill Berkrot | NEW YORK  NEW YORK Celgene Corp raised its 2016 profit forecast and exceeded expectations for second-quarter earnings on Thursday on the strength of its flagship multiple myeloma drug Revlimid and growth in newer medicines, sparking a 2 percent jump in its shares.Revlimid sales soared about 18 percent to $1.70 billion, above Wall Street's consensus estimate of about $1.66 billion.With Revlimid sales driven by new patient market share gains and longer duration of use, Celgene raised the full-year sales forecast for the medicine to $6.8 billion from $6.7 billion.Celgene suffered a setback this week in efforts to expand Revlimid's uses when the drug failed to extend survival as a maintenance therapy for a type of lymphoma after patients had responded to prior treatment.But the company said it would be wrong to draw conclusions from that data regarding three other late-stage Revlimid lymphoma trials in different patient populations and treatment settings, and expressed confidence in its potential there.""Lymphoma will be a major growth driver in 2020 and beyond,"" Michael Pehl, head of hematology and oncology, told analysts on a conference call. Celgene's new psoriasis drug Otezla, which is also being tested for atopic dermatitis and ulcerative colitis, posted sales of $274 million in the quarter.""Otezla is on its way to hitting the $1 billion revenue milestone this year,"" said Chief Operating Officer Jackie Fouse, adding that it would become the company's fourth blockbuster product.The company also highlighted the potential of its experimental Crohn's disease drug GED-301 as a key future growth driver, with important data expected this quarter. ""If that data looks good, we think that could be a big catalyst for the stock,"" said RBC Capital Markets analyst Michael Yee, who called it a potential $2 billion a year product.Celgene raised its adjusted earnings forecast for 2016 to a range of $5.70 to $5.75 per share, from $5.60 to $5.70.Excluding items, Celgene earned $1.44 per share in the quarter, topping analysts' average expectations by 6 cents, according to Thomson Reuters I/B/E/S. ""They continue to execute and outperform,"" Yee said, calling Celgene a standout among large biotechs.Total revenue rose about 21 percent to $2.75 billion in the quarter, roughly in line with estimates.Net income rose to $598.2 million, or 75 cents per share, from $356.2 million, or 43 cents per share, a year earlier.Celgene shares rose 2.2 percent to $110.44 on Nasdaq after rising as high as $111.70. (Additional reporting by Natalie Grover in Bengaluru; Editing by Maju Samuel and Jeffrey Benkoe)",2016-07-28,CELG,"Thu Jul 28, 2016 | 11:04am EDT",UPDATE 3-Sales of flagship drug Revlimid drive Celgene profit; forecast raised,http://www.reuters.com//article/celgene-results-idUSL4N1AE4AS?type=companyNews
101,"  July 28 U.S. biotechnology company Celgene Corp  reported a 21 percent jump in quarterly revenue, driven by demand for its key multiple myeloma drug, Revlimid.Revenue rose to $2.75 billion from $2.28 billion in the second quarter ended June 30.  The company's net income rose to $598.2 million, or 75 cents per share, from $356.2 million, or 43 cents per share, a year earlier.   (Reporting by Natalie Grover in Bengaluru; Editing by Maju Samuel) ",2016-07-28,CELG,"Thu Jul 28, 2016 | 7:40am EDT",Celgene revenue rises on higher demand for flagship drug Revlimid,http://www.reuters.com//article/celgene-results-idUSL4N1AE4A1?type=companyNews
102,"  July 28 Celgene Corp* Celgene reports second quarter 2016 operating and financial results* Q2 adjusted earnings per share $1.44* Q2 revenue $2.754 billion versus I/B/E/S view $2.7 billion* Q2 GAAP earnings per share $0.75* Q2 earnings per share view $1.38 -- Thomson Reuters I/B/E/S * Abraxane sales for Q2 were $249 million, a 2 percent increase year-over-year* Sees 2016 adjusted diluted EPS $5.70 to $5.75 * Sees 2016 revlimid net sales about $6.8 billion* FY2016 earnings per share view $5.70, revenue view $11.01 billion -- Thomson Reuters I/B/E/S* 2016 net product sales guidance for Pomalyst/Imnovid, Abraxane and Otezla remain unchanged * 2016 guidance updated: revlimid  and total net product sales; EPS* Sees 2016 adjusted operating margin approximately 54.0%* Sees 2016 GAAP diluted eps $3.82 to $4.05* Sees 2016 total net product sales about $11 billion  Source text for Eikon:  Further company coverage:    (Bengaluru Newsroom: +1-646-223-8780)",2016-07-28,CELG,"Thu Jul 28, 2016 | 7:39am EDT",BRIEF-Celgene reports Q2 GAAP earnings per share $0.75,http://www.reuters.com//article/idUSASC08Z38?type=companyNews
103,"  July 29 (Reuters) - * Sanofi, Pfizer, Gilead & Celgene interested in Medivation as company asks for indications of interest by mid-August - CNBC citing sources   Further company coverage:    (Bengaluru Newsroom: +1 646 223 8780)  ",2016-07-29,CELG,"Fri Jul 29, 2016 | 9:40am EDT","BRIEF-Sanofi, Pfizer, Gilead & Celgene interested in Medivation - CNBC citing sources",http://www.reuters.com//article/idUSFWN1AF0WB?type=companyNews
104,"  Aug 24 Oncomed Pharmaceuticals : * Celgene Corporation reports 8.1 pct passive stake in Oncomed Pharmaceuticals Inc as of August 23, 2016 - SEC filing  Source text: (bit.ly/2bBcQ6P) Further company coverage:  ",2016-08-24,CELG,"Wed Aug 24, 2016 | 6:23am EDT",BRIEF-Celgene reports 8.1 pct passive stake in Oncomed Pharmaceuticals,http://www.reuters.com//article/idUSFWN1B505D?type=companyNews
105,  Sept 7 Sutro Biopharma Inc* Receives two milestone payments from Celgene * Sutro Biopharma Inc says financial terms of milestones are not being disclosed.  * Stage preclinical phase into clinical development  Source text for Eikon:  Further company coverage:,2016-09-07,CELG,"Wed Sep 7, 2016 | 11:03am EDT",BRIEF-Sutro Biopharma receives 2 milestone payments from Celgene,http://www.reuters.com//article/idUSASC095K6?type=companyNews
106,  Sept 7 Agios Pharmaceuticals Inc -* Celgene corporation expects to submit a new drug application to U.S. FDA for Enasidenib (ag-221)  * NDA submission is expected to occur by year-end 2016  Source text - bit.ly/2ca2s41 Further company coverage: ,2016-09-07,CELG,"Wed Sep 7, 2016 | 8:28am EDT",BRIEF-Agios Pharma says Celgene expects to submit NDA to U.S. FDA for enasidenib,http://www.reuters.com//article/idUSFWN1BJ0BX?type=companyNews
107,  Sept 16 Celgene Corp * Celgene Corp -Oral Ozanimod efficacy and safety results at 2 years from Phase 2 RADIANCE trial of patients with relapsing multiple Sclerosis presented at 32nd Ectrims * Celgene Corp -No new safety or tolerability issues were identified during ongoing blinded extension * Celgene Corp -Radiance met its primary efficacy endpoint _ reduction in cumulative number of total gadolinium-enhancing lesions  Source text for Eikon:  Further company coverage:,2016-09-16,CELG,"Fri Sep 16, 2016 | 10:43am EDT",BRIEF-Celgene Corp- releases data on Phase 2 RADIANCE trial,http://www.reuters.com//article/idUSFWN1BS09M?type=companyNews
108,"   By Natalie Grover  Amgen Inc said on Tuesday its multiple myeloma drug, Kyprolis, did not fare better than Takeda Pharmaceutical Co Ltd's older therapy Velcade in a study involving patients who had not yet been treated for the disease.The U.S. Food and Drug Administration has already approved Kyprolis for patients with relapsed or refractory multiple myeloma who have previously undergone treatment.Patients treated with Kyprolis did not show a statistically significant improvement in slowing the cancer's progression compared with those given Velcade in the late-stage study.Expectations of peak annual sales of about $2.3 billion for Kyprolis are now likely to cool, particularly since newly diagnosed patients constitute the largest market in terms of the number of patients and duration of therapy, some analysts said.Multiple myeloma, a type of aggressive and incurable blood cancer that develops in the bone marrow, kills about 12,600 people annually and will be diagnosed in about 30,000 Americans this year, according to the American Cancer Society.Baird analyst Brian Skorney said approval for previously untreated patients was ""off the table"" for now. The head-to-head study tested Kyprolis against the older Velcade in patients who were also given the chemothereutic agent melphalan and the immunosuppressant prednisone, and were deemed to be ineligible for stem-cell transplants.On a conference call with analysts, the company and experts said the ""treatment landscape"" for multiple myeloma was evolving dramatically and that melphalan/prednisone-based regimens were now rarely used due to their low efficacy and high toxicity. Dr. Andrzej Jakubowiak, who was involved in the development of the Amgen drug, said on the call that the study was not the ideal way to evaluate Kyprolis in previously untreated patients. Amgen, whose shares were down 1.2 percent at $171.45, said it would continue to explore the drug's benefit in combination with other agents.Kyprolis is also being tested in a separate late-stage trial in combination with Celgene Corp's Revlimid and the steroid dexamethasone, or KRd, in this ""front-line setting.""Jakubowiak said KRd was his first choice for previously untreated patients, and the results of the melphalan/prednisone study would not change this. Kyprolis has already been shown to be superior to Velcade, which is expected to go generic in 2017, in the later stages of multiple myeloma.Kyprolis faces greater competitive pressure as newer entrants in the multiple myeloma market gain traction, including Johnson & Johnson's Darzalex, Bristol-Myers Squibb Co's Empliciti and Takeda's Ninlaro.The Amgen drug generated $172 million in revenue in the second quarter. (Reporting by Natalie Grover in Bengaluru; Additional reporting by Abinaya Vijayaraghavan; Editing by Maju Samuel and Ted Kerr)",2016-09-27,CELG,"Tue Sep 27, 2016 | 11:06am EDT",UPDATE 3-Amgen's multiple myeloma drug falls short in new-patient study,http://www.reuters.com//article/amgen-study-idUSL3N1C32YD?type=companyNews
109,"  Oct 12 Abbott Laboratories :* Celgene and Agios announce collaborations with Abbott for diagnostic identification of IDH mutations in AML * Celgene - companion diagnostic technology to be utilized with Enasidenib, AG-120 development programs for relapsed/refractory acute myeloid leukemia  * Celgene-Agreements with abbott to develop,commercialize companion diagnostic tests on Abbott's M2000 realtime system to identify IDH mutations in AML  Source text for Eikon:  Further company coverage:",2016-10-12,CELG,"Wed Oct 12, 2016 | 8:03am EDT",BRIEF-Celgene & Agios collaborates with Abbott to develop diagnostic tests for leukemia,http://www.reuters.com//article/idUSFWN1CI0CS?type=companyNews
110,  Oct 18 Celgene Corp :* Celgene Corporation and Sage Bionetworks announce technology collaboration to develop observational study using the apple researchkit framework * Celgene Corp - observational study to examine burden of chronic anemia in myelodysplastic syndromes and beta-thalassemia  * Co and Sage Bionetworks have chosen to address chronic anemia caused by myelodysplastic syndromes and beta-thalassemia  Source text for Eikon:  Further company coverage:,2016-10-18,CELG,"Tue Oct 18, 2016 | 7:54am EDT",BRIEF-Celgene & Sage Bionetworks use apple researchkit for observational study,http://www.reuters.com//article/idUSFWN1CO0FM?type=companyNews
111,  Oct 27 Celgene Corp * Files for potential mixed shelf; size not disclosed - sec filing  Source: bit.ly/2eg2oOZ Further company coverage:  ,2016-10-27,CELG,"Thu Oct 27, 2016 | 5:27pm EDT",BRIEF-Celgene files for potential mixed shelf offering,http://www.reuters.com//article/idUSFWN1CX1KG?type=companyNews
112,"   By Natalie Grover  U.S. biotechnology company Celgene Corp (CELG.O) raised its profit and revenue forecast for the year after posting third-quarter results ahead of Wall Street estimates, lifted by higher demand for its flagship multiple myeloma drug, Revlimid.Celgene's shares jumped about 6.9 percent to $105.29 in Thursday morning trading.The drugmaker's top-selling treatment generated sales of $1.89 billion, beating the consensus estimate of $1.74 billion, according to Barclays. Revlimid sales accounted for about two-thirds of Celgene's total revenue in the quarter ended Sept. 30.Revlimid is in ""beast mode"" and had a ""monster"" quarter, Cowen & Co analyst Eric Schmidt wrote in a client note, adding that European sales may finally be seeing the inflection that investors had hoped for following reimbursement approval in previously untreated myeloma patients.With Revlimid sales driven by new patient market share gains and longer duration of use, Celgene raised its full-year sales forecast for the medicine to $7 billion from $6.8 billion. Data from multiple studies on the drug is still to come, which could be a major growth driver for Revlimid, Celgene executives highlighted on a post-earnings call. Celgene also upped its adjusted full-year earnings forecast to a range of $5.88-$5.92 per share from a previous forecast of $5.70-$5.75 per share.The Summit, New Jersey-based company revised its revenue forecast to $11.2 billion from a previous estimate of $11 billion. The drugmaker said it now expected adjusted earnings and net product sales in the higher end of its projected 2017 forecast, and sales of Revlimid to cross $8 billion.Celgene has forecast full-year 2017 earnings of $6.75-$7.00 per share on net product sales of $12.7 billion-$13.0 billion.The company's new psoriasis drug Otezla, which is also being tested for atopic dermatitis and ulcerative colitis, generated sales of $274.6 million in the third-quarter, roughly in line with the consensus estimate of $275 million. Its cancer treatment Abraxane generated sales of $233 million, trailing the consensus estimate by $17 million, while its other multiple myeloma drug Pomalyst brought in $341.1 million, ahead of expectations of $327 million.Excluding items, Celgene earned $1.58 per share in the quarter, beating analysts' average estimate by 10 cents, according to Thomson Reuters I/B/E/S.Total revenue rose about 28 percent to $2.98 billion, in the quarter, above the average analyst estimate of $2.83 billion, driven primarily by rising sales volumes. (Reporting by Natalie Grover in Bengaluru; Editing by Martina D'Couto)",2016-10-27,CELG,"Thu Oct 27, 2016 | 11:16am EDT","Celgene's Revlimid sales spark forecast raise, shares jump",http://www.reuters.com//article/us-celgene-results-idUSKCN12R1J6?type=companyNews
113,"   By Natalie Grover  U.S. biotechnology company Celgene Corp (CELG.O) raised its profit and revenue forecast for the year after posting third-quarter results ahead of Wall Street estimates, lifted by higher demand for its flagship multiple myeloma drug, Revlimid.Celgene's shares jumped about 6.9 percent to $105.29 in Thursday morning trading.The drugmaker's top-selling treatment generated sales of $1.89 billion, beating the consensus estimate of $1.74 billion, according to Barclays. Revlimid sales accounted for about two-thirds of Celgene's total revenue in the quarter ended Sept. 30.Revlimid is in ""beast mode"" and had a ""monster"" quarter, Cowen & Co analyst Eric Schmidt wrote in a client note, adding that European sales may finally be seeing the inflection that investors had hoped for following reimbursement approval in previously untreated myeloma patients.With Revlimid sales driven by new patient market share gains and longer duration of use, Celgene raised its full-year sales forecast for the medicine to $7 billion from $6.8 billion. Data from multiple studies on the drug is still to come, which could be a major growth driver for Revlimid, Celgene executives highlighted on a post-earnings call. Celgene also upped its adjusted full-year earnings forecast to a range of $5.88-$5.92 per share from a previous forecast of $5.70-$5.75 per share.The Summit, New Jersey-based company revised its revenue forecast to $11.2 billion from a previous estimate of $11 billion. The drugmaker said it now expected adjusted earnings and net product sales in the higher end of its projected 2017 forecast, and sales of Revlimid to cross $8 billion.Celgene has forecast full-year 2017 earnings of $6.75-$7.00 per share on net product sales of $12.7 billion-$13.0 billion.The company's new psoriasis drug Otezla, which is also being tested for atopic dermatitis and ulcerative colitis, generated sales of $274.6 million in the third-quarter, roughly in line with the consensus estimate of $275 million. Its cancer treatment Abraxane generated sales of $233 million, trailing the consensus estimate by $17 million, while its other multiple myeloma drug Pomalyst brought in $341.1 million, ahead of expectations of $327 million.Excluding items, Celgene earned $1.58 per share in the quarter, beating analysts' average estimate by 10 cents, according to Thomson Reuters I/B/E/S.Total revenue rose about 28 percent to $2.98 billion, in the quarter, above the average analyst estimate of $2.83 billion, driven primarily by rising sales volumes. (Reporting by Natalie Grover in Bengaluru; Editing by Martina D'Couto)",2016-10-27,CELG,"Thu Oct 27, 2016 | 11:16am EDT","UPDATE 3-Celgene's Revlimid sales spark forecast raise, shares jump",http://www.reuters.com//article/celgene-results-idUSL4N1CX4KM?type=companyNews
114,"  Oct 27 Celgene Corp -* Says q3 growth rate was predominantly volume driven: conf call* Celgene says Abraxane is maintaining its position the U.S. with stable market share in breast, lung and pacreatic cancer: conf call * Celgene says Pomalyst continues to grow in spite of some competitive pressure in certain patients : conf call * Celgene says they are confident that experimental Crohn's disease drug GED-301 will be transformational for patient care: conf call * Celgene says multiple catalysts ahead give co high confidence in ability to deliver on 2017 and 2020 targets: conf call* Celgene says high confidence in Otezla market launches in 2017 in geographies such as Wales and Japan; U.S. market continues to grow: conf call  Further company coverage:",2016-10-27,CELG,"Thu Oct 27, 2016 | 11:05am EDT",BRIEF-Celgene says Q3 growth rate mainly volume driven - conf call,http://www.reuters.com//article/idUSFWN1CX122?type=companyNews
115,"  * Qualcomm top stock on S&P on NXP buyout deal* Bristol-Myers, Celgene lead health stocks higher post results* Weekly jobless claims fall to 258,000 from 260,000* Indexes up: Dow 0.17 pct, S&P 0.18 pct, Nasdaq 0.32 pct   (Updates to open)By Yashaswini SwamynathanOct 27 Wall Street opened higher on Thursday as a flurry of strong corporate results from healthcare companies and a multi-billion dollar deal in the technology sector boosted sentiment about equity markets.Profits at S&P 500 companies have largely exceeded analysts' estimates for the third quarter so far, setting up for the first profit growth since the second quarter of 2015.Overall earnings for the S&P 500 companies in the latest quarter are expected to rise 2.2 percent, according to Thomson Reuters I/B/E/S.Investors also took Qualcomm's deal to buy NXP Semiconductors for about $47 billion as a sign of confidence in the U.S. equity market. NXP's shares rose 2.32 percent, while Qualcomm was the top stock on the S&P at 4 percent higher. Stocks of other chipmakers including Micron Tech were also higher.The health sector rose 0.78 percent, the top gainer among the 11 major S&P 500 indexes, led by gains in Bristol-Myers and Celgene following strong results.The health sector has been among the worst performers this month as investors remain concerned about policies such as drug pricing which has been a key point of discussion in the run-up to the Nov. 8 U.S. presidential election. ""Thus far with low expectations for earnings growth, profits have pleasantly surprised to the upside and there is a little bit of a rotation taking place out of big single names like Apple into other names like Tesla,"" said John Brady, senior vice president at R.J. O'Brien & Associates in Chicago.""Likewise, energy names are under-owned and if crude stays around the $50 level, money is going to come out of the sidelines and into these companies.""Oil prices rose for the first time this week on Thursday as a further drop in U.S. crude inventories countered investor doubts that OPEC will be able to implement a production cut.At 9:38 a.m. ET (1338 GMT), the Dow Jones Industrial Average  was up 30.44 points, or 0.17 percent, at 18,229.77. The S&P 500 was up 3.84 points, or 0.18 percent, at 2,143.27 and the Nasdaq Composite was up 16.57 points, or 0.32 percent, at 5,266.84.Data on Thursday showed the number of American filing for jobless claims fell last week, pointing to a firming labor market, while a separate report showed new orders for U.S. manufactured capital goods unexpectedly fell in September amid weak demand for electronic products.The data will play into the Federal Reserve's decision on interest rates at its policy meeting next week. Though a rate hike is not the likely outcome of the meeting that falls days before the U.S. presidential election, traders expect the Fed to chalk a more definite path for a move in December.Twitter rose nearly 5 percent after its quarterly results beat expectations. The technology sector was the second biggest boost on the S&P.Tesla jumped 4.4 percent to $211.33 after the electric carmaker reported its first quarterly net profit in more than three years.F5 Networks jumped nearly 10 percent and was the biggest gainer on the S&P, after its quarterly revenue beat estimates.Advancing issues outnumbered decliners on the NYSE by 1,395 to 1,200. On the Nasdaq, 1,400 issues rose and 763 fell.The S&P 500 index showed 11 new 52-week highs and two new lows, while the Nasdaq recorded 32 new highs and 24 new lows.   (Reporting by Yashaswini Swamynathan in Bengaluru; Editing by Don Sebastian)",2016-10-27,CELG,"Thu Oct 27, 2016 | 9:56am EDT","US STOCKS-Healthcare, tech stocks drive Wall Street higher",http://www.reuters.com//article/usa-stocks-idUSL4N1CX52D?type=companyNews
116,"  Oct 27 Celgene Corp* Celgene reports third quarter 2016 operating and financial results* Q3 adjusted earnings per share $1.58* Q3 GAAP earnings per share $0.21* Q3 earnings per share view $1.48 -- Thomson Reuters I/B/E/S* Celgene Corp says Revlimid sales for Q3 increased 30 percent year-over-year to $1,891 million* Celgene Corp - 2016 guidance and 2017 targets updated* Celgene Corp - - 2016 guidance and 2017 targets updated * Celgene Corp sees 2016 GAAP diluted EPS $3.12 to $3.29* Celgene Corp - Sees 2016 total net product sales of approximately $11.2 billion* Celgene Corp sees 2016 adjusted diluted eps $5.88 to $5.92 * Celgene Corp says Abraxane sales for Q3 were $233 million, a 1 percent increase year-over-year* FY2016 earnings per share view $5.77 -- Thomson Reuters I/B/E/S* FY2016 revenue view $11.07 billion -- Thomson Reuters I/B/E/S* Celgene Corp says total net product sales are expected to be at high end of range of $12.7 billion to $13.0 billion in 2017 * Celgene Corp - sees 2016 Revlimid net sales in the range of approximately $7.0 billion* Celgene corp says adjusted diluted EPS is expected to be at high end of range of $6.75 to $7.00 in 2017* Celgene corp - sees 2017 Revlimid net sales are expected to be more than $8.0 billion versus previous target of approximately $8.0 billion* Sees 2016 adjusted operating margin approximately 54 percent* FY 2017 earnings per share view $6.99 -- Thomson Reuters I/B/E/S* FY 2017 revenue view $13.09 billion -- Thomson Reuters I/B/E/S  Source text for Eikon:  Further company coverage:",2016-10-27,CELG,"Thu Oct 27, 2016 | 7:39am EDT",BRIEF-Celgene Q3 adjusted earnings per share $1.58,http://www.reuters.com//article/idUSASC09DNA?type=companyNews
117,"  Oct 27 U.S. biotechnology company Celgene Corp  reported a 28  percent jump in quarterly revenue, fueled by higher demand for its flagship multiple myeloma drug, Revlimid.The company said net income rose to $174 million, or 21 cents per share, in the third quarter ended Sept. 30, compared with a loss of $34.1 million, or 4 cents per share, a year earlier, primarily due to deal-related expenses.  The Summit, New Jersey-based company's revenue rose to $2.98 billion from $2.33 billion.     (Reporting by Natalie Grover in Bengaluru; Editing by Martina D'Couto) ",2016-10-27,CELG,"Thu Oct 27, 2016 | 7:38am EDT",Celgene quarterly revenue rises 28 percent as Revlimid shines,http://www.reuters.com//article/celgene-results-idUSL4N1CX4JB?type=companyNews
118,"   By Brendan Pierson  A U.S. Patent and Trademark Office tribunal has invalidated two Celgene Corp patents related to its cancer drugs Revlimid, Pomalyst and Thalomid, marking a second victory for hedge fund manager Kyle Bass in his ongoing campaign of challenging drug patents. A panel of three administrative patent judges of the PTO's Patent Trial and Appeal Board ruled Wednesday that both patents, which cover safety measures for administering the drugs, were invalid because they were obvious in light of earlier publications.  To read the full story on WestlawNext Practitioner Insights, click here: bit.ly/2fnViwa",2016-10-28,CELG,"Fri Oct 28, 2016 | 2:40pm EDT",Fund manager wins challenge to Celgene drug safety patents,http://www.reuters.com//article/health-celgene-idUSL1N1CY1OI?type=companyNews
119,  Oct 31 Celgene Corp : * Celgene Corp reports 12.3 percent stake in CRISPR Therapeutics Ag as of October 24 - SEC filing  Source text for Eikon:  Further company coverage:    ;))  ,2016-10-31,CELG,"Mon Oct 31, 2016 | 5:32pm EDT",BRIEF-Celgene Corp reports 12.3 pct stake in CRISPR Therapeutics AG - SEC filing,http://www.reuters.com//article/idUSFWN1D113F?type=companyNews
120,"  Nov 2 Celgene Corp :* Celgene and IBM Watson Health forge collaboration designed to transform patient safety monitoring  * Celgene Corp -  IBM Watson for patient safety, a new offering, will run on Watson Health cloud  Source text for Eikon:  Further company coverage: ",2016-11-01,CELG,"Tue Nov 1, 2016 | 5:26pm EDT",BRIEF-Celgene and IBM Watson Health collaborate to transform patient safety monitoring,http://www.reuters.com//article/idUSFWN1D20SV?type=companyNews
121,  Nov 14 Celgene Corp :* Celgene Corp - active trial in biologic-nave patients met its primary endpoint* Celgene - improvements in acr20 and other measures of disease seen as early as week 2 * Celgene - acr20 response rate increased from 38 percent at week 16 to 67 percent at week 52 for patients who received otezla therapy from baseline * Celgene - active trial demonstrating significant improvement in acr20 response rate at week 16 with otezla versus placebo * Data on early onset of efficacy for oral otezla (apremilast) in active psoriatic arthritis presented at american college of rheumatology  Source text for Eikon:  Further company coverage:,2016-11-14,CELG,"Mon Nov 14, 2016 | 7:38am EST",BRIEF-Celgene - Data on early onset of efficacy for oral otezla in active psoriatic arthritis presented at American College Of Rheumatology,http://www.reuters.com//article/idUSFWN1DF0XZ?type=companyNews
122,  Nov 18 PharmAkea:* Pharmakea extends collaboration with Celgene Corporation  * Pharmakea Inc-extension of strategic collaboration with Celgene for its drug discovery platform and novel small-molecule therapies targeting fibrotic diseases  Source text for Eikon: ,2016-11-18,CELG,"Fri Nov 18, 2016 | 7:22am EST",BRIEF-PharmAkea extends collaboration with Celgene,http://www.reuters.com//article/idUSFWN1DJ0CR?type=companyNews
123,"  Nov 17 Triphase Accelerator:* says Celgene Corp, through an affiliate, has acquired co's assets related to its proteasome inhibitor, marizomib* under terms of agreement, Celgene will make an upfront payment plus additional regulatory, approval and sales milestone payments * specific financial terms were not disclosed * says Celgene will pay it to complete ongoing clinical studies with marizomib * Triphase Accelerator announces acquisition of its first compound, marizomib, by Celgene Corporation  Source text for Eikon:  Further company coverage:",2016-11-18,CELG,"Thu Nov 17, 2016 | 8:36pm EST",BRIEF-Triphase Accelerator says Celgene will buy co's assets related to marizomib,http://www.reuters.com//article/idUSASC09JOO?type=companyNews
124,"  Nov 21 MaRS Innovation:* Triphase accelerator to sell assets relating to Marizomib to Celgene, via affiliate, for undisclosed amount  * MaRS Innovation announces acquisition of first compound from portfolio company triphase by Celgene  Source text for Eikon:  Further company coverage: ",2016-11-21,CELG,"Mon Nov 21, 2016 | 11:41am EST",BRIEF-MaRS Innovation announces acquisition of first compound from Triphase by Celgene,http://www.reuters.com//article/idUSL8N1DM4C9?type=companyNews
125,"  Nov 29 Celgene Corp -* Celgene enters service,license arrangement for rights to operate GNS Healthcare REFS(TM) causal machine learning and simulation platform  * Celgene has made a second equity investment in GNS  Source text for Eikon:  Further company coverage: ",2016-11-29,CELG,"Tue Nov 29, 2016 | 8:48am EST",BRIEF-Celgene enters into service and license arrangement for GNS Healthcare's causal machine learning platform,http://www.reuters.com//article/idUSFWN1DU0GT?type=companyNews
